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9ABSTRACT
The human ether á-go-go related gene (hERG1 or KCNH2) encodes the pore forming subunit
of the cardiac delayed rectifier potassium (IKr) channel. Its unique kinetics result in a resurgent
current crucial for the repolarisation of the cardiac action potential and a capability to suppress
premature excitation. hERG1 is widely expressed with roles e.g. in neuronal firing, intestinal
and uterine contractility, and insulin secretion. Furthermore overexpression and ectopic
expression of hERG1 occurs in cancer where it is involved in proliferation, migration,
chemotherapy resistance etc.
The long QT syndrome (LQTS) often presents as sudden cardiac death in children and young
adults. LQTS is characterised by electrocardiogram abnormalities with arrhythmia that can lead
to palpitations, syncope, seizure, cardiac arrest and death. Underlying the congenital form of
LQTS are mutations in ion channel proteins (including hERG1, the loss-of-function of which
gives rise to LQT2) and their interacting proteins. Carriers of a particular mutation may be
symptomatic (to varying extents) or asymptomatic, with the deleterious effects only emerging
due to the presence of other factors. This is analogous to drug-induced LQTS where arrhythmia
may occur in 1 of 120,000 users of certain non-cardiac drugs. Virtually all drug-induced LQTS
is caused by inhibition of hERG1. Consequently in the field of safety pharmacology the hERG1
channel has for the last 20 years and continues to have a huge impact as the primary in vitro
predictor of the proarrhythmic risk for a drug.
Various aspects of the hERG1 channel are investigated in the studies presented in this thesis.
The effect of prucalopride, a gastrointestinal prokinetic drug, on hERG1 was examined.
Prucalopride exhibited rapid state and concentration dependent inhibition of hERG1 however,
at therapeutic concentrations block is insignificant (hERG safety margin of ≥300). This in vitro
prediction has translated to the clinical studies of this drug and the market.
The heterogeneous phenotype associated with LQTS may arise from genetic modifiers such
polymorphisms and mutations. Heterologous expression of the prevalent hERG1 K897T
polymorphism identified a reduced hERG1 current density as the primary difference from wild-
type, a result of decreased protein expression. Additionally a slowing of deactivation and
alteration of inactivation was evident. Also studied but using induced pluripotent stem cell
(iPSC) derived cardiomyocytes was hERG1 R176W. Unlike previous LQT2 iPSC models the
origin here was a relatively asymptomatic individual. The phenotypic characteristics of LQT2
were however still reproduced in vitro (i.e. a decrease in IKr and action potential prolongation)
though as a milder version.
Finally the effect of ceramide, a sphingolipid which accumulates in heart failure and is involved
in lipotoxicity, on hERG1 was investigated. Ceramide was found to reduce hERG1 current in a
time dependent manner through tagging (ubiquitination) of the cell surface protein for
internalisation and targeting to lysosomes.
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1. INTRODUCTION
Plasma membranes of the cell and its organelles, e.g. sarcoplasmic reticulum (SR) and
mitochondria, with their hydrophobic core of phospholipid fatty acyl chains and cholesterol
form an impermeable barrier to ion movement. The passage of ions between the aqueous
compartments on either side is enabled by the incorporation in plasma membranes of specific
proteins: ion channels, transporters and pumps. Ion channels are gated pores through which ions
flow by passive diffusion down their electrochemical gradient (Ashcroft, 2006). The
fundamental properties of ion channels, and a basis for classification, are selectivity and gating
(Ashcroft, 2006; Grant, 2009). Gating is the mechanism of transition between the closed and
open states (Fig. 1), and is random (stochastic) with the occupancy of a state determined by
probability which can be influenced by e.g. transmembrane voltage (as in Fig. 1), ligand-
binding etc. When channels are opened the selectivity exhibited by some for one type of ion
over others biases the membrane potential of the cell towards the equilibrium potential of that
conducting ion (Marbán, 2002).
Figure 1. The movement of ions through a channel pore is dependent on its permeability and the electrochemical
gradient across the membrane. Single potassium channel currents at different membrane potentials measured with
the patch-clamp technique. From the open state during maintained stimulation Na+, Ca2+ and certain K+ channels
enter another state: inactivated, which is non-conducting and the occupancy of which is the basis of refractoriness
(Grant, 2009). The K+ selectivity is determined by the selectivity filter and under physiological conditions the current
through such channels is outward as membrane potentials more negative than the K+ equilibrium potential are
never reached.
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2. REVIEW OF THE LITERATURE
2.1. THE CARDIAC ACTION POTENTIAL
The heart functions as a pump maintaining systemic and pulmonary circulation. Each
heartbeat, a cycle of relaxation (diastole) and contraction (systole), is initiated by the electrical
excitation of a population of pacemaker cells that then spreads throughout the heart as evident
on the surface electrocardiogram (ECG; Fig. 2A; Marbán, 2002). The cellular representation of
the  electrical  excitation,  i.e.  the  sequential  activation  and  inactivation  of  inward  and  outward
current, is seen as a change in the transmembrane potential with time: the action potential (Fig
2; Grant, 2009; Nerbonne and Kass, 2005; Schmitt et al., 2014). The action potential differs in
the distinct types of myocardial cells (cardiomyocytes) found in the conduction system (the
sinoatrial node, atrioventricular node, His-Purkinje fibres) and the contractile cells of the atria
and ventricles (Fig. 2A; Nerbonne and Kass, 2005; Schram et al., 2002). Underlying the action
potential is the existence of an electrochemical gradient across the surface membrane of each
cardiomyocyte. This differential distribution of ions across the cell membrane is generated and
maintained by the action of ion pumps and transporters such as the Na+/K+ pump and Na+/ Ca2+
exchanger. At rest the surface transmembrane potential is set by the resting potassium
conductance which in non-nodal cells is substantial, through inward rectifier current (IK1)
channels, and consequently close to the K+ equilibrium potential (EK) of ~-90mV.
The action potential of ventricular (Fig. 2B) and atrial myocytes, as well as Purkinje fibres,
begins with a rapid depolarisation (phase 0) due to a large inward sodium current (INa) through
the opening of voltage-gated Na+ channels (Nerbonne and Kass, 2005). This depolarisation
activates a number of currents including the rapidly activating and inactivating transient
outward K+ current (Ito)  that  gives  rise  to,  along  with  Na+ channel inactivation, a brief
repolarisation phase (phase 1). This phase increases the electrochemical gradient for Ca2+, and
influences the height and duration of the plateau phase (phase 2). During phase 2 there is
balance between the inward L-type Ca2+ current (ICaL) at the myocyte T-tubules and the
outward delayed rectifier K+ current (IK), which includes rapid and slow components (IKr and
IKs). This extended phase (lasting >200ms in humans) enables the influx of Ca2+ to trigger
sufficient Ca2+ release from the adjacent internal SR stores through cardiac ryanodine receptors
(RyR2). The increase in the cytosolic [Ca2+] activates the contractile machinery i.e. excitation-
contraction coupling, the en masse occurrence  of  which  causes  contraction  and  ejection  of
blood.  As  Ca2+ channels undergo voltage- and Ca2+/calmodulin-dependent slow inactivation
and IK becomes predominant repolarisation (phase 3) takes place. Three different K+ currents
(IKr,  IKs and  IK1) are primarily responsible for the repolarisation of human (and other large
mammal)  ventricular  cardiomyocytes  (Schmitt  et  al.,  2014).  The  partial  overlap  of  these
currents (Fig. 2B) affords some redundancy in the system; this compensatory safe-guard is
known as the repolarisation reserve (Roden, 1998, 2006). Following restoration of the resting
membrane potential (phase 4) the intracellular Ca2+ level is returned to the basal state, through
extrusion by the electrogenic Na+/Ca2+ exchanger (NCX1.1) and SR reuptake via SERCA2a,
which at the organ level manifests as diastole enabling the filling of blood.
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Figure 2. (A) Action potential waveforms from various regions (adapted from Nerbonne and Kass, 2005) and how
they correlate with the surface ECG. The numbers refer to membrane potential, in mV (Drouin et al., 1995; Schram
et al., 2002). Excitation originates from the spontaneous regular firing of the SA node and spreads to the atria (the P
wave of the ECG) resulting in contraction. From the AV node the impulse is conducted through the bundle of His to
the Purkinje fibre system resulting in the synchronous excitation of the endocardial surface, ventricular
depolarisation (the QRS complex of the ECG) and contraction that generates the systolic blood pressure.
Ventricular repolarisation appears as the T wave on the ECG. The propagation of activity is dependent on the
electrical coupling between cells, mediated by gap junctional channels formed by connexin proteins (Grant, 2009).
Cardiac action potentials are modulated most conspicuously by the autonomic nervous system e.g.
parasympathetic stimulation activates, via M2 receptors, the G-protein coupled inward rectifier IKACh which is
prominent in the nodes and atria (but also present in the ventricles) resulting in negative chronotrophy and
dromotrophy (Liang et al., 2014; Schmitt et al., 2014). (B) A prototypical human ventricular action potential with its
five (0-4) phases (middle) and the associated inward (above) and outward (below) ion channel currents (adapted
from Sanguinetti and Tristani-Firouzi, 2006). It should be noted that INa has a small persistent (“window”) component
(up to 1% of the peak current termed late INa (INa-L); Antzelevitch et al., 2014) present during phase 2 and that other
currents, e.g. via Na+/Ca2+ exchanger (INCX), also underlie the action potential.
The  distinct  electrophysiological  phenotypes  of  the  cardiomyocytes,  which  contributes  to
unidirectional excitation propagation and the generation of normal cardiac rhythms, is achieved
by quantitative and qualitative differences in ion channel expression (Chandler et al., 2009;
Gaborit et al., 2007; Nerbonne and Kass, 2005; Ördög et al., 2006; Schram et al., 2002). While
most evident for the pacemaker cells of the sinoatrial (SA; or atrioventricular, AV) node, versus
the cardiomyocytes of the atrium or ventricle, differences are also apparent between atrium and
ventricle (Fig. 2A). The triangular shape of the atrial action potential and its shorter duration
(APD) is derived from additional repolarising K+ currents including the atrially restricted ultra-
rapid delayed rectifier IKur and  the  Ca2+-activated IKCa (Schmitt et al., 2014). Futhermore the
ventricular myocardium is not a homogenous structure with differences in action potential
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configuration and APD between right and left ventricle, between and within  the septum and
free walls (i.e. transseptal and transmural), and along the apico-basal axis (Drouin et al., 1995;
Nerbonne and Kass, 2005; Sicouri et al., 2010; Szentadrassy et al., 2005). Transmurally three
myocyte populations (epicardial, endocardial and midmyocardial) have been described with
differing densities of INaL, INCX, Ito and IKs resulting in APD differences that contribute, together
with the degree of electrotonic coupling, to the dispersion of repolarisation (Fig. 2A;
Antzelevitch, 2007; Glukhov et al., 2010; Li et al., 2002).
Disruption of the finely orchestrated activity of ion channels and transporters, through
changes in properties or expression as a result of e.g. mutation, drug block and/or myocardial
disease, can alter action potential waveforms and thus orderly synchronisation/propagation
predisposing to arrhythmias which destabilise coordinated contraction and lead to insufficient
pressure for blood circulation. Arrhythmia induced haemodynamic collapse, primarily in the
setting of acute or chronic ischaemia associated with coronary heart disease, results in sudden
cardiac death (SCD), ~200,000 cases of which occur (~8% of all deaths) each year in the U.S.
(Deo and Albert, 2014; Stecker et al., 2014).
2.2. THE IKr/hERG1 CHANNEL
The rapid component of the delayed rectifier K+ current is found in various cardiac cell
types (nodal, atrial, Purkinje and ventricular) from a variety of species, including human (Jost et
al., 2005; Li et al., 1996; Tseng, 2001; Veldkamp et al., 1995; Wang et al., 1994). IKr is
primarily  responsible  for  the  termination  of  the  action  potential  plateau  (phase  2)  and  the
initiation of final repolarisation as IK1 activates, and thus influences APD (Li et al., 1996;
Gintant, 2000; Jost et al., 2005). In contrast the slow component, IKs, has a limited role in
cardiac repolarisation in the absence of β–adrenergic stimulation under physiological conditions
(Banyasz et al., 2014; Jost et al., 2005).
Block  of  IKr, e.g. by the methanesulfonanilides E-4031 or dofetilide, results in a delay in
repolarisation which on the ECG appears as a prolongation of the QT interval or when
corrected for heart rate QTc interval (Katritsis et al., 1997; Vicente et al., 2015). The QTc
interval is considered prolonged if >440 ms, though up to 460 ms in females can be normal
(with the Bazett correction formula; Schwartz and Crotti, 2014). The delay in action potential
repolarisation and concomitant increase in the effective refractory period (i.e. when the tissue is
inexcitable, a result of Na+ channel inactivation) reduces the risk of re-entrant arrhythmias such
as ventricular and atrial fibrillation (VF, AF), atrial flutter (Riera et al., 2008). This
antiarrhythmic mechanism, a class III drug effect, was actively sought however excessive
action potential prolongation, particularly in the setting of hypokalemia (i.e. serum [K+] <3.5
mM) and bradycardia (i.e. slow heart rate, <60 bpm), is associated with the long QT syndrome
(LQTS; Fig. 3).
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Figure 3. Arrhythmogenesis associated with IKr deficit (adapted from Antzelevitch and Sicouri, 2012; Yap and
Camm, 2003). This is commonly in the setting of a reduced repolarisation reserve such as IKs loss e.g.due to latent
LQT1 (Napolitano et al., 2000; Veerman et al., 2013). Prolongation or more specifically triangulation of the action
potential leads to the occurrence of membrane oscillations or EADs (*). On the ECG the QTc interval is prolonged
and considered proarrhythmic if >500 ms (Goldenberg et al., 2008, 2011; Migdalovich et al., 2011; Schwartz and
Crotti, 2014). A flattening and notching (bifid, ‡) of the T wave may be seen (Dausse et al., 1996; Etheridge et al.,
2003; Vicente et al., 2015). EADs are generated by L-type Ca2+ channels as the slowing of repolarisation allows
their recovery from inactivation and for reactivation (D. Guo et al., 2007; January and Riddle, 1989), with the
involvement of INCX due  to  SR  Ca2+ leak (hyperphosphorylation of RyR2) suggested (Terentyev et al., 2014).
Alternatively the spontaneous systolic SR release, due to Ca2+ overload as a result of a prolonged phase 2, may
have a more central role in EAD generation (Kim et al., 2015). If the EAD occurs synchronously in enough myocytes
(the source) this will bring the neighbouring repolarised tissue (the sink) to its activation threshold and trigger an
action potential (Xie et al., 2010). Propagation of triggered activity appears as ventricular extrasystoles (ectopic
beats) on the ECG. In addition to this triggered activity, the other prerequisite for reentrant arrhythmias such as TdP
is a substrate (Schmitt et al., 2014). This may be a morphological change, e.g. after infarction, or amplification of the
inherent spatial dispersion of repolarisation, particularly transmurally due to preferential prolongation of
midmyocardial (M) cell APD, which leads to heterogeneity of refractoriness within the ventricular myocardium
(Antzelevitch and Sicouri, 2012; Brunner et al., 2008; Shah and Hondeghem, 2005). This is further augmented, at
least transiently, by β-adrenergic stimulation (Antzelevitch and Sicouri, 2012). Recently such heterogeneous APD
prolongation giving rise to regions with steep dispersion gradients was shown in the intact human ventricular
epicardium of congenital LQTS patients (Vijayakumar et al., 2014). It should be noted that due to the abnormal Ca2+
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levels mechanical alterations also occur (Haugaa et al., 2010), e.g. a reduction in systolic function at rest (Leren et
al., 2015).
LQTS, whether acquired (i.e. due to an environmental stressor e.g. metabolic abnormality,
drug-induced) or congenital, manifests in the setting of a structurally normal heart as syncope
and/or seizures due to impairment of cerebral circulation resulting from torsade de pointes
(TdP; Schwartz and Crotti, 2014; Shah, 2005). This polymorphic ventricular tachycardia, where
the QRS complexes change amplitude appearing to sinusoidally twist around the isoelectric
line, can either spontaneously cease or, in ~20 % of cases, degenerate into VF with cardiac
arrest and sudden death (Fig. 3; Shah, 2005). An overall mortality of 10-17 % is associated with
TdP. Historically two inherited LQTS forms were described: the autosomal dominant Romano-
Ward syndrome (i.e. phenotype obtained by alteration of a single allele; Romano et al., 1963;
Ward, 1964) and the autosomal recessive Jervell and Lange-Nielsen syndrome, in which
deafness is also present (Jervell and Lange-Nielsen, 1957). Later LQTS linkage was found to
various loci, including chromosome 7q35-36 (LQT2; Jiang et al., 1994), indicating a
heterogeneous molecular basis. Following mapping to the LQT2 locus and screening of the
gene, affected members of LQT2 kindreds were discovered to have mutations (including a de
novo mutation in a sporadic case) in the then recently found human ether á-go-go (EAG)
related gene (hERG1 or KCNH2; Curran et al., 1995).
hERG1 was isolated from a human hippocampus cDNA library and identified as a member
of a novel family of voltage-gated potassium channel (KV) genes (Warmke and Ganetzky,
1994). The gene encoded a polypeptide of 1159 amino acids with a molecular mass of 127 kDa.
When expressed in Xenopus oocytes  the  hERG1 channels  (KV11.1) conducted a voltage
activated, potassium selective, inwardly rectifying current (Sanguinetti et al., 1995; Trudeau et
al., 1995). As hERG1 was  already  shown  to  be  the  LQT2  gene  and  its  mRNA  was  strongly
expressed in the heart (Curran et al., 1995), the identification of the physiological counterpart of
its current was simplified. The hERG1 current-voltage relationship exhibited similar
rectification properties and voltage-dependence of activation to IKr, in addition to reproducing
IKr’s paradoxical modulation by extracellular [K+]  i.e.  lowering  K+o decreases the outward
current despite increasing the electrochemical driving force (Sanguinetti et al., 1995). At the
elemental level the conductance and kinetics of single hERG1 channels were also comparable
to those of IKr channels (Kiehn et al., 1996). Furthermore like IKr the  hERG1 current was
sensitive to methanesulfonanilide drugs (Kiehn et al., 1996; Snyders and Chaudhary, 1996;
Spector et al., 1996a; Trudeau et al., 1995).
Consequently hERG1 encodes  the  pore  forming  (α)  subunit  of  the  cardiac  IKr channel, an
origin for both inherited and drug-induced LQTS/TdP.
2.2.1 EXPRESSION
ERG1 is expressed in the heart, at the mRNA and/or protein level, in various species
including human, dog, horse, ferret, rabbit, guinea pig, rat and mouse (Brahmajothi et al., 1997;
Finley et al., 2002; Pond et al., 2000; Szabó et al., 2005; X. Wang et al., 2008; Wymore et al.,
1997; Zicha et al., 2003). In atrial and ventricular myocytes ERG1 protein was shown to be
primarily localised to T-tubules, the site of excitation-contraction coupling, (Jones et al., 2004;
Rasmussen et al., 2004) or uniformly distributed in T-tubular and surface sarcolemma
(Balijepalli et al., 2007; Ehrlich et al., 2004; Finley et al., 2002; Pond et al., 2000).
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In the healthy human heart ERG1 mRNA is one of the most abundant α-subunit coding
transcripts with similar expression in atria, ventricles and Purkinje fibres (Gaborit et al., 2007;
Ördög et al., 2006). In another study transcript expression of hERG1 isoforms was higher in the
right heart chambers (Luo et al., 2008). Though abundantly expressed in human SA node the
level of ERG1 transcript is about half that of the right atrium (Chandler et al., 2009). In the left
ventricular free wall ERG1 mRNA is significantly more expressed in human than either rabbit
or guinea pig (Zicha et al., 2003). In human undiseased left ventricular myocardium ERG1
protein is similarly expressed in apical and basal regions, however expression (as in other
species except dog) is significantly greater in the epicardium (Brahmajothi et al., 1997; Szabó et
al., 2005; Szentadrassy et al., 2005; X. Wang et al., 2008).
  IKr, unlike e.g. IKs, is present throughout development from embryonic stem cells to
cardiomyocytes of the foetus and neonate through to adult (Danielsson et al., 2013;
Obreztchikova et al., 2003; Sartiani et al., 2007). However changes in IKr do occur
developmentally e.g. a decline postnatally in dog and most dramatically in mouse ventricular
myocytes  where  it  is  the  sole  IK component of the foetus but absent from the adult
(Krishnamurthy et al., 2004; Obreztchikova et al., 2003; Wang et al., 1996; Yang et al., 2014).
Underlying this is a lower mERG1 protein level and alteration in the composition of the IKr
channel  i.e.  a  switch  in  the  ratio  of  the  ERG1 variants  and  lower  availability  of  an  accessory
subunit protein (X. Wang et al., 2008). The relative importance of IKr therefore alters, e.g. it is
the dominant repolarising current across species for the period from foetal to neonatal
development (Cordeiro et al., 2013a; Wang et al., 1996). Thus in teratology studies using rats
its inhibition, while little affecting the maternal heart where Ito is dominant, can cause
embryonic bradycardia and arrhythmia with the resulting episodes of hypoxia/reperfusion and
reactive oxygen species (ROS) generation leading to foetal death and malformations
(Danielsson et al., 2007).
There are gender differences in potassium channel subunit expression. The mRNA levels of
KCNQ1 and hERG1 from human blood samples of healthy females were significantly lower
than those of males (Moric-Janiszewska et al., 2011). In human female non-diseased right
ventricle there was a reduction in hERG1 transcript (by 30–40 %) and protein in both the
epicardium and endocardium compared to male hearts (Gaborit et al., 2010). Unfortunately data
on any cellular electrophysiological differences from healthy humans is lacking.
In response to cardiac disease states, e.g. heart failure (HF) and AF, adaptive changes in
conduction, repolarisation and Ca2+ handling can occur as part of a bid to maintain
cardiovascular function (Michael et al., 2009). For instance in HF, where the heart is unable to
meet the metabolic demands of the body, the electrophysiological remodelling includes an
increase in INaL and INCX but a decrease in Ito,fast and IK1 due to downregulation of respectively
KV4.3 and Kir2.1 subunits (Li et al., 2004; Michael et al., 2009). The result is a prolongation of
the ventricular APD (Glukhov et al., 2010; Holzem et al., 2016; Li et al., 2004); the longer
depolarisation during the cardiac cycle increasing the time for excitation-contraction coupling
so mitigating the decrease in cardiac output. In the chronic setting such remodelling often gives
rise to secondary cardiac dysfunction in particular arrhythmia, a primary cause of death in HF
(Michael et al., 2009; Schmitt et al., 2014). In animal models of HF the IKr amplitude is also
significantly, but not always (e.g. Li et al., 2002), reduced (Tsuji et al., 2000; H. Wang et al.,
2012). Recently it was shown that though IKr block induces further APD prolongation in each
transmural region of the failing human left ventricle, the extent was attenuated compared to
healthy donor (~30 % vs ~70 %; Holzem et al., 2016). Underlying this apparent reduction of IKr
in HF was a decrease in hERG1a protein, but not hERG1b which consequently altered the
isoform stoichiometry.
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ERG1 is also expressed widely outside of the heart. In humans (and rats or mice) its mRNA
is expressed in e.g. the adrenal glands, jejunum and colon, kidney, pancreatic islets, and brain
(Farrelly et al., 2003; Rosati et al., 2000; Sarzani et al., 2006; Wymore et al., 1997). The
expression of hERG1a mRNA in human prefrontal cortex increases during foetal development,
with the level from birth then sustained throughout life (Huffaker et al., 2009). At the protein
level for instance contrasting ERG1 expression was shown in the human jejunum and colon,
being present in the former in longitudinal and circular muscle as well as enteric neurones while
in the latter being mainly in pacemaker (the interstitial cells of Cajal and PDGFRα+) cells
(Farrelly et al., 2003; Tomuschat et al., 2016). The expression and function of extra-cardiac IKr
is detailed later (section 2.4).
2.2.2 STRUCTURE-FUNCTION RELATIONSHIP
BIOPHYSICAL PROPERTIES OF THE hERG1 CHANNEL
The hERG1 channel adopts one of three basic conformations (Fig. 4): closed (non-
conducting), open (conducting) or inactivated (non-conducting). In a physiological K+ gradient
at negative voltages (e.g. −80 mV) hERG1 channels are in the closed state. Upon depolarisation
of the membrane potential beyond the threshold of ~−50 mV hERG1 channels enter the open
state (Fig. 5A; Sanguinetti et al., 1995; Zhou et al., 1998a). The transition involves the opening
of an intracellular activation gate so allowing the outward diffusion of K+ down the
electrochemical gradient, with hERG1 being selectively permeable to K+ over Na+ by a factor
of >120 (Sanguinetti et al., 1995; Torres et al., 2003; Zhou et al., 1998a).
Figure 4. The hERG1 channel exists in three voltage-dependent states. From single hERG channel recordings the
dwell time distributions suggest at least two open and closed states (Zou et al., 1997) or one open and three closed
states (Kiehn et al., 1999). At the whole-cell level transition through at least three closed states is seen from the
sigmoidal shape of the activation time course (Wang et al., 1997a; II Fig. 2B). Furthermore single channel data
indicates a direct transition from a closed state to the inactivated state that is significant, at least, during strong
depolarisation and may contribute to hERG rectification (Kiehn et al., 1999). Two non-K+ conducting inactivated
states are evident in non-physiological solutions with the initial state being Na+ permeable (Gang and Zhang, 2006).
These multiple states and their kinetics have been incorporated into various computational models to simulate or
describe different aspects of hERG channel gating and its effects on AP repolarisation (see e.g. Bett et al., 2011 for
a comparison of five such models).
At potentials of ≥0 mV inward rectification (i.e. for the same electrochemical potential the
magnitude of the outward current is smaller than the inward current) occurs (Fig. 5A;
Sanguinetti et al., 1995; Zhou et al., 1998a). This is also evident at the level of the single
hERG1 channel, where the conductance of inward and outward currents is respectively 10-12
pS and 4-5 pS in a symmetrical K+ gradient (Bian et al., 2001; Kiehn et al., 1996, 1999; Zou et
al., 1997). Unlike IK1 channels where intracellular Mg2+ or polyamines block the outward
current (Schmitt et al., 2014), the mechanism of rectification is caused by rapid voltage-
dependent inactivation, which is ≈100 times faster than activation (Schönherr and Heinemann,








1996; Smith et al., 1996; Snyders and Chaudhary, 1996; Spector et al., 1996b). This rapid
transition between the open and inactivated state involves the closure and opening of an
extracellular gate and can be revealed by incorporation of a brief hyperpolarisation step,
between depolarising pulses, which removes inactivation (Smith et al., 1996; Spector et al.,
1996b). A large outward current is evident upon return to the depolarising voltage which then
decays as the channels re-inactivate (Fig. 5B).
The activation and inactivation gating properties of hERG1 are unique compared to the
other  KV channels. Activation gating is relatively slow (with time constants (τ) ranging from
hundreds of milliseconds to seconds) while inactivation gating is very fast (τ of milliseconds to
tens of milliseconds) and both are voltage sensitive (Snyders and Chaudhary, 1996; Spector et
al., 1996b; Zhou et al., 1998a). The unusual kinetics of hERG1 underlie the IKr current profile
during  the  ventricular  action  potential  and  are  thus  crucial  to  normal  and  aberrant  cardiac
function:
· Following IKr activation during the cardiac action potential upstroke and early part
of the plateau (phase 2), inactivation results in channels rapidly accumulating in the inactivated
state. This limits the outward current during depolarisation thus contributing to the low
conductance and maintenance of the plateau phase of the action potential ensuring adequate
time for Ca2+ entry as well as preventing premature excitation by rendering the cell refractory
(Banyasz et al., 2014; Hancox et al., 1998; Jost et al., 2005; Spector et al., 1996b; Vandenberg
et al., 2012). Inhibition of IKr has little effect on these phases of the action potential (Gintant,
2000; Jost et al., 2005; Li et al., 1996; Sanguinetti and Jurkiewicz, 1990).
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· As phase 2 proceeds with gradual repolarisation hERG channels recover from the
inactivated state increasing the outward K+ current, despite the diminished electromotive force
as Em is closer to EK, so sustaining further repolarisation as the channels only slowly deactivate.
This resurgent current peaks during the transition to phase 3, at potentials negative to -30 mV,
after which it rapidly declines as the membrane voltage returns to resting potential (Fig. 5C;
Banyasz et al., 2014; Gintant, 2000; Hancox et al., 1998; Jost et al., 2005). Of note in terms of
arrhythmia is that the voltage of peak hERG current occurs in the window current voltage range
of the L-type calcium channel and thus opposes its reactivation. The current profile and peak
potential  depend on  the  action  potential  waveform,  so  that  for  an  epicardial  waveform hERG
conductance is ~8 times greater than for atrial as full activation can occur during the more
depolarised plateau (Lu et al., 2001). Such differences may be offset by a higher atrial IKr
density (Gintant, 2000).
· Furthermore the slow deactivation ensures channels are available to counteract
premature stimuli that can initiate arrhythmias and to potentially modulate conduction and the
early phase of the AP (Larsen et al., 2010a; Lu et al., 2001; Verkerk et al., 2005). A premature
stimulus evokes an instantaneous opposing large transient outward current through the
open/slowly deactivating hERG channels, due to the increase in the electrochemical gradient
for K+ and the channels rapidly inactivating (Fig. 5C; Lu et al., 2001).
· In  the  post-repolarisation  interval  of  SA  and  AV  node  cells  IKr is a major
determinant of the maximum diastolic potential, which since being positive to EK results in
residual deactivating outward current. The deactivation of IKr contributes  to  phase  4
depolarisation and pacemaking, thus its inhibition slows spontaneous SA node firing (Couette
et al., 2006; Vandenberg et al., 2012; Zhou et al., 1998a).
STRUCTURAL BASIS OF hERG1 CHANNEL FUNCTION
The first atomic resolution K+ channel structure, KcsA of Streptomyces lividans (Doyle et
al., 1998), and subsequent X-ray crystallographic structures including the rat KV1.2 and the so
called KV1.2/KV2.1 paddle chimera (X. Chen et al., 2010; Long et al., 2005a, 2007) have
revolutionized the understanding of the mechanisms and dynamics of conduction, selective K+
permeability and channel gating. The use of these structures as templates for homology models,
as no complete crystal structure for hERG1 is currently available, and molecular dynamics
simulations  (e.g.  Dempsey  et  al.,  2014;  Stansfeld  et  al.,  2008)  as  well  as  the
electrophysiological investigation of numerous site-specific mutations have provided insights
into the structural basis of hERG1 channel function. This will be furthered by the very recently
reporting of a rat EAG1 channel structure (Whicher and MacKinnon, 2016).
Like other KV subunits the hERG1 subunit has six α-helical transmembrane segments (S1-
S6), the first four (S1-S4) of which constitute the voltage-sensing domain (VSD) while the last
two together with the intervening pore loop (S5-P-S6) form the pore domain, with cytoplasmic
amino and carboxy temini (Fig. 6). Functional KV, including hERG1, channels are composed of
four subunits, their pore domains line a central conduction pathway while their VSDs lie at the
periphery spanning the membrane with an hourglass appearance (X. Chen et al., 2010; Long et
al., 2005a; L. Wang et al., 2009; Whicher and MacKinnon, 2016).
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Figure 6. (A) Structural features of the hERG1 subunit (KV11.1 splice variant 1a; the transmembrane segment
residues are designated as in the sequence alignment of Whicher and MacKinnon, 2016). In the pore domain (S5-
P-S6) the residues that form the selectivity filter of the pore (S624-G628) and the glycosylation site (N598) are
shown. In the VSD (S1-S4) the basic Lys (K) and Arg (R) residues of S4 and the negatively charged acidic Asp (D)
residues of S1-3 are indicated. During gating these negatively charged residues, as well as the phospholipid head
groups and hydration waters in the vestibules (Islas, 2016), stabilise the positively charged S4 residues within the
membrane’s hydrophobic environment by forming transient salt bridges (Liu et al., 2003; Zhang et al., 2005).
Possibly such interactions preferentially form in the closed states, slowing S4 outward movement. A common
binding site for divalent cations and protons is shown (Fernandez et al., 2005; Shi et al., 2014). In the intracellular
amino terminal the structure of the PAS domain is shown as deduced by X-ray crystallography (Morais-Cabral et al.,
1998). The secondary structure of the hERG cNBD, with its 9 β strands and 4 α helices, is shown (Li et al., 2014).
Beneath the pore domain of EAG1 the C-linkers form a ring under which the cNBDs are docked with the PAS
domains at their periphery able to interact with the VSDs (Whicher and MacKinnon, 2016) (B) Structure of KcsA
channel, with only two of the four subunits that form these channels shown, crystallized in the closed (Doyle et al.,
1998; Figure by Boghog2, https://commons.wikimedia.org/w/index.php?curid=3471420). In the selectivity filter two
potassium ions are shown occupying S2 and S4 (purple spheres) while two water molecules occupy the other sites
(their oxygen atoms depicted as red spheres).
The pore domain and permeation
Potassium channels are both efficient and highly selective. The throughput is in part
optimised by limiting the interaction between ions and the channel to the extracellular end of
the  pore,  the  selectivity  filter  (Fig.  6B;  Doyle  et  al.,  1998).  Beneath  the  selectivity  filter  is  a
water-filled cavity in the middle of the channel protein that is lined by the S6 helices. Typically
from the electrochemical gradient, hydrated K+ ions enter from the cytoplasm and are held due
to the nature of the lining, both via hydrogen bonding interactions and its hydrophobicity, at the
centre of the cavity for passage through the selectivity filter to the extracellular entryway (Zhou
et al., 2001).
The selectivity filter (of 12 Å in length) is formed by a highly conserved stretch of amino
acids (Thr/Ser-X-Gly-Tyr/Phe-Gly) contained in each pore loop (Fig. 6). The selectivity filter is
a highly electronegative environment with the backbone carbonyl oxygen atoms of the
signature sequences together with the side chain hydroxyl oxygen atom of the
threonines/serines directed towards the pore (Fig. 6B; Doyle et al., 1998; Long et al., 2005a,
2007; Morais-Cabral et al., 2001). This structure underlies selective ion conduction. The
oxygen atoms of the filter act as surrogate waters coordinating the dehydrated K+ ions creating
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four  K+ binding sites in a row (S1-S4), occupied alternately by K+ ions and water molecules
(Fig. 6B; Doyle et al., 1998; Morais-Cabral et al., 2001; Zhou et al., 2001). The translocation of
K+ ions bound within the selectivity filter from S4,S2 to S3,S1 and finally S2,S0 (at the
extracellular entryway) is driven by an incoming third ion from the cavity (Bernèche and Roux,
2001; Jensen et al., 2010; Morais-Cabral et al., 2001)1. Permeation through the hERG1
selectivity filter appears less energetically favourable and particularly by this knock-on
mechanism, which could account for the low conductance (2 pS in a physiological K+ gradient;
Kiehn et al., 1996) of the channel (Ceccarini et al., 2012). Also likely contributing is the few
negative charges at the intracellular vestibule which is formed by the cyclic nucleotide binding
homology domain (cNBD, Fig. 6) of the C-terminus (Whicher and MacKinnon, 2016).
From the KcsA crystal structure it was posited that the carbonyl groups, while perfectly
positioned for K+ ions, are unable to move to coordinate the Na+ ion so compensation for the
loss  of  hydration  is  less  favourable  for  the  Na+ ion than for the K+ ion (Doyle et al., 1998).
However this snug-fit view does not take into account the inherent structural flexibility of the
channel (Noskov and Roux, 2006). Alternative determinants, such as the magnitude of the
repulsive interactions of the partial negative charge of the binding site carbonyl oxygen atoms
being lessened by the larger cation (Noskov and Roux, 2006), are proposed but the primary
mechanism of the inherent preference for K+ is unresolved (Lockless, 2015). However as this
binding site equilibrium selectivity can also be exhibited by non-selective channels it is
insufficient to explain the selectivity of K+ ion permeation (Lockless, 2015). It seems, as with
permeation, that multiple K+ ions simultaneously bound in the selectivity filter is critical with
the queue of ion-binding sites functioning as a unit. The mechanism underlying how a multi-ion
queue determines selective ion conduction in K+ channels is unclear.
Activation & deactivation
In K+ channels the activation gate is formed by the criss-crossing of the four S6 helices near
the cytoplasmic interface constricting the ion conduction pathway (Fig. 6B; Doyle et al., 1998).
For hERG1 the gate is proposed to be the side chain of Gln664, located at the intracellular
extreme of S6 more than one helical turn distal to that of the archetypal KV channel Shaker
(Thouta et al., 2014; Wynia-Smith et al., 2008). In the open state the S6 helices display a bend
which  splays  the  carboxy  terminal  ends  outwards  from  the  central  axis  of  the  pore  thus
removing the physical barrier to ion passage between the intracellular solution and the
selectivity filter (Jiang et al., 2002; Long et al., 2005a). Comparison of the presumed closed and
open crystallographic structures gives a picture of the nature of activation-deactivation gating as
a swinging motion of the S6 helices about a hinge, which for the bacterial channels is proposed
to be a highly conserved glycine and for KV1-KV4 channels a Pro-X-Pro motif (Jiang et al.,
2002; Long et al., 2005a; Yellen, 2002). The Pro-X-Pro motif is absent from hERG1, while
substitution of Gly648 and/or Gly657, which is in the analogous position to the motif’s second
Pro, has relatively minor effects or shifts the gating equilibrium to the open state (Hardman et
al., 2007; Mitcheson et al., 2000a). In contrast to Shaker, the hERG1 pore is more stable in the
open  than  closed  conformation  with  the  inherent  flexibility  of  the  S6  helices  sufficient  for
activation gating (Hardman et al., 2007; Whicher and MacKinnon, 2016).
Activation of hERG1 involves transitions between several closed states prior to the final
step where a concerted interaction of all four S6 helices opens the activation gate (Wang et al.,
1 This commonly accepted view of permeation, intervening water molecules and therefore weakened Coulomb repulsion between
the cations, has been challenged (Köpfer et al., 2014).
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1997a). These early transitions, as in other KV channels, are thought to correspond to the
independent serial movements of each subunit’s S4 helix leading to its outward displacement
while the other VSD segments remain largely static (Jensen et al., 2012; Tao et al., 2010; Wang
et al., 2013). This S4 movement must be completed by all four subunits for the pore to open. In
hERG1 the S4 residues L523 to L529 move from the membrane into the extracellular solution
during depolarisation (Elliott et al., 2009). The S4 of KV channels is the primary sensor of the
transmembrane electric field, with its positively charged Arg or Lys residues at every third
position (Fig. 6; Sanguinetti and Tristani-Firouzi, 2006). The change in polarity of the
transmembrane voltage with depolarisation exerts an electrostatic force on those positive
charges that are within the focused electric field at the waist of the VSD’s hourglass structure
resulting in a change in their position (Islas, 2016; Long et al., 2005b; M. Zhang et al., 2004).
This region of the VSD separates aqueous inner and outer vestibules and contains an aromatic
residue from S2 (Phe463 in hERG1) which together with two negatively charged residues form
the charge transfer centre that facilitates the sequential movement the S4 gating charges (Cheng
et al., 2013; Islas, 2016; Tao et al., 2010). For the KV S4  this  equates  to  a  ~15Å  movement
across the membrane, though for EAG family members the magnitude may be less (Jensen et
al., 2012; Tao et al., 2010; Whicher and MacKinnon, 2016). In hERG1 F463 and D466 interact
with the outer S4 charge (K525) in the resting configuration of the voltage sensor i.e. the closed
state (Cheng et al., 2013). The first three S4 positive charges (K525, R528 and R531) were
initially identified as the gating charges, with a wider scanning mutagenesis study adding
further residues such that a spiral thread around the S4 was formed (Piper et al., 2005; M.
Zhang et al., 2004) which equates with the notion of its movement being a helical twist or
rotation (Pathak et al., 2007).
From where does the unusually slow activation gating of hERG1 originate? Slow S4
movement was the general view (Piper et al., 2003; Smith and Yellen, 2002), however more
recent gating current, S4 accessibility, and voltage-clamp fluorometry measurements suggest
that ionic current activation is preceded by S4 translocation, which occurs at a more
hyperpolarised potential and is ~4-fold faster at 0mV than channel opening (Es-Salah-
Lamoureux et al., 2010; Goodchild et al., 2015; Wang et al., 2013). Events subsequent to S4
movement are then suggested to harbour the rate limiting step.
In  KV channels  the  intrasubunit  transmission  of  S4  motions  to  the  activation  gate  of  S6
(electromechanical coupling) occurs via the S4-S5 linker. The intracellular S4-S5 linker forms
an amphipathic α-helix that runs parallel to the membrane and acts as a rigid lever on the
carboxy portion of the S6 helix which it passes over (Long et al., 2005b). However, this is not
the case with hERG1 since physical continuity between the voltage sensing and pore domains is
not completely necessary for voltage-dependent gating as shown by the functional coupling of
co-expressed independent hERG1 modules split at Y545 of the S4-S5 linker (Lörinczi et al.,
2015). Moreover the S4-S5 linker of the EAG family members is much shorter and forms a
loop resulting in a fundamentally different voltage dependent gating mechanism to KV channels
(Whicher and MacKinnon, 2016). It is proposed that in its resting state S4 would interact
directly with the C-linker to induce a bend in S6 after Gln664 closing the channel, while the
outward movement of S4 would enable the rotation of the C-linker and S6 relieving the high-
energy bend and opening the channel. This mechanism consequently allows the cytoplasmic
domains of EAG family members to modulate both the activation gate and VSDs.
For  hERG1  the  slow  rate  dependent  on  the  interaction  between  cytoplasmic  domains.
Deletion of the N-terminus (Δ2-354/373) substantially accelerates deactivation (τ decreased
~10-fold), an effect that can be attenuated or mimicked by, respectively, intracellular
application of an exogenous peptide corresponding to the channel’s first 16 amino acid residues
or deletion of residues 2-12 (Schönherr and Heinemann, 1996; Spector et al., 1996b; Wang et
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al., 1998, 2000). These initial residues act as a dynamic flexible tail and together with the
subsequent amphipathic α-helix (residues 13-23) comprise the cap region of the N-terminus eag
domain (Li et al., 2010; Muskett et al., 2011; Ng et al., 2011). The remainder of this domain is a
Per-Arnt-Sim (PAS) domain, a helix-loop-helix motif, formed by residues 26-135 (Fig. 6;
Morais-Cabral et al., 1998). The N-terminus eag domain interacts with the cNBD of the
adjacent subunit (Gianulis et al., 2013; Gustina and Trudeau, 2011; Li et al., 2014; Whicher and
MacKinnon, 2016). The deletion of the cNBD has an effect analogous to that of N-terminus
deletion and negates the normalising effect to the latter construct of recombinant eag domain
expression (Gianulis et al., 2013; Gustina and Trudeau, 2011). Stable interactions form between
the  PAS  and  cNBD  which  position  and  allow  the  tail  of  the  N-terminus  cap  to  dynamically
interact with the C-linker, via charge-charge interactions of its arginines 4 and 5, and/or the S4-
S5 linker (de la Peña et al., 2015; Ng et al., 2014). This more transient interaction would then
modulate the closure of the activation gate and result in the stabilisation of the open state (as
evident from the single-channel open times) and allosterically of the activated S4 limiting its
rate of return (Goodchild et al., 2015; Ng et al., 2014; Wang et al., 2000). Slow deactivation
seems to be a concerted process requiring all four hERG1a subunits (Thomson et al., 2014).
Inactivation
hERG1 is devoid of N-type inactivation, with its inactivation resembling C-type (Schönherr
and Heinemann, 1996; Smith et al., 1996; Spector et al., 1996b). C-type inactivation results
from structural changes in the selectivity filter, which fluctuates between conductive and non-
conductive conformations2 (Cordero-Morales et al., 2006, 2007; Cuello et al., 2010; Zhou et al.,
2001). Determining the stability of the selectivity filter’s conductive conformation and its
transitions to a non-conductive state as well as collapse into a more stable inactivated state are
hydrogen bond networks (Cordero-Morales et al., 2006, 2007). Though none of the residues
taking part in these networks within KcsA are conserved in hERG1 (Cordero-Morales et al.,
2007; Doyle et al., 1998; Vandenberg et al., 2012), molecular dynamic simulations do show an
intra-subunit network involving a water molecule behind the selectivity filter, F627 and G628
of the selectivity filter, N629 and from the pore helix S620 (Stansfeld et al., 2008). This
hydrogen bond network and/or inter-subunit hydrogen bonds between N629 and G628 stabilise
the backbone of the selectivity filter, however these are unstable (Köpfer et al., 2012; Stansfeld
et al., 2008). Their breakdown and S620-N629 interaction, within all four subunits (Wu et al.,
2014), is suggested to allow the flipping of backbone carbonyls of the selectivity filter away
from the conduction path thus disrupting the K+ coordination sites resulting in a collapsed
conformation (Köpfer et al., 2012; Stansfeld et al., 2008).
Often omitted from these models is the S5-P linker, this plays a crucial role in hERG1
inactivation (Liu et al., 2002). The S5-P linker is much longer in the EAG family than other KV
channels (~40 amino acids in hERG1 compared with typically 12-15; Torres et al., 2003). Some
of the residues here, as well as in the pore helix and outer mouth e.g. S620 and S631, are
though not conserved in the related reduced or non-inactivating EAG1 and ELK2 (Clarke et al.,
2006; Köpfer et al., 2012; McPate et al., 2008; Perrin et al., 2008). A segment of S5-P linker
forms an amphipathic α-helix that is hypothesised to be involved in inactivation voltage
sensing, the N588/Q592 face of the helix interacting with a charged residue in the outer pore
(Clarke et al., 2006; Torres et al., 2003). Inactivation voltage sensing appears distinct from that
2 The correspondence of these non-conductive conformations of the K+ channel selectivity filter to the inactivated state structure is
disputed (Devaraneni et al., 2013).
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of activation as they are differentially affected by mutation (e.g. McPate et al., 2008) and
external cations (e.g. Fernandez et al., 2005). Moreover S4 movement does not report
inactivation and disruption of inactivation has little impact according to gating currents or
fluorescence signals (Es-Salah-Lamoureux et al., 2010; Piper et al., 2003). However
inactivation was suggested, by alanine substitution induced perturbations in ionic and gating
currents, to localise to a helical face of S4 which is distinct from areas involved in activation
gating (Piper et al., 2005).
Prior to the collapse of the selectivity filter and stabilisation of the final inactivated state
there are widespread rearrangements of the hERG1 channel. The trigger is the loss of K+ from
the selectivity filter which leads to conformational rearrangements in the pore helix, then S5,
S5P linker, S4, S4-S5 linker, S6 and again in the pore helix (Perry et al., 2013a, b; Wang et al.,
2011). The pore helix acts as the selectivity filter interface, initially through coupling (e.g.
T618) with S5 residues of the same subunit and later, via intra- and inter-subunit interactions
with S6, when to signal the final step (Perry et al., 2013b). The intervening motions in the
sequence are coordinated by other domain-domain interactions e.g. between hydrophobic S4
and S5 residues of neighbouring subunits (Perry et al., 2013a).
2.2.3 ERGs AND ERG1 VARIANTS
To customise the properties of the hERG channel to the requirements and various roles in
the multitude of hERG1 expressing cell types, the channel is both spatially and temporally
heterogeneous. Thus the cardiac IKr, though this is itself heterogeneous, has e.g. much faster
activation and deactivation kinetics than the hERG1 current (Sanguinetti et al., 1995;
Weerapura et al., 2002). Native IKr/hERG channels are dynamic heteromeric macromolecular
complexes. The diversity originates from various mechanisms (compositional and regulatory):
· Heteromultimeric assembly of a-subunits, which are encoded by related genes and/or splice
variants of hERG1
· Association of b-subunits and interaction with other proteins
· Post-translational modifications
The EAG family
The EAG family (KCNH1-8) consists of three subfamilies: EAG, ERG, and ELK, each with
multiple members in mammals (Ganetzky et al., 1999; Gutman et al., 2005). Although the
members encode voltage-activated potassium channel subunits in which structural elements
(GFG selectivity filter, eag and cNBD domains) are conserved, heteromultimers can only be
formed within a subfamily due to recognition domains in the N- and C-termini (Lin et al., 2014;
Schönherr et al., 2002; Wimmers et al., 2001; Zou et al., 2003).
Originally ERG2 (KV11.2, KCNH6) and ERG3 (KV11.3, KCNH7) were thought to be found
exclusively in the nervous system (Shi et al., 1997). Moreover hERG3 mRNA expression
appeared confined to the human brain (Kang et al., 2001a). However more recently it was
shown that transcripts of all three ERG members were expressed by mouse and human
pancreatic islets (Hardy et al., 2009) and that ERG3 was functionally expressed by the GI tract
interstitial cells of Cajal influencing their spontaneous pacemaker activity which drives the slow
waves in membrane potential of the smooth muscle determining phasic contraction (White et
al., 2008). There is also transient expression of both ERG2 and ERG3 mRNA in the developing
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mouse heart (Polvani et al., 2003). In the adult mouse CNS ERG1 and 3 proteins are widely
coexpressed although in some areas (e.g. superior colliculus and substantia nigra) ERG3 protein
is more expressed while in other areas (e.g. hippocampal dentate gyrus) ERG1 is more
expressed (Guasti et al., 2005). ERG2 protein expression is low and restricted.
As with hERG1 the other ERG channels display at positive potentials inward rectification of
the steady-state current and elicit upon repolarisation large tail currents (Einarsen et al., 2009;
Kang et al., 2001a; Shi et al., 1997; Wimmers et al., 2002). Consistent with the conservation of
residues  in  the  P  and  S6  domains  ERG2  and  ERG3  are  also  sensitive  to  the  small  molecule
blockers of ERG1 (Elmedyb et al., 2007; Kang et al., 2001a; Shi et al., 1997). Peptide toxins,
e.g. APETx1 (from the sea anemone Anthopleura elegantissima) and various ones from
Grammostola rosea tarantula, and the agonist RPR260243 exhibit some selectivity between
ERG subtypes (Kang et al., 2005; Redaelli et al., 2010; Restano-Cassulini et al., 2006).
The formation of heteromeric KV11 channels has not been conclusively shown in vivo yet,
though individual rat lactotrophs express either ERG mRNA  transcripts  alone  or  in  various
combinations (Schäfer et al., 1999). In brain regions where co-expression occurs there is
evidence for the formation of heteromeric channels (ERG1/ERG3) as the functional properties
appear distinct from those of the homomers (Hardman and Forsythe, 2009; Hirdes et al., 2005).
Using a concatemer approach to define the subunit composition the biophysical properties of
heteromeric rat ERG channels were investigated (Wimmers et al., 2002). Whereas the
activation rate was dominated by the quicker activating subunit, the rates of recovery from
inactivation and deactivation were dominated by the KV11.1 subunit.
ERG1 variants
The human KCNH2 gene spans approximately 33 kb of the long arm (q) of chromosome 7 at
position 36.1 (Farrelly et al., 2003; Splawski et al., 1998; Vandenberg et al., 2012). A number
of variants are generated from it:
· hERG1a, the full-length transcript from 15 exons encodes a protein of 1159 amino acid
residues.
· hERG1b, an independent transcript with its own transcription start sites and promoter
within intron 5 (Luo et al., 2008). This isoform starts from an alternative exon (1b) prior
to exon 6 so it has a 56 amino acid long N-terminus, of which the initial 36 residues are
unique and the others identical to hERG1a from residue 377 onwards, and a total length
of 819 residues (Phartiyal et al., 2007; Sale et al., 2008; Splawski et al., 1998).
· hERG1-3.1, a primate specific N-terminal variant of hERG1a with a transcription start
site in intron 2 (Huffaker et al., 2009; Vandenberg et al., 2012). The first 102 residues,
which are encoded by the missing first two exons, are replaced with 6 unique amino
acids.
· hERG-USO is a C-terminal variant, generated by polyadenylation of intron 9 instead of
splicing, that results in the last 359 amino acids of hERG1a/b (i.e. from within the
cNBD) being substituted by 88 residues encoded by the USO exon (Gong et al., 2010;
Guasti et al., 2008; Kupershmidt et al., 1998).
The ERG1b transcript and protein is expressed within the cardiac tissue of various
mammals including humans (Jones et al., 2004; London et al., 1997; X. Wang et al., 2008). In
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human right atrium and left ventricle hERG1b mRNA constitutes 19 % and 12 % respectively
of  the  total  hERG1a/1b  mRNA  (Larsen  et  al.,  2008).  However  there  is  a  shift  in  the  relative
expression of the transcripts with human developmental age, in foetal heart hERG1b is 2-fold
more abundant than hERG1a (Crotti et al., 2013). Whereas hERG1a transcript expression was
far greater in the heart than other human tissues, for the hERG1b transcript its expression in the
pancreas and colon was over double the level in the heart (Luo et al., 2008). In mouse hepatic
portal vein the expression of ERG1b mRNA is nearly 4-fold greater than ERG1a mRNA (Ohya
et al., 2002a). Both of these ERG1 transcripts are expressed in adult mouse brain with the
expression level of the ERG1b transcript, in contrast to the ERG1a transcript, being greater in
the brain than the heart (Guasti et al., 2005). Furthermore both proteins are highly expressed in
the mouse brain with similar expression patterns and intensities. In vivo coassembly  of  these
variants was found in human neuroblastoma cells (Crociani et al., 2003), in mouse brain and
heart (Guasti et al., 2005) and in canine and human ventricular myocytes (Jones et al., 2004).
Thus the composition of endogenous ERG channels includes both ERG1a and ERG1b subunits.
The expression of mouse and human orthologs of ERG1b results most noticeably in
currents with accelerated deactivation kinetics (Larsen et al., 2008; Lees-Miller et al., 1997;
London et al., 1997; Trudeau et al, 2011). Homomeric ERG1b channels though are poorly
expressed (London et al., 1997; Sale et al., 2008), due to retention within the endoplasmic
reticulum (ER; Phartiyal et  al.,  2008).  Coexpression with ERG1a rescues the ERG1b subunits
and produces tail currents with novel intermediate deactivation kinetics even with RNA ratios
equivalent to those found in the human heart (Larsen et al., 2008; London et al., 1997).
hERG1a/1b currents exhibit less rectification, due to a faster activation rate but an unaltered
inactivation rate, and approximately three-fold faster deactivation kinetics than hERG1a
currents, properties emanating from the presence of fewer eag domains (Larsen et al., 2008;
Sale et al., 2008; Trudeau et al, 2011). Thus during a ventricular action potential hERG1a/1b
currents are larger and peak earlier (i.e. at a more depolarised potential) resulting in 80 % more
charge transferred (Sale et al., 2008). The current of these heteromeric channels bears closer
resemblance to IKr and indeed hERG1b was shown to functionally contribute to human
cardiomyocyte IKr (Jones et al., 2014). The disruption of hERG1b, as expected from the above,
reduced the magnitude of native IKr and slowed its deactivation consequently prolonging APD
and triggering EADs. Differences in the relative abundance of ERG1b in cardiomyocytes may
underlie the variability in IKr, present at least in the canine heart (Gintant, 2000; Szabó et al.,
2005), and contribute to APD dispersion (Larsen and Olesen, 2010). Finally the importance of
hERG1b is underlined by the identification of hERG1b specific mutations (A8V and R25W) in
a LQTS patient and an intrauterine foetal death which in vitro result in loss-of-function (Crotti
et al., 2013; Jones et al., 2016; Sale et al., 2008).
hERG1-3.1 mRNA is found in various brain regions at comparable levels to hERG1a but
within the heart there is a difference of over three orders of magnitude (Huffaker et al., 2009).
Of note is that hERG1-3.1 mRNA is most abundant prenatally, at least in the human prefrontal
cortex. Homomeric hERG1-3.1 channels also poorly express and exhibit impaired trafficking
(Calcaterra et al., 2016). The most obvious functional difference between hERG1-3.1 and
hERG1a is in deactivation which is substantially faster for hERG1-3.1 and becomes
intermediate with co-expression (Heide et al., 2012; Huffaker et al., 2009).
hERG-USO fails to form functional channels when expressed by itself in mammalian
systems but when coexpressed with either hERG1a or hERG1b there is coassembly and a
reduction in the current density (Guasti et al., 2008; Kupershmidt et al., 1998). The hERG-USO
containing heteromeric channels are retained within the ER and undergo ubiquitin-dependent
degradation (Guasti et al., 2008). However more recently minimal association of hERG-USO
with hERG1a was reported and that hERG-USO had little effect on hERG1a trafficking or
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function (Stump et al., 2012a). Anyway the nonfunctional hERG-USO variant at least regulates
the post-transcriptional expression of hERG1a/b through competition between alternate
processing of a single pre-mRNA precursor (Gong et al., 2010).
 hERG-USO mRNA is found in human left ventricle, atrium and midmyocardium as well as
uterus, lung, lymphocytes, jejunum, colon, pancreas and brain (Farrelly et al., 2003; Gong et al.,
2010; Kupershmidt et al., 1998). Moreover expression varies in different tissues, e.g. about
two-thirds of hERG1 pre-mRNA is processed to hERG-USO in the heart compared to equal
amounts in the brain, suggesting regulation of alternative processing possibly through tissue-
specific variability in the relative strengths of the splice site and poly (A) signal (Gong et  al.,
2010). The importance of the relative expression of these variants is highlighted by a LQT2
mutation IVS9-2delA which disrupts the splicing of intron 9 thus resulting solely in
polyadenylation and so a switch from hERG1a to hERG1a-USO (Gong et al., 2014a).
2.2.4 BIOGENESIS AND TRAFFICKING
The start site for hERG1a transcription is upstream of the ATG translation start codon by 79
base pairs (bp), and the immediate upstream 5´-untranslated region (UTR) to 487 bp forms the
core promoter (Luo et al., 2008). As there is differential spatial and temporal expression of the
hERG transcript variants, transcription is clearly regulated though until recently this had
received little attention. The expression of hERG1 is regulated in the embryonic development
of, at least, mouse by the homeobox transcription factor Nkx2-5, which is essential for cardiac
specification during development and homeostasis thereafter (Furtado et al., 2016). Both
mERG1a and particularly mERG1b mRNA was down-regulated in Nkx2-5 knockout mice
embryo hearts, with Nkx2-5 and its partners (Gata4 and Tbx5) shown to bind to the mERG1b
promoter region and transactivate transcription. The hERG1 promoter  was  also  shown  to  be
transactivated by transcription factors BMAL1 and CLOCK which form the positive limb of the
loop that coordinates circadian expression (Schroder et al., 2015). Furthermore, due to the
cardiomyocyte molecular clock, hERG1 transcripts were shown to exhibit a circadian pattern of
expression in the rodent heart (the peak at the light to dark transition and the trough at the
reverse transition 12 hrs later).
Various sequence and structure-specific elements, i.e. noncoding information, within the
hERG1 mRNA affect translation and the protein trafficking efficiency (Sroubek et al., 2013).
The hERG pre-mRNA undergoes alternative polyadenylation, with polyadenylation at a
poly(A) signal in exon 15 or within intron 9 generating the hERG1a and hERG-USO variants
respectively (Gong et al., 2010). Moreover LQT2 mutations have highlighted the importance of
pre-mRNA splicing to mRNA as well  as the stability of those mRNA templates (Fig.  7).  The
spliceosome deposits onto the mRNA 20-24 nucleotides upstream of each splice junction an
exon  junction  protein  complex,  which  plays  a  key  role  in  mRNA  quality  control.  During  the
pioneer round of translation these complexes are displaced by the ribosome. However for LQT2
mutations which result in premature termination codons that occur >54-60 nucleotides upstream
of the most 3´ splice junction, i.e. the junction of exons 14-15 in hERG1a, the downstream exon
junction complex serves as a marker and platform for the recruitment of factors that trigger the
nonsense mediated decay (NMD) of the mRNA transcript (Gong et al., 2014b).
MicroRNAs (miRNAs), endogenous non-coding RNAs of ~22 nucleotides, can through
Watson-Crick base pairing to the 3´-UTR of mRNA inhibit  the expression of proteins.  Of the
>50 miRNAs predicted to target hERG (Wang et al., 2015), miRNA-133 which is specifically
28
expressed in adult cardiac and skeletal muscle as well as miRNA-34a, miRNA-96 and miRNA-
362-3p were shown to reduce the expression of ERG protein and therefore IKr (Feng  et  al.,
2014; Shan et al., 2013; Shao et al., 2013; Wang et al., 2015). Additionally miRNA-365-3p also
targets and suppresses ERG1, in the spinal cord this interaction contributes to mouse
nociception (Pan et al., 2016).
Figure 7. The biogenesis and trafficking of hERG (adapted from Vandenberg et al., 2012). Anterograde
(biosynthetic delivery and recycling of endocytic channels; blue arrows) and retrograde (endocytosis; orange arrow)
trafficking determine the density of hERG channels at the plasma membrane. About 60 % of the core-glycosylated
hERG1 in the ER is processed to the mature form (Gong et al., 2005).
After the hERG mRNA is processed in the nucleus it reaches the cytosol whereupon
translation is initiated by ribosomes (Vandenberg et al., 2012). In the first few codons is a
signal which when recognised results in halting of translation and targeting of the
RNA/ribosome/polypeptide complex to the ER. Here translation is resumed with the nascent
hERG1 polypeptide translocated across the ER membrane via the translocon and the N-termini
emerging into the luminal space of the ER where they interact (Phartiyal et al., 2007). In
addition to the cotranslational interaction of the nascent polypeptides, the hERG1a and 1b
transcripts are associated facilitating the synthesis and assembly of the heteromeric channels
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within the ER (Liu et al., 2016). The interaction with hERG1a subunit masks the Arg-X-Arg
(RXR)  ER  retention  motif  in  the  hERG1b  N-terminus  enabling  ER  export  and  surface
expression of the subunit (Phartiyal et al., 2008). As the nascent oligopeptide exits the ribosome
there is a risk for aggregation, especially for hydrophobic residues exposed to the aqueous
environment, until the proper secondary structure is assumed (Chen et al., 2009). The binding
of chaperones such as the cytosolic heat shock proteins (Hsp70 and Hsp90α) and their co-
chaperones (e.g. FKBP38 in the ER membrane) to at risk sites in hERG1 prevents this
misfolding (Ficker et al., 2003; Li et al., 2011; Peterson et al., 2012; Walker et al., 2007). The
detection of local misfolding is probably aided by the presence of multiple RXR motifs in
hERG1, such as at residues 1005-1007 (Kupershmidt et al., 2002), which would be hidden in
the correctly folded protein (Vandenberg et al., 2012). Quality control is also likely similarly
ensured by the numerous diacidic motifs, which are a classic ER export signal.
Folding  and  tetrameric  assembly  appears  to  be  a  difficult  process  with  the  majority  of
hERG1 protein as a consequence residing in the ER (Sroubek et al., 2013). Furthermore
perturbation of this process underlies the deleterious nature of most LQT2 mutations (C.
Anderson et al., 2006, 2014; Gong et al., 2006; Jones et al., 2016). With misfolding the
association of hERG protein with Hsp70 and Hsp90 is increased and the chaperones remain
bound in a sustained effort to direct the folding intermediates into the native conformation, thus
facilitating the maturation of mutant as well as wild type hERG protein (Ficker et al., 2003;
Iwai et al., 2013; Li et al., 2011). Moreover they inhibit the binding to hERG of  heat shock
cognate 70 (Hsc70), which has the opposite action to Hsp70, and the ubiquitin ligase CHIP,
which ubiquitinates hERG i.e. the covalent binding of one or a chain of ubiquitin proteins (Iwai
et al., 2013; Li et al., 2011). The outcome of such competitive interactions in the chaperone
network  determines  the  fate  of  the  hERG  protein  with  the  hERG-DJA-Hsc70-CHIP  complex
leading to polyubiquitination of hERG and therefore active removal from the ER to the cytosol
for degradation by the proteasome (Ficker et al., 2003; Gong et al., 2005; Walker et al., 2010).
In addition to this ER-associated degradation (ERAD), trafficking-deficient hERG mutants can
activate ER stress pathways, which have a general negative impact on cellular function, such as
the unfolded protein response that leads to increased synthesis of ER chaperones (Keller et al.,
2005; Mehta et al., 2014; Y. Wang et al., 2012).
hERG1 contains two consensus extracellular N-glycosylation sites (Petrecca et al., 1999),
but only Asn598 is glycosylated within the ER lumen (Gong et al., 2002). The core
glycosylated hERG protein is then exported in COPII vesicles along microtubules,
unconventionally via a Rab11B GTPase dependent pathway, to the Golgi apparatus with the
interaction between hERG1 and the Golgi protein GM130 tethering the vesicles to the cis face
(Fig. 7; Delisle et al., 2009; Roti Roti et al., 2002; Smith et al., 2013). In the Golgi apparatus
hERG1 undergoes further glycosylation to render the fully mature glycosylated form. The
glycosylation process is readily traceable in Western blots of hERG expressing cell lines as two
bands, weighing ~135 and ~155 kDa in the case of hERG1a or ~85 and ~95 kDa in the case of
hERG1b, representing the immature, core-glycosylated and the maturely glycosylated cell
surface expressed species (Crociani et al., 2003; Jones et al., 2004; Zhou et al., 1998a, b). While
glycosylation is not obligatory for trafficking to the cell surface, it is required for the interaction
with the ER chaperone calnexin and plays a role in the stability of hERG1 protein at  the cell
surface i.e. nonglycosylated hERG has a faster turnover rate (Chen et al., 2015; Gong et al.,
2002, 2006).
The mature hERG channels are exported from the Golgi apparatus to the plasma membrane,
where in heterologous systems they reside with a half-life of ~11 hrs (Ficker et al., 2003; Ke et
al., 2013). In both native and heterologous systems hERG1 channels are localised in cholesterol
and sphingolipid enriched membrane microdomains (Balijepalli et al., 2007), specifically
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caveolae. This is a form of lipid raft with a flask-shaped morphology attained by the insertation
of caveolins (Cav) into the cytoplasmic leaflet of the bilayer. Cav3 in muscle and Cav1 in other
cell types physically interacts with and negatively regulates hERG1 (Guo et al., 2012; Lin et al.,
2008; Massaeli et al., 2010a; but see also Balijepalli et al., 2007). Underlying the inhibitory
effect  of  Cav3  on  IhERG is  the  recruitment  from  the  cytosol  to  the  membrane  by  Cav3  of  the
ubiquitin-protein ligase Nedd4-2 (Guo et al., 2012). Nedd4-2 binds to a PY motif in the C-
terminus of hERG1 mediating its ubiquitination, tagging the target protein for endocytosis and
degradation (Albesa et al., 2011; Guo et al., 2012). The interaction of hERG1 with Nedd4-2
mediates the homeostatic regulation of hERG1 channel expression at the cell membrane and
therefore IhERG/IKr density (Kang et al., 2015).
The internalisation of hERG1 is clathrin-independent, though the exact mechanism may
depend on the circumstance. The rapid constitutive endocytosis of hERG1 was found to involve
the small GTPase Arf6 and not dynamin (Karnik et al., 2013). This excludes a dynamin-
dependent Cav mechanism, which was earlier shown to underlie hERG1 internalisation in
response hypokalaemia and the cholesterol lowering agent probucol (Guo et al., 2011a;
Massaeli et al., 2010a). The endocytic vesicles then deliver the internalised protein to early
endosomes for recycling or sorting to intraluminal vesicles and eventually lysosomal
degradation. The recycling of hERG1 to the plasma membrane is Rab11-mediated and is
constitutive in hERG-HEK cells (Chen et al., 2015). This process is also enhanced, possibly via
phosphatidylinositol-3-phosphate-5-kinase PIKfyve (Pakladok et al., 2013), by serum and
glucocorticoid inducible kinases (SGK1 and SGK3), which additionally inactivate Nedd4-2,
increasing hERG1 channel expression (Lamothe and Zhang, 2013).
2.2.5 hERG1-PROTEIN INTERACTIONS
In addition to the interactions already mentioned, e.g. with Hsp70 and 90, the hERG1
protein associates with various other proteins including the tumour necrosis factor-α (TNF- α)
receptor 1 (Wang et al., 2002), sigma-1 receptor (Crottès et al., 2011), K+ channel regulator 1
(KCR1; Kupershmidt et al., 2003), kinases (e.g. various protein kinases, Src tyrosine kinase)
and viral proteins (HIV Tat and coxsackie). hERG1 also co-immunoprecipitates with epidermal
growth factor receptor in pancreatic ductal adenocarcinoma and regulates the receptor’s
signaling (Lastraioli et al., 2015). Moreover in cancer cells but not in the heart hERG1
associates with β-integrin to form signalling hubs (see section 2.4.3).
A reduction in IKr by drugs results in functional as well as expressional, through post-
transcriptional upregulation, compensatory increases in IKs (Jost et al., 2005; Xiao et al., 2008).
Furthermore a physical interaction between the hERG1 and KCNQ1 proteins, which involves
their C-termini, of the distinct channels occurs (Ehrlich et al., 2004; Guo et al., 2011b; Organ-
Darling et al., 2013; Ren et al., 2010; cf. Finley et al., 2002). This interaction affects the surface
expression of hERG1 (cf. Guo et al., 2011b), however the consequences are unclear with both
increased  and decreased IhERG reported (Biliczki et al., 2009; Ehrlich et al., 2004; Hayashi et
al., 2010; Ren et al., 2010).
 Another significant interaction is with the single transmembrane domain KCNE family, in
particular  with  KCNE1  (or  minK,  which  partners  with  KCNQ1  to  form  IKs channels) and
KCNE2 (or MiRP1, minK-related peptide 1). The latter, a 123 amino acid protein, was initially
suggested to be the hERG1 β-subunit (Abbott et al., 1999). Upon co-expression the current
density (along with the single-channel conductance) of hERG1 was decreased and deactivation
was accelerated at hyperpolarised potentials but in the physiologically relevant voltage range
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deactivation was unaltered or slowed (Abbott et al., 1999; Gordon et al., 2008; Lu et al., 2003;
Mazhari et al., 2001; Scherer et al., 2002; Weerapura et al., 2002). In contrast co-expression of
hERG1 with KCNE1 resulted in an increase in the current density, while the single-channel
conductance remained unchanged, and a small negative shift in the activation curve (Du et al.,
2013; McDonald et al., 1997). Also differentially KCNE1 primarily associates with hERG in
the ER, whereas KCNE2 trafficks independently to the cell membrane (Moungey et al., 2008;
Um and McDonald, 2007). The inclusion of KCNE1 and KCNE2 in the cardiac IKr channel
complex of various species is evident from their co-immunoprecipitation with ERG1
(Balijepalli et al., 2007; Finley et al., 2002; Jiang et al., 2004; X. Wang et al., 2008).
Furthermore knockdown of KCNE1 expression by antisense oligonucleotides eradicated IKr
from cultured neonatal mouse ventricular myocytes (Ohyama et al., 2001). KCNE2, like
KCNE1, is promiscuous and exhibits differential interactions with its α-subunit partners such as
KCNQ1 and HCN4 (Nawathe et al., 2013; Roepke et al., 2008; Y. Yang et al., 2004).
Alterations in those complexes as well as the hERG1-KCNE2 channel complex will contribute
to KCNE2 linked inherited and drug-induced LQTS (Abbott et al., 1999; Gordon et al., 2008;
Sesti et al., 2000; Y. Yang et al., 2004). Key is probably KCNE2’s localisation to Purkinje
fibers  with  their  important  role  in  cardiac  electrophysiology  and  arrhythmias  (Pourrier  et  al.,
2003). The significance of the hERG1-KCNE1 interaction is evident clinically. While KCNE1
variants mostly affect IKs, some such as the single nucleotide polymorphism (SNP) D85N and
the A8V mutation also or only cause loss-of-function through their interaction with hERG1
resulting in a LQT5 phenotype that mimicks LQT2 (Du et al., 2013; Nishio et al., 2009; Nof et
al., 2011; Ohno et al., 2007). Though the underlying pathogenic mechanisms in regards to
hERG1 have yet to be elucidated, the KCNE1 D85N and KCNQ1 interaction appears to result
in enhanced degradation of the protein via the ubiquitin-proteasome system (Sakata et al.,
2014).
2.2.6 REGULATION
IhERG can be modulated not only by protein interactions but by a multitude of other factors
e.g. acidosis, alkali and transition metal cations, ATP, lipids (e.g. long chain fatty acids and
acylcarnitines, phospholipids), oxidative stress. In regards to LQTS and particularly LQT2 three
modulators standout: sex hormones extracellular K+ and adrenergic stimulation (Roden, 1998,
2006). The latter is discussed below as it has most relevance to this thesis.
Adrenergic
To increase cardiac performance for the flight-or-fight response the sympathetic nervous
system accelerates heart rate and increases contractility amongst other effects (Lymperopoulos
et al., 2013). The positive chronotropy and inotropy upon adrenergic stimulation occurs through
mainly β1–adrenergic receptor (β1AR) mediated adenosine 3´,5´-monophosphate (cAMP) and
cAMP-dependent protein kinase (PKA) modulation of HCN channels, L-type calcium channels
and Ca2+ handling  proteins  e.g.  RyR,  SERCA and CaMKII.  Similar  modulation  of  IKs brings
about  a  concomitant  shortening  of  the  cardiac  APD,  i.e.  rate-dependent  adaptation,  to  ensure
diastolic  filling  time  (Harmati  et  al.,  2011;  Terrenoire  et  al.,  2005).  The  role  of  IKr is  not  so
clear, e.g. following βAR activation IKr either increases (Balijepalli et al., 2012; Harmati et al.,
2011; Heath and Terrar, 2000) or decreases (Karle et al., 2002). Most recently IKr evoked in AP
clamp from guinea pig ventricular myocytes was shown to be largely insensitive to
32
isoproterenol,  while the augmentation of IKs resulted in it becoming the dominant repolarising
current (Banyasz et al., 2014).
While it was controversial (Cui et al., 2000, 2001; Sanguinetti et al., 1995), cAMP (or
cGMP) does not directly modulate hERG1 as the site in the cNBD, the β-roll cavity, is
negatively charged and occupied by a unique β9-strand (Brelidze et al., 2009, 2013; Li et al.,
2016). However a number of components within the β–adrenergic signalling pathway have a
direct action on the hERG1 channel complex. The hERG1 subunit contains four PKA
phosphorylation sites with phosphorylation of the channel resulting in a reduction of current
amplitude, a depolarising shift in the voltage-dependence of activation and an acceleration of
deactivation (Cui et al., 2000; Thomas et al., 1999). This regulation is mediated by A-kinase
anchoring proteins (AKAP) that target PKA to hERG, though which AKAP and how remains
unknown (Li et al., 2008). Furthermore PKA phosphorylated hERG1 channels can interact with
14-3-3 proteins (Kagan et al., 2002). These proteins exist as dimers and bind to a
phosphorylated PKA site in both the N- and C-termini of hERG1 resulting in inter- and
intrasubunit cross-linking. Consequently there is a hyperpolarising shift in the voltage-
dependence of activation, an acceleration of the activation rate and a prolongation of the
phosphorylation state (Choe et al., 2006; Kagan et al., 2002). However a determinant of this
association and thus whether the IhERG has a 14-3-3 or PKA phenotype is the local concentration
of free 14-3-3 with hERG1 competing against other targets including the β1–adrenoceptor itself
(Tutor et al., 2006).
Adrenergic activity also stimulates the cardiac α1A–adrenoceptor which, like other Gαq-
coupled receptors such as metabotropic glutamate, angiotensin II, endothelin and muscarinic
receptors (Cockerill et al., 2007; Hirdes et al., 2009; Kruse and Hille, 2013; Magyar et al.,
2000; Niculescu et al., 2013; Selyanko et al., 1999; Y. Wang et al., 2008), leads to inhibition of
IKr/IhERG (Bian et al., 2001, 2004; Thomas et al., 2004; Wang et al., 2009; Zankov et al., 2009).
The subsequent Gαq-protein activation of phospholipase C results in hydrolysis of PIP2 into the
second messengers inositol 1,4,5-phosphate and diacylglycerol (DAG) (Lymperopoulos et al.,
2013). The consumption of PIP2 decreases hERG1 current density, though in the heart this may
have little effect as PIP2 resynthesis can keep up with its breakdown (Bian et al., 2001; Kruse
and Hille, 2013; Rodriguez et al., 2010). PIP2 binds to a polycationic region in the C-terminus
(Bian et al., 2004) and appears to act on a late voltage-independent transition stabilising the
hERG1 open state (Rodriguez et al., 2010). DAG and/or the rise in Ca2+i activates protein
kinase C (PKC), which can directly phosphorylate sites on the hERG1 N-terminus (Cockerill et
al., 2007; Gómez-Varela et al., 2003). Though different to the PKA sites, PKC causes similar
effects on hERG1 functioning (Barros et al., 1998; Cockerill et al., 2007; Thomas et al., 2003).
The effect of PKC activation on ventricular myocyte IKr however varies in different reports
(Bian et al., 2004; Heath and Terrar, 2000; Wang et al., 2009).
In e.g. HF there is a chronic elevation in sympathetic activity as well as other
neurohormonal mechanisms (e.g. renin-angiotensin system) in an effort to compensate for the
decreased cardiac function (Lymperopoulos et al., 2013; Michael et al., 2009). Over time as
cardiac function cannot be maintained it becomes counterproductive with β1AR selectively
down-regulated, β2AR signalling altered and the presynaptic α2AR autoinhibitory feedback lost
(Lymperopoulos et al., 2013). In chronic HF β–blockers are the therapeutic mainstay
substantially reducing mortality. The inhibitory effect of β2–adrenergic stimulation on IKr was
shown to be enhanced in a guinea-pig HF model (H. Wang et al., 2012). However, though
evidence in disease states is lacking, chronic β– and α-adrenergic stimulation results in
augmentation of native and heterologously expressed ERG1 protein, but not other cardiac K+
channel proteins (Chen et al., 2009, 2010). The increase in hERG1 protein is due to enhanced
translation, as a consequence of kinase phosphorylation of the protein, and produces an increase
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in IhERG. There is partial overlap of the PKC and PKA phosphorylation sites involved and cross-
talk between the pathways (Chen et al., 2010), though the identity of the mechanisms and the
co-factor(s)  remains  unknown  (Krishnan  et  al.,  2012).  However  PKC,  possibly  a  different
isoform, is involved in the loss of surface hERG protein, due to enhanced proteasomal
degradation, that occurs with chronic angiotensin II exposure (Cai et al., 2014).
2.3 hERG1 AND THE HEART: PATHOPHYSIOLOGY
The importance of hERG1 to cardiac function is underscored by the association of its
mutation, both loss- and gain-of-function, and inhibition by drugs with QT interval changes,
tachycardia and sudden cardiac death (Bhuiyan et al., 2008; Brugada et al., 2004; De Bruin et
al., 2005; van Noord et al., 2011).
2.3.1 CONGENITAL LQTS
Congenital LQTS often presents in an otherwise healthy young individual (termed the
proband) as unexplained syncope or seizures, though for a significant portion (13%) the first
manifestion is cardiac arrest and sudden death (Priori et al., 2003; Tester and Ackerman, 2007).
Approximately 10-15 % of sudden infant death syndrome (SIDS) and ~20 % of sudden
unexplained death (SUD) in the young may be caused by LQTS (Arnestad et al., 2007;
Gladding et al., 2010; Tester and Ackerman, 2007; Tester et al., 2012; D. Wang et al., 2014).
The prevalence of congenital LQTS was estimated to be at least 1 in 2534 apparently healthy
live births (Schwartz et al., 2009), though in some populations it is higher (Lahtinen et al.,
2013). In line with such prevalence is the relatively common occurrence (5-11 % of carriers) of
multiple  (≥2)  mutations,  i.e.  compound,  in  the  same  or  different  LQTS  genes,  and  rarely
homozygous mutations (Itoh et al., 2010; Kapplinger et al., 2009; Lieve et al., 2013; Napolitano
et al., 2005; Stattin et al., 2012; Tester et al., 2005). While inheritance of the mutation
predominates, sporadic (or de novo) mutations occurs in ≤12 % of cases (Napolitano et al.,
2005)
Mutations, predominantly missense and family specific (Christiansen et al., 2014;
Kapplinger et al., 2009; Lieve et al., 2013; Splawski et al., 2000; Tester et al., 2005), in 15
different LQTS-associated genes (Romano-Ward syndrome) have been identified (Table 1;
Schwartz et al., 2013). However loss-of-function mutations in KCNQ1 and KCNH2, the LQT1
and LQT2 genotypes respectively (Hedley et al., 2009), accounts for about two thirds of
patients with clinically definite LQTS (Napolitano et al., 2005; Tester et al., 2006).
Homozygous or compound heterozygous mutations of KCNQ1 (or KCNE1 in ~10 %) are also
the basis of Jervell and Lange-Nielsen (J-LN) syndrome, the most severe LQTS variant in
which 86 % exhibit cardiac events with 50 % occurring before 3 years of age (Schwartz et al.,
2006). LQT3, the other major LQTS susceptibility genotype, results from gain-of-function
mutations in SCN5A which encodes NaV1.5, the predominant cardiac NaV α-subunit, leading to
increased inward Na+ current that prolongs the APD (Hedley et al., 2009).
Gene Protein Frequency Pathophysiological mechanism
Major LQTS genes
KCNQ1 (LQT1/J-LN) KV7.1 47.3 ↓ IKs → ↓ adaptive QT shortening
KCNH2 (LQT2) KV11.1 33.6 ↓ IKr
SCN5A (LQT3) NaV1.5 11.6 ↑ INa-L
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Minor LQTS genes
KCNE1 KCNE1 2.5 ↓ IKs
KCNE2 KCNE2 1.2 ↓ IKr
CACNA1C CaV1.2α1 0.8 ↑ ICaL
CAV3 Caveolin-3 ↑ NaV1.5 nitrosylation → ↑ INa-L
SCN4B NaVβ4 ↑ INa-L
AKAP9 Yotiao ↓ adrenergic (PKA) regulation of IKs
SNTA1 α1-syntrophin ↑ NaV1.5 nitrosylation → ↑ INa-L
KCNJ5 Kir3.4 - ↓ IKACh
CALM1 Calmodulin - ↓ Ca2+/CaM mediated
CALM2 Calmodulin - inactivation of CaV1.2
Atypical LQTS
Ankyrin-B syndrome
ANKB Ankyrin B 0.4
Loss of anchor ↓ Na+/K+ pump & NCX
at T-tubule → ↑ Na+i & SR Ca2+ load
Andersen-Tawil
KCNJ2 Kir2.1 2.5 ↓ IK1
Timothy syndrome
CACNA1C CaV1.2α1 ↑ ICaL (impaired inactivation)
Table 1. LQTS a cardiac channelopathy: the associated genes, the protein encoded, frequency of mutation (% for
each LQT gene in the 241 single mutation positive individuals of the 855 referred for LQT1-12 genetic testing; Lieve
et al., 2013) and the proposed underlying pathopathological mechanism (Adsit et al., 2013; Curran and Mohler,
2011; Limpitikul et al., 2014; Tester and Ackerman, 2014). Many of the minor susceptibility genes encode
interacting proteins of Nav1.5, Kv7.1 &/or Kv11.1 thus mutations in e.g. AKAP9 and SNTA1 result in impairment of
IKs and  INa and so a clinical phenotype analogous to LQT1 and 3. The three atypical LQTS are multisystem
disorders, in ankyrin-B syndrome and Andersen-Tawil syndrome (formerly LQT4 and LQT7) the QT prolongation is
modest (Schwartz and Crotti, 2014). Mutations in CACNA1C yield Timothy Syndrome as well as nonsyndromic
LQTS (Boczek et al., 2013). In addition to supporting the diagnosis, the identification of the genotype enables gene-
specific management and finding of carriers through cascade screening of the proband’s relatives. Furthermore this
enables risk stratification of LQTS patients, within LQT2 the risk of life-threatening cardiac events is 17-fold greater
for those who have experienced prior syncope and have a QTc ≥ 500 ms and/or are female > 13 years than for
those with no such risk factors (Migdalovich et al., 2011). It should be noted that for ~20 % of patients with clinically
unequivocal LQTS the genetic basis is elusive, explanations for this include large deletions/duplications in KCNH2
and KCNQ1 (Eddy at al., 2008; Koopmann et al., 2006), mutations in noncoding regions (e.g. in KCNH2 as Crotti et
al., 2009a), mutation detection misses (Medlock et al., 2012), mosaicism (Priest et al., 2016) and novel LQTS genes
(Altmann et al., 2015; Reed et al., 2015).
The genotype significantly influences the clinical course of LQTS including the incidence
of life-threatening (i.e. aborted cardiac arrest and SCD) or any (inclusion of syncope) cardiac
events (Priori et al., 2003). Together with other variables like QTc and gender the risk in LQTS
is modulated. Thus for instance, in LQT2 the risk of life-threatening cardiac events for females
after adolescence is more than double that of males (Migdalovich et al., 2011). Furthermore
while the risk for any cardiac event is reduced in pregnancy, it as well as the risk of life-
threatening events is increased (3 and 4-fold) during the 9-month postpartum period (Seth et al.,
2007). This is primarily among LQT2 women, the rate being ~4-fold greater than that for
LQT1.
The majority of LQT1 and approximately half of LQT2 and LQT3 individuals experience
no cardiac events (Priori et al., 2003). Furthermore 25 % of LQT1-3 mutation carriers exhibit a
normal QTc (silent or subclinical mutation carriers) and though their risk for life-threatening
cardiac events is significantly less (4 % vs 15 % over the first 40 years of life) it is still 10-fold
greater than wild-type (WT) family members (Goldenberg et al., 2011). Thus LQTS displays
incomplete penetrance i.e. expression of the clinical phenotype can vary between and within
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families carrying the same pathogenic mutation so carriers may either be symptomatic (with
variable expressivity) or asymptomatic (Priori et al., 1999). This variable penetrance and
expressivity is exemplified by KCNQ1 A341V which, due to a common ancestral origin
(founder effect), occurs in over 25 South African LQTS families (Brink and Schwartz, 2009).
Underlying this phenomenon is the heterogeneity of the repolarisation reserve. In addition to
established repolarisation reserve modifiers (e.g. gender, hypokalaemia and use of QTc
prolonging drugs) are the increasing explored common genetic variants. Preeminent in this
regard are SNPs in noncoding regions of NOS1AP, the gene encoding nitric oxide synthase 1
adaptor protein, which are shown to modulate the QT interval and risk of life-threatening events
in e.g. the KCNQ1 A341V founder population and LQT2 (Crotti et al., 2009b; Earle et al.,
2014; Kolder et al., 2015; Tomás et al., 2010). Another genetic modifier mechanism is
compound mutations; these LQTS patients exhibit a longer QTc and more severe phenotype
(Itoh et al., 2010; Mullally et al., 2013). Analogously a severe LQTS phenotype associated with
a  KCNQ1  mutation  may  arise  from  a  disruption  of  the  hERG  chaperone  effect, in vivo
transfection of KCNQ1 T587M into adult guinea pig myocardium results in a large reduction in
IKr (Biliczki et al., 2009).
The  triggering  of  cardiac  events  exhibits  genotype  specificity  so  in  LQT1 (and  J-LN)  the
majority occur during exercise (e.g. swimming) while in LQT3 it is during sleep/rest (Schwartz
et al., 2001, 2006), which correlates with the high prevalence of SCN5A mutations in SIDS
(Arnestad et al., 2007; D. Wang et al., 2014). In LQT2 the most common trigger is emotional
stress, such as anger and sudden arousal from sleep by an alarm clock or ringing of telephone,
where there is an abrupt neural release of noradrenaline while the vagal tone is high (heart rate
is low) which impairs the required QT shortening (Schwartz et al., 2001; Wilde et al., 1999).
This trigger likely contributes to the predominance of LQT2 in postpartum cardiac events (Seth
et al., 2007). Furthermore in LQT2 the risk for arousal-triggered cardiac events is higher in
women likely a consequence of gender differences in the repolarisation reserve and the baseline
autonomic tone (Kim et al., 2010). While the adrenergic regulation of LQT2 mutant channels
may be unaltered, the α1A–adrenoceptor mediated reduction in IKr may underlie this link
(Zankov et al., 2009). Another potential mechanism is hyperexcitability in the sympathetic
outflow to the heart and/or increase in circulating catecholamines as ERG1 is present in
peripheral sympathetic ganglia and the adrenal glands (Gullo et al., 2003; Shi et al., 1997). The
rapid onset, within 10s, would preclude a systemic effect though evidence for hERG affecting
cardiac autonomic control was recently reported. Inhibition of hERG was shown to enhance the
endogenous parasympathetic rhythms (i.e. high frequency oscillations) of heart rate which
increased the short-term variability in QT interval and led to triggering of TdP in cynomolgus
monkeys (Champeroux et al., 2015).
As sudden sympathetic activity is the predominant trigger the first line and mainstay
treatment for prevention of cardiac events in LQT2 (as with the other forms, whether the patient
is symptomatic or not) is β-blocker pharmacotherapy e.g. propranolol (Schwartz and Crotti,
2014). Though beneficial in LQT2 (Seth et al., 2007), β-blockers are less efficacious than in
LQT1 due to associated bradycardia (Migdalovich et al., 2011; Priori et al., 2004). For those
who remain symptomatic despite β-blocker therapy, another antiadrenergic strategy left cardiac
sympathetic denervation (where the lower ⅔ of the left stellate ganglion and the thoracic
ganglia T2-T4 are ablated) is adjunctly implemented and/or an implantable cardioverter
defibrillator used (Mizusawa et al., 2014). The latter alternative, which does not prevent
arrhythmias but acts as a safety net, is immediately implanted in cases of cardiac arrest
(Schwartz and Crotti, 2014). Additional LQT2 management approaches include K+




Loss-of-function mutations in hERG1 underlie ~37 % of LQTS (Kapplinger et al., 2009;
Lieve et al., 2013; Napolitano et al., 2005; Tester et al., 2005) and are an etiology of
intrauterine foetal death (Bhuiyan et al., 2008; Crotti et al., 2013), SIDS (accounting for ~1 %;
Arnestad et al., 2007) and SUD (where it accounts for ~4 %; Tester et al., 2012).
Approximately 600 LQT2-associated mutations are reported (Human Genetic Mutation
Database, http://www.hgmd.cf.ac.uk/ e.g. C. Anderson et al., 2014; Kapplinger et al., 2009;
Lieve et al., 2013; Napolitano et al., 2005; Splawski et al., 2000; Tester et al., 2005), though
many may be classified as variants of uncertain significance as their pathogenicity awaits
verification or are questionable/innocuous (Ackerman et al., 2003; Refsgaard et al., 2012).
Missense mutations are the most frequent (~62 %) followed by frameshift (~25 %) with the
remaining ~13 % consisting of nonsense, splice site, and inframe insertions/deletions
(Kapplinger et al., 2009; Shimizu et al., 2009). Mutations are located throughout the hERG1
subunit, with ~29 % in the N-terminus, ≈36 % in its transmembrane spanning region (≈73 % of
which are located within the pore domain and these are predominantly missense), and ≈35 % in
the C-terminus (Kapplinger et al., 2009; Shimizu et al., 2009). Unlike for radical mutations, the
site of the missense mutation is an important determinant of pathogenicity with subjects in
general having significantly higher cardiac event rates for mutations in the pore domain than the
termini (Kapa et al., 2009; Migdalovich et al., 2011; Shimizu et al., 2009).
Frameshift mutations, deletions and insertions likely result in premature termination codons
which, if detected and are not so early within the mRNA to enable reinitiation of translation at
in-frame downstream methionine codons (Gong et al., 2014b; Stump et al., 2012b, 2013), lead
to NMD of the mRNA (Gao et al., 2013; Gong et al., 2007; Sun et al., 2009; Zarraga et al.,
2011). NMD is predicted to occur in 161 of the 196 reported LQT2 mutations that introduce
premature termination codons (Gong et al., 2014b). Thus the production of truncated proteins
which may be nonfunctional and often have dominant negative effects is minimised resulting in
a milder heterozygous phenotype by conversion to haploinsufficiency i.e. the WT subunits are
able to form homotetrameric channels consequently there is a 50 % or less loss-of-function. A
dominant negative phenotype arises from the multimeric nature of the channel so when e.g.
N470D subunits, which are trapped in an intermediate folding state (Gong et al., 2006), or
G572S subunits assemble with WT subunits the entire channel may be retained by quality
control in the transitional ER and degraded by ERAD resulting in suppression of hERG channel
surface expression and a loss of current of up to ~90 % (Gong et al., 2004a, 2005; Smith et al.,
2011, 2013; Zhao et al., 2009). Such behaviour is common for pore domain mutations, unlike
other regions, which may explain the more severe clinical phenotype associated with this
location (C. Anderson et al., 2014).
Trafficking deficiency can arise from mutations throughout hERG1 and underlies the loss-
of-function for ~90 % of LQT2 missense mutations (C. Anderson et al., 2006, 2014), the extent
of the deficit can vary between mutations (Gianulis and Trudeau, 2011; Ke et al., 2013; Perry et
al., 2016). A subset of these mutants can be rescued by low temperature, chemical chaperones
(e.g. glycerol) and/or IKr inhibitors (C. Anderson et al., 2006, 2014; Ficker et al., 2002; Gong et
al., 2004a; Harley et al., 2012; Jones et al., 2016; Lin et al., 2010; Zhou et al., 1999). The
inhibitors  bind  to  and  stabilise  the  inner  cavity  soon  after  the  assembly  of  the  tetramer
promoting native-like folding, hence restoring protein trafficking and functional expression of
the channel (Ficker et al., 2002; Gong et al., 2006). As a therapy for mutants which also
function normally at the cell membrane, e.g. G601S (Furutani et al., 1999), it is inherently
limited, but as a prolonged corrective effect can be obtained without continual channel
inhibition a drug with a short half-life may have potential (Smith et al., 2013). Furthermore
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pharmacological rescue can occur without significant or in the absence of IhERG inhibition
(Delisle et al., 2003; Rajamani, et al., 2002). However rescued mutant channels have increased
turnover at the plasma membrane (Apaja et al., 2013; Ke et al., 2013), likely due to their innate
conformational instability e.g. G601S channels are >5-fold more sensitive to trypsinolysis
(Apaja et al., 2013).
The loss-of-function in LQT2 can arise from other mechanisms (Zhou et al., 1998b).
Mutations in splice sites can affect pre-mRNA processing resulting in intron retention and/or
use of a cryptic splice site with insertion of intronic sequence/deletion of exonic sequence
(Crotti et al., 2009a; Gong et al., 2008; Stump et al., 2011; Zhang et al., 2004). The
consequence can be a frame-shift that introduces a premature termination codon into the
transcript leading to NMD or if in-frame an approximate full length trafficking impaired protein
which has a dominant negative effect on WT subunits. Other mutations may alter channel
gating, e.g. the LQT2 mutants G584S and R56Q exhibit primarily enhanced inactivation and
accelerated deactivation respectively (Berecki et al., 2005; Gianulis and Trudeau, 2011; Zhao et
al., 2009), or permeation as with G628S where conduction is blocked by physiological [K]i (Es-
Salah-Lamoureux et al., 2011). These loss-of-function mechanisms may coexist e.g. T421M
exhibits both trafficking deficiency and closed-open state gating abnormalities (Balijepalli et
al., 2012).
2.3.2 DRUG-INDUCED LQTS
First recognised, as syncope associated, in the 1920s with the introduction of quinidine
(Roden, 2006), the potential of not only class I but class III antiarrhythmic and antianginal
drugs to induce LQTS is clear with TdP incidences of 0.5-8 % and 0-10.5 % during quinidine
and dofetilide therapy (Roden, 1998; Yap and Camm, 2003). A TdP/QTc liability is also carried
by numerous noncardiovascular drugs from a wide range of structural and therapeutic (e.g.
antipsychotics, antibiotics, antidepressants) classes (Poluzzi et al., 2009; Redfern et al., 2003;
Yap and Camm, 2003). Due to reported adverse cardiac events certain noncardiac drugs have
had prescribing information revised, been refused approval or been withdrawn from the market
(Roden, 2004; Shah, 2005; Stockbridge et al., 2013). Among the thirteen latter drugs deemed to
have an unacceptable risk/benefit ratio (i.e. prescribed for benign conditions and/or safer
alternatives available) was cisapride, a gastrointestinal prokinetic popular for the treatment of
nocturnal heartburn due to gastro-oesophageal reflux disease. In the period from its marketing
(1993) till the end of 1999 the US Food and Drug Administration (FDA) received reports of
serious cardiac adverse drug reactions (including 107 TdP and 18 VF reports) in 341 patients,
80 of whom died (Wysowski et al., 2001). The incidence of arrhythmia with cisapride was
estimated to be 1 in 120,000 patients (Ahmad and Wolfe, 1995).
Drug-induced LQTS and TdP predominantly, though not exclusively as with antimony-
based leishmaniasis treatments (Kuryshev et al., 2006) and the benign prostatic hyperplasia
medication alfuzosin (Lacerda et al., 2008), occurs through selective inhibition of the hERG1
current at relevant plasma concentrations (Table 2; Crumb et al., 2016; Lacerda et al., 2001;
Mohammad et al., 1997; Redfern et al., 2003; Roden et al., 1996). However not all drugs that
block hERG1 are associated with TdP, as exemplified by the angina drugs verapamil and
ranolazine, due to concurrent equipotent, at least, ICaL and/or  INaL inhibition which prevents
EAD formation (Table 2; Crumb et al., 2016; Kramer et al., 2013). Block of hERG1 is also
present in a large proportion of new chemical entities (NCEs i.e. a drug with no active moiety
that has regulatory approval; Lu et al., 2008; Shah, 2005) so the question arises why is the
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hERG1 channel so susceptible to direct drug blockade? The basis for this may be attributed to
various unique structural features of the hERG1 central inner cavity, the occupancy of which
obstructs ion conduction through the pore (Mitcheson et al., 2000a). Firstly the hERG1 inner
cavity is large, though the underlying explanation is unclear (Mitcheson, 2008). hERG1, like
other  members  of  the  EAG  family,  lacks  the  S6  Pro-X-Pro  motif  of  most  other  KV channels
which may kink the domain reducing the volume of and restricting access to the inner cavity
(Fernandez et al., 2004). Access to the inner cavity and the drug binding site is gained from the
cytoplasmic aspect (e.g. Rajamani et al., 2008; Zhang et al., 1999) by the opening of the
activation gate resulting in state dependence of block (Kamiya et al., 2006; Kiehn et al., 1996;
Snyders and Chaudhary, 1996; Spector et al., 1996a). The size of the hERG inner cavity is such
as to accomodate diverse structures without impediment to activation gate movement thus drugs
can be trapped upon repolarisation by closure of the gate prohibiting recovery from block
(Kamiya et al., 2006; Mitcheson et al., 2000b; Stork et al., 2007).
Table 2. Comparison of the inhibitory potencies of cardiac drugs (above the line) and noncardiac drugs withdrawn
from the market at cardiac ion channels (underlying IKr,  IKs (KCNQ1/KCNE1), Ito,  ICaL and INa), expressed in
mammalian cells. The IC50 values are given or denoted as >> insensitivity to (i.e. <10 % block)/ > maximal tested
concentration, (in µM) and were obtained using the manual patch-clamp technique. NaV1.5 refers to block of late
and/or peak current. Chronic exposure to dofetilide increases the late (and peak) INa due to PI3K pathway inhibition
affecting gating (Yang et al., 2014). * For these drugs Kir2.1 (IK1) was also measured, it was insensitive to the
maximal tested concentration and in the case of dofetilide IC50 was  98.8  µM3. § In the presence of a CYP3A4
inhibitor, otherwise FTPC is 0.3 nM. For each drug the maximal estimated effective free therapeutic plasma
concentration, FTPC, in humans is shown and the increase in QTc at FTPC is given for some drugs. # average
steady-state concentration as monotherapy and when clarithromycin coadministered since average QTc over 24 hr
were given. References: 1Crumb et al., 2016; 2Vicente et al., 2015; 3 Obejero-Paz et al., 2015; 4van Haarst et al.,
1998; 5Champeroux et al., 2011; 6Kongsamut et al., 2002; 7Katchman et al., 2002; 8Kang et al., 2003.
Secondly facing the central cavity is the S6 aromatic residues Tyr652 and Phe656, which
are absent from homologous positions in non-EAG family KV channels and when mutated in
hERG1 substantially reduce the potency of high (nM) and low (µM) affinity blockers (e.g.
Dong et al., 2013; Guo et al., 2006; Jehle et al, 2013; Kamiya et al., 2006; Lees-Miller et al.,
2000; Mitcheson et al., 2000a; Perry et al., 2004; Sánchez-Chapula et al., 2002; Takemasa et
al., 2007). A compound binds in a number of different configurations as the eight aromatic
residues of the hERG1 inner cavity offer multiple diverse potential interactions (Dempsey et al.,
2014). These are thought to include π-stacking and hydrophobic interactions, in addition for
those drugs with a protonated basic nitrogen a cation-π interaction with Y652 may occur
(Aronov, 2008; Fernandez et al., 2004). For most drugs the interaction with F656 appears the
more important (Melgari et al., 2015; Mitcheson, 2008). Interestingly F656 also interacts with
the aromatic ring of 17β-oestradiol (E2), the resulting gating modification acutely reducing
IhERG by 21 % at 3 nM (Kurokawa et al., 2008). Other less unique residues at the base of the
pore helix (the polar Thr623 and Ser624) are also differentially implicated in the binding of
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blockers (Guo et al., 2006; Kamiya et al., 2006, 2008; Mitcheson et al., 2000a; Perry et al.,
2004), though this may not be a direct interaction (Dempsey et al., 2014).
These pore features are conserved within the EAG and ERG subfamilies, though hELK2
(KV12.2) lacks an aromatic residue and is >1000-fold less sensitive than hERG1 to dofetilide
and astemizole (Becchetti et al., 2002). While the difference from hEAG1 (KV10.1), which is
e.g. 57-fold less sensitive to E-4031 (Gessner and Heinemann, 2003), is suggested to arise from
the orientation of the aromatic residues with respect to the cavity. In hERG1 these may be
optimally positioned for interaction through the rotation of S6 that precedes inactivation state
entry (Chen et al., 2002; Lin et al., 2005; Stansfeld et al., 2007). Inactivation is absent from
EAG, but linked to the binding affinity of some drugs (Ficker et al., 1998, 2001; Gerlach et al.,
2010; Gomez-Varela et al., 2006; Guo et al., 2006; McPate et al., 2008; Perrin et al., 2008;
Ulens and Tytgat, 2000; Wang et al., 1997b; Yang et al., 2004).
Other binding determinants for hERG blockers (e.g. F557 in S5; Saxena et al., 2016) and
secondary drug binding sites may exist as neither S6 aromatic residue is critical for block by the
antidepressant fluvoxamine, the high affinity antiarrhythmic dronedarone or the macrolide
antibiotic erythromycin (Duncan et al., 2006; Milnes et al., 2003a; Ridley et al., 2004).
Erythromycin was proposed to bind externally, with occupancy of the site allosterically
affecting the inner cavity binding site (Crumb, 2014). A similar negative allosteric effect on the
affinity of classical inhibitors is also seen with recent novel compounds (Yu et al., 2016). The
most prominent external binders are peptide toxins e.g. BeKm-1, from the scorpion Buthus
eupeus, which binds to the outer vestibule of the hERG1 channel (Tseng et al., 2007).
Furthermore the S5-P linker was also proposed as the binding site for anti-Ro/SSA antibodies,
which can arise in the course of autoimmune diseases such as Sjögren syndrome and systemic
lupus erythematosus but are also present in the general population (Lazzerini et al., 2016; Yue
et al., 2015). The resulting off-target direct inhibition of hERG1 current by these antibodies
underlies a novel acquired autoimmune-associated LQTS in adults and may act as risk factor.
Another mechanism underlying drug-induced LQTS is disruption of hERG1 channel
trafficking (Ficker et al., 2004), emulating the congenital LQT2 mechanism. Pentamidine, an
antiprotozoal drug, is associated with LQTS/TdP as prolonged exposure selectively reduces
hERG1 channel surface expression due to occupancy of the conventional drug binding site in a
folding intermediate which arrests its maturation (Cordes et al., 2005; Dennis et al., 2012;
Kuryshev et al., 2005). Pentamidine, like cardiac glycosides e.g. digoxin (Wang et al., 2007)
which are used in the treatment of congestive HF and also disrupt hERG1 trafficking, has little
acute effect on hERG1 with its IC50 being >450-fold the therapeutic free concentration (Cordes
et al., 2005). For cardiac glycosides, which inhibit the Na+/K+ pump, it is proposed that the
depletion of [K+]i induces conformational changes in hERG originating from the normally K+
stabilised selectivity filter (L. Wang et al., 2009). The structural destabilisation of hERG
induced by low [K+]i also accelerates turnover at the plasma membrane by the peripheral
quality control machinery (Apaja et al., 2013). Though appearing to be a trafficking blocker
probucol is different (J. Guo et al., 2007, 2011a). Instead of blocking the forward trafficking of
hERG1 the disruption of the cholesterol level by the drug destabilises and accelerates surface
membrane  caveolin  turnover  and  concomitantly,  due  to  their  physical  association,  hERG1
degradation (Guo et al., 2011a). Importantly a number of direct hERG1 blockers (e.g. the
antidepressant fluoxetine and the antifungal ketoconazole) also exhibit, in a similar
concentration range, trafficking hERG1 inhibition (Rajamani et al., 2006; Takemasa et al.,
2007).
The incidence of drug-induced LQTS/TdP has been estimated at 3.2 per million per year
(Sarganas et al., 2014). Thus drug-induced TdP is a rare event arising in only a subset of
patients e.g. with methadone maintenance 16 % and 4 % were reported to have respectively a
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QTc of ≥500ms and TdP (Ehret et al., 2006). Prior to and after washout of drug the QTc
interval may appear normal (Itoh et al., 2009a; Napolitano et al., 2000; Paulussen et al., 2004),
furthermore TdP may occur after weeks or months of drug treatment (Pratt et al., 2006; Zeltser
et al., 2003). This reinforces the supposition that evolving/existing subclinical decrements to the
repolarisation reserve, due to e.g. hypokalaemia, HF, and female gender, underlies the
predisposition of an individual (Roden, 1998, 2006; Sarganas et al., 2014; Zeltser et al., 2003).
In addition to decreasing IKr and IK1, hypokalaemia potentiates the block of hERG1 by some,
but not all (Guo et al., 2006; Pareja et al., 2013), drugs (Wang et al., 1997b; Yang et al., 2004).
The mechanisms underlying the differential sensitivity of drugs, e.g. due to trapping by closure
of the activation gate, or the potassium dependency of block, e.g. via enhancement of
inactivation, are not clear. Similarly, as well as their genomic and non-genomic effects on
cardiac electrophysiology, sex hormones may influence hERG1 drug sensitivity, e.g. E2
enhances E-4031 and erythromycin inhibition (Ando et al., 2011; Kurokawa et al., 2008), and
contribute to the gender-related difference in drug-induced LQTS/TdP (van Noord et al., 2011).
A common feature in terfenadine and cisapride induced LQTS cases was the concomitant
administration of other substrates, such as erythromycin, of their metabolizing cytochrome
P450 isoenzyme (CYP3A4), this pharmacokinetic interaction led to an increase in the drug
plasma concentration (Roden, 2006; Wysowski et al., 2001). Pharmacogenetic variables in
drug-induced LQTS exist (Kannankeril et al., 2005) including an increased burden of K+
channel LQTS gene rare variants (Ramirez et al., 2013; Weeke et al., 2014), subclinical or
latent LQTS mutations (e.g. Donger et al., 1997; Itoh et al., 2009a; Napolitano et al., 2000;
Yang  et  al.,  2002)  and  SNPs e.g. in NOS1AP (Jamshidi et al., 2012), the metabolising CYP
isozymes (Eap et al., 2007; Roden, 2006) and KCNEs (Paulussen et al., 2004; Weeke et al.,
2014). While the sensitivity of hERG1 towards a culprit drug is unaltered for those cases
involving its mutation (Bellocq et al., 2004; Itoh et al., 2009a), this is not necessarily so when
coexpressed with variants of KCNE1 and KCNE2 (Abbott et al., 1999; Du et al., 2013;
Friederich et al., 2004; Sesti et al., 2000). For example the IhERG inhibitory effect of cisapride
was enhanced (the IC50 halved) by hERG-KCNE1 D85N, whereas quinidine potency was
unaffected (Du et al., 2013). It is unknown how these variants can affect the drug binding site
and  why  drugs  are  differentially  affected.  So  in  addition  to  possibly  reducing  IKs and the
repolarisation reserve, KCNE1 D85N reduces IKr (Du et al., 2013; Nishio et al., 2009; Nof et
al., 2011) and for some drugs may directly increase susceptibility to inhibition (Du et al., 2013).
KCNE1 D85N was associated with a 9-fold risk for drug-induced TdP (Kääb et al., 2012).
2.3.3 hERG1 GAIN-OF-FUNCTION
Congenital short QT syndrome (SQTS) was first described as an inherited clinical entity by
Gussak et al. (2000). It is characterised by a constantly shortened QTc (QTc ≤340 ms or ≤360
ms with symptomaticity or family history) and poor rate adaptation of the QT interval as well as
risk of syncope, AF, cardiac arrest and sudden death (Giustetto et al., 2011; Mazzanti et al.,
2014). Underlying the symptoms is an abbreviation of myocardial repolarisation, both in the
atria and ventricles, and consequently the effective refractory period which then provides a
substrate for re-entry resulting in atrial and ventricular tachyarrhythmias including VF which is
invariably fatal. The probability of cardiac arrest by 40 years of age is 40-50 % with recurrence
in ⅔ of the survivors and since e.g. the degree of QTc shortening does not predict risk an
implantable cardioverter defibrillator is the primary therapy (Mazzanti et al., 2014).
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A gain-of-function mutation (N588K, located in the α-helix of the S5-P linker) of hERG1
was  the  first  identified  in  SQTS  (Brugada  et  al.,  2004).  The  primary  functional  effect  of  the
mutation is to abolish inactivation within the physiological range of membrane potentials, as the
V½inact shifts by >+100 mV (Cordeiro et al., 2005; Grunnet et al., 2008; Perrin et al., 2008),
leading to greater IhERG in the plateau phase and overall a dome-shaped current profile during a
ventricular AP (Brugada et al., 2004; McPate et al., 2005). The potency of blockers, e.g. sotalol,
dofetilide and cisapride, is also decreased, though those with less affinity for the inactivated
state, such as disopyramide and quinidine, may have therapeutic value (McPate et al., 2006,
2008; Perrin et al., 2008; Schimpf et al., 2007; Wolpert et al., 2005). Other hERG1 (SQT1)
mutations (E50D, I560T and T618I) were subsequently identified (El Harchi et al., 2012;
Harrell et al., 2015; Hu et al., 2011; Martinez et al., 2011; Y. Sun et al., 2011). These later
mutations also augment the current density on depolarisation and shift, though to a lesser extent
(from +12 to +49 mV), steady-state inactivation.
So far gain-of-function mutations in two other K+ channel genes (KCNQ1 and KCNJ2) have
also been associated with SQTS (SQT2 and 3; Schwartz and Crotti, 2014). Additionally a
mixed SQT/Brugada phenotype results from loss-of-function mutations to the  L-type  Ca2+
channel subunit genes CACNA1C and CACNB2b (SQT4 and 5; Antzelevitch et al., 2007).
However,  none  of  the  SQT  genotypes  accounts  for  >5  %  of  the  clinically  affected  probands
(Mazzanti et al., 2014). A genotype-phenotype correlation is becoming apparent e.g.
manifestation  occurs  later  in  SQT1  than  the  other  genotypes  and  penetrance  appears  to  be
higher for SQT1-3 (Harrell et al., 2015). Though as with LQTS, the clinical phenotype is
variable even with the same mutation (e.g. N588K in KCNH2) between patients and in families
ranging from asymptomatic through to only AF or AF and VT to sudden death/SIDS (Brugada
et al., 2004; Hong et al., 2005; Suzuki et al., 2014). Recently mutation of SLC22A5, an organic
cation transporter, which results in reduced cellular uptake of carnitine was also shown to
induce SQTS (Roussel et al., 2016).
Several hERG1 agonists have been identified which exhibit distinct mechanisms of action
(Sanguinetti, 2014): slowing of deactivation (e.g. RPR260243; Kang et al., 2005), depolarising
shift in the voltage dependence of inactivation (e.g. ICA-105574; Gerlach et al., 2010),
hyperpolarising shift in the voltage dependence of activation (e.g. mallotoxin) and increased
channel open probability (e.g. PD-118057). Most agonists including those listed affect multiple
gating properties, typically at µM concentrations. Though their primary gating effects differ, the
hERG1 agonists so far investigated interact with a similar region of the pore domain at
overlapping but not identical residues (Sanguinetti, 2014). The putative binding site is a
hydrophobic pocket between two adjacent subunits, i.e. distinct from the antagonist inner cavity
binding site, and occupancy of all four sites in the channel is required for maximal achievement
of the primary effect (Garg et al., 2011; Sanguinetti, 2014; Wu et al., 2015). Also the
conformational changes induced by agonist binding appear to be restricted by N-terminal
interactions with the pore domain since the effects of agonists are more pronounced with
ERG1b channels (Larsen et al., 2010b; Schuster et al., 2011).
hERG1 agonists were proposed as a novel pharmacotherapy for LQTS (Bentzen et al.,
2011; H. Zhang et al., 2012). However excessive shortening of APD and refractoriness is a real
safety concern as some of these agonists, at least in ex vivo preparations, can produce AF or VT
and VF (Bentzen et al., 2011; Lu et al., 2008; Nof et al., 2010a; Patel and Antzelevitch, 2008).
Other reported hERG agonist effects include an increase in heart rate and slowing of conduction
which also shortens the cardiac wavelength increasing the risk for reentry arrhythmia (Bentzen
et al., 2011; Larsen et al., 2010a). Furthermore it is interesting to note that the tail IhERG was
enhanced  when  exposed  to  the  serum  of  HF  patients  with  a  history  of  VT/VF,  but  not  with
serum  of  HF  patients  without  VT/VF,  compared  to  control  (Sugiyama  et  al.,  2011).  The
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emergence of hERG1 agonists and other APD/QT shortening compounds in preclinical
pharmaceutical development has led to debate of the potential significance for NCEs and
clinically used drugs (Holbrook et al., 2009; Lu et al., 2008; Shah, 2010). The incidence of
drug-induced SQT is unknown, possibly in part due its malignancy, but is occasionally
associated  with  digitalis  toxicity  (Garberoglio  et  al.,  2007).  In  the  FDA  Adverse  Event
Reporting System (2004-2010) there were 42 cases of QT-interval shortening (cf 5323 QT
prolongation reports) of which 83 % were associated with arrhythmia related events (Raschi et
al., 2011). The most suspected drugs were paracetamol, digoxin and ziprasidone but there are
inherent data issues (e.g. evaluation of causality). The present deficit in understanding along
with the generally heightened concerns of a drug’s proarrhythmic potential and risk adverse
environment has made for a cautious approach to drug-induced SQT by both the companies and
regulatory authorities (Himmel and Hoffmann, 2010; Holbrook et al., 2009; Shah, 2010). A
noteable exception is rufinamide, which at therapeutic dose shortens QTc by a mean of up to 20
ms, approved in 2007/2008 as an antiepileptic add-on drug in Lennox-Gastaut syndrome
(Schimpf et al., 2012; Shah, 2010).
2.3.4 ATRIAL FIBRILLATION AND BRUGADA SYNDROME
AF  is  the  most  common  clinical  arrhythmia  with  a  prevalence  of  1  –  2  %  in  the  general
population and is associated with significant morbidity and mortality due to risk of stroke and
worsening HF (Andrade et al., 2014). AF and particularly the subgroup of lone AF, i.e. AF
without any apparent cardiovascular disease, have a significant genetic basis. Nine common
non-coding SNPs and many monogenic mutations, including both loss-of-function and
particularly gain-of-function in a number of K+ channel subunits e.g. KCNQ1, KCNA5 and
KCNEs, have been identified (Hayashi et al., 2015; Olesen et al., 2014a). In LQTS, where atrial
APD can also be prolonged, the prevalence of early onset AF is 1.7 % which is ~20 times the
expected background, the susceptibility mediated by an atrial torsade mechanism (Johnson et
al., 2008; Kirchhof et al., 2003). LQT2 mutations, e.g. E939X, and hERG1 gain-of-function
mutations, e.g. T895M and the SQTS mutation N588K, can cause paroxysmal or persistant AF
and atrial tachycardia (Hayashi et al., 2015; Hong et al., 2005; Kirchhof et al., 2000, 2003).
However such monogenic causes of AF are scarce (Andreasen et al., 2013) and other sources
must contribute to the complex heritability. One source may be the presence and interaction
(epistatic effects) of rare variants in K+ channel and other AF candidate genes, their frequency
being significantly higher in AF (Mann et al., 2012; Olesen et al., 2014b). While individually
the variants may have a modest effect (e.g. E444K in hERG1), in combination with common
variants the net effect though could be substantial but this total variant burden is difficult to
predict/show pathogenicity (Mann et al., 2012; Weeke et al., 2015).
Gain-of-function hERG1 mutations are also associated with Brugada syndrome (BrS), a
heritable arrhythmia disorder characterised by ST-segment elevation and male predominance
(Schwartz et al., 2013). While loss-of-function SCN5A mutations are the major (20-25 %)
cause, hERG1 mutations were found in 1.7 % of a population of BrS probands (Q. Wang et al.,
2014).  These  patients  also,  mostly,  exhibit  a  shortened  QTc interval.  The  six hERG1 variants
thus far identified all reside in either the N- or C-termini and increase IhERG density without the
SQT1 depolarising shift in V½inact (Itoh et al., 2009b; Verkerk et al., 2005; Q. Wang et al.,
2014). While not causative, these variants likely act as modifiers of BrS with simulation studies
showing a larger transient IhERG elicited by the upstroke resulting in a loss of the epicardial AP
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dome in the right ventricle, a key mechanism in BrS, at faster stimulation rates (Verkerk et al.,
2005; Wilders and Verkerk, 2010).
2.4 EXTRA-CARDIAC hERG: PHYSIOLOGY & PATHOPHYSIOLOGY
2.4.1 THE NERVOUS SYSTEM
IKr is found in mouse cerebellar Purkinje neurones, mouse embryonic GABAergic spinal
ventral interneurones, rat embryonic serotonergic neurones, mouse mitral/tufted olfactory bulb
neurones, mouse vestibular nucleus neurones, mouse vomeronasal neurones and mouse (but not
rat) auditory brainstem neurones (Furlan et al., 2005; Hagendorf et al., 2009; Hardman and
Forsythe, 2009; Hirdes et al., 2005, 2009; Niculescu et al., 2013; Pessia et al., 2008; Sacco et
al., 2003). The neuronal IKr displays both functional and temporal diversity to tailor to the needs
thus it may activate and deactivate faster, the latter by 5-fold, than or be similar to IERG1a
(Hirdes et al., 2005, 2009; Sacco et al. 2003). Moreover in basal vomeronasal neurones
expression of ERG1 (mRNA and protein) and IKr is increased with pheromone exposure, along
with a concomitant alteration of the slopes of both activation and availability curves and slower
deactivation as the relative composition of subunits (ERG1a/b:ERG3:KCNE2) changes
(Hagendorf et al., 2009). Similar changes in IKr, which results from heteromeric ERG1/ERG3
channels, occur in auditory brainstem neurones as IKr increases with age (Hardman and
Forsythe, 2009).
Due to the short duration (~1 ms) of the action potential and its slow activation, IKr has little
effect on the resting membrane potential, shape or duration of individual neuronal action
potentials (Hardman and Forsythe, 2009; Pessia et al., 2008; Sacco et al., 2003). However with
repetitive or prolonged depolarisation, such as the postsynaptic complex spike of the adult
Purkinje neurone, channels begin to accumulate in the open state due to the slow deactivation
kinetics of IKr at the resting membrane potential resulting in mounting, sustained current (Sacco
et al., 2003; Schönherr et al., 1999). This can then contribute to repolarisation and to the
gradual termination of the burst of evoked action potentials, spike frequency adaptation (Chiesa
et al., 1997; Sacco et al., 2003; Schönherr et al., 1999). Thus for many of the neuronal cell types
described IKr inhibition increases firing frequency and the firing pattern becomes repetitive,
non-adapting (Furlan et al., 2007; Hardman and Forsythe, 2009; Pessia et al., 2008; Sacco et al.,
2003). In neonatal Purkinje and rat midbrain dopaminergic neurones IKr appears though not to
play a part in spike frequency adaptation but in respectively setting the action potential
threshold, due to the temporary abundance of ERG3, and in the slow afterhyperpolarisation
following a long lasting depolarising stimulus (Nedergaard, 2004; Niculescu et al., 2013).  Thus
in these dopaminergic neurones its major role in vivo is to control the incidence and mean
frequency of bursting activity (Ji et al., 2012; Nedergaard, 2004). Furthermore during
spontaneous firing in these cells (which is ~3 Hz) and others IKr is active, due to the pacemaker
induced depolarisation traversing the activation threshold and only partial deactivation
occurring during the hyperpolarised state between the action potentials, thus its block removes
inhibitory drive on the pacemaker activity increasing the resting firing frequency (Ji et al.,
2012; Nedergaard, 2004; Pessia et al. 2008).
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 IERG1 is found in rat hippocampal astrocytes with its blockade increasing the basal and the
neuronal activity induced [K+]o so that, together with inward rectifier currents, it appears to play
a role in the voltage dependent buffering by glia of the extraneuronal space [K+] (Emmi et al.,
2000). However Fano et al. (2012) reported E-4031 had no effect on [K+]o. IKr is also present in
rat microglia and the intermediate cells of the stria vascularis with ERG1 protein expressed in
these and other cells (e.g. hair cells) of the mouse inner ear (Nie et al., 2005; Zhou et al., 1998).
Only ERG1 transcript, according to single-cell RT-PCR, and its protein are expressed and
functional in the cell bodies, but not the axon terminals, of horizontal cells of the mouse retina
(Feigenspan et al., 2009). In these cells IKr controls the depolarised (-33 mV) resting membrane
potential that occurs in the dark due to the constant presynaptic glutamate release from
photoreceptors. However in a subsequent study ERG1 protein was not found in horizontal cells
but to be abundant particularly in rod bipolar cells and photoreceptors (Cordeiro et al., 2011).
In the anterior pituitary both gonadotropes and lactotropes exhibit IKr which contributes to
the maintenance of the resting membrane potential (Bauer et al., 1999; Hirdes et al., 2010).
Thyrotropin-releasing hormone (TRH) and gonadotropin-releasing hormone, via G protein
coupled receptor phospholipase C activation and the former at least by a pathway independent
of PKA and PKC, inhibit IKr by decreasing the maximal current amplitude and a depolarising
shift in the activation curve (Hirdes et al., 2010; Schäfer et al., 1999; Schledermann et al.,
2001). This leads to depolarisation of the lactotrope and gonadotrope, calcium influx and
stimulation of prolactin and luteinizing hormone secretion (Bauer et al., 1999; Hirdes et al.,
2010). Furthermore in corticotrophs IKr underlies the delayed glucocorticoid inhibition of
adrenocorticotropin release, which may involve upregulation of ERG1 mRNA (Yamashita et
al., 2009).
LQTS  when  evident  as  syncope  and  seizures  has  often  been  initially  misdiagnosed  as
epilepsy and retrospectively ascribed in cases of sudden unexplained death in epilepsy3
(MacCormick et al., 2009; Tu et al., 2011). However, seizure is 3-fold more prevalent in LQTS
(even with β-blocker use) with the highest prevalence occurring in LQT2 patients (Auerbach et
al., 2016; Johnson et al., 2009). This suggests that rather than seizures being cardiogenic in
origin there may be a relationship between hERG1 mutation and neuronal hyperexcitability,
that LQT2 and epilepsy could coexist as highlighted by case reports (Anderson et al., 2012;
Partemi et al., 2013; Zamorano-León et al., 2012). The prevalence of concomitant epilepsy
(electroencephalogram-documented) and LQT2 was found to be 3.7 %, significantly greater
than the other LQT subtypes (J. Anderson et al., 2014). In addition a pilot study showed that
abnormal EEG activity, indicative of cortical hyperexcitability, was more frequent in LQT2
(and LQT1) individuals than healthy controls (Haugaa et al., 2013). A mechanism for hERG1
involvement in seizure susceptibility of temporal lobe origin could be through impairment of its
role in potassium homeostasis by hippocampal glia which would result in accumulation of
[K+]o, known to be pro-epileptogenic (Emmi et al., 2000). Alternatively ERG channel inhibition
was also shown to enhance stimulus-induced and neuronal excitability in the hippocampus
(Fano et al., 2012).
Many first and second generation antipsychotics inhibit hERG1 (and when tested hERG3)
at concentrations comparable to the affinities of these compounds for dopamine D2 and 5-HT2A
receptors, the antagonism of one or both of which is believed to underlie therapeutic efficacy
(Kang et al., 2001a; Kongsamut et al., 2002; Shepard et al., 2007). It raises the question of
3 Though what role antiepileptic drugs have in sudden unexplained death in epilepsy is subject to debate (Hesdorffer and Tomson,
2013), they can block hERG at clinically relevant concentrations and reduce hippocampal ERG protein expression (Danielsson et
al., 2005; Heo and Kang, 2012).
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whether  block  of  CNS  IKr contributes  to  their  therapeutic  action  or  neurological  side  effects.
One side effect is hyperprolactinaemia which though attributed to dopamine receptor
antagonism, dopamine being an inhibitor of prolactin secretion, may also result from block of
native lactotroph IKr (Bauer et al., 1999, 2003; Cookson et al., 2012).
An increased incidence of schizophrenia and related intermediate phenotypes (cognitive
deficits, hippocampal volume reduction and inefficient information processing in healthy
controls) was shown to be significantly associated with SNPs within intron 2 of hERG1
(Huffaker et al., 2009). For the one SNP tested subsequently in other populations these
associations were confirmed (Atalar et al., 2010; Hashimoto et al., 2011). The SNPs promote
transcription from an alternative start site and the expression of the hERG1-3.1 isoform
(Huffaker et al., 2009). As this is a primate brain specific isoform with markedly faster
deactivation kinetics a role in normal human higher order cognition is suggested where
sustained high-frequency firing patterns, as seen in prefrontal cortex neurones, may be vital.
Also hERG1a mRNA, unlike hERG1b, is decreased in individuals with schizophrenia so that
the ratio of hERG1-3.1 to hERG1a is 2.5-fold higher. This imbalance towards a more rapid
deactivating current and consequent lessening of hERG1 current accumulation would give rise
to an increase in spike frequency and conversion of firing patterns to non-adapting resulting in
neuronal dysfunction consistent with the pathogenesis of the disorder. Furthermore whether the
therapeutic effects of antipsychotics may be related in part to activity at hERG1-3.1 has been
studied. The hERG1 genotype impacts on antipsychotic treatment response, with those
genotypes associated with schizophrenia and expression of hERG-3.1 exhibiting greater
efficacy in terms of positive syndrome and general psychopathology ratings (Apud et al. 2012).
This is particularly in response to risperidone in the setting of slow metabolism (Heide et al.,
2016). Moreover unlike other antipsychotic drugs, risperidone inhibits hERG1-3.1 to a greater
extent than hERG1a (IC50 220 nM vs 508 nM).
2.4.2 SMOOTH MUSCLE, ENDOCRINE AND OTHER CELLS
IKr contributes significantly to the resting membrane potential (Vrest) of smooth muscle as
this potential (from ~-60 to -40 mV) falls within the range of potentials where the channels are
open (the overlap of activation and inactivation curves) conducting window current. Thus
hERG block has been shown to depolarise the membrane potential and increase contractility of
smooth muscle from the opossum oesophagus (Akbarali et al., 1999), rat stomach (Ohya et al.,
2002b), human jejunum (Farrelly et al., 2003), guinea pig gallbladder (Parr et al., 2003), mouse
hepatic portal vein (Yeung and Greenwood, 2007) and bovine epididymus (Mewe et al. 2008).
Dynamic  regulation  of  IKr function is clearly illustrated by uterine smooth muscle. In the
myometrium of non-pregnant mice or late pregnant humans IKr block and activation increases
and inhibits respectively contractility (Greenwood et al., 2009; Parkington et al., 2014). These
effects are absent or blunted in the myometrium of late pregnant mice and in-labour humans,
coinciding with a significant reduction in IKr amplitude and no change in ERG1 but a marked
increase in KCNE2 protein expression. Furthermore in mice post partum (within 8 hrs), the
myometrial IKr sensitivity was regained. In humans the loss of IKr in-labour likely contributes to
the change in action potential pattern, from plateau-type to a long duration bursting form, which
is necessary for parturition (Tong et al., 2014). The absence of this IKr dynamism in obese
laboring women and resultant suppression of contractile strength may explain the higher
prevalence of labour progression failure and consequent need for caesarean delivery
(Parkington et al., 2014).
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IKr does  not  contribute  to  the  Vrest of human pancreatic β-cells, which is ~-60 mV, but
blockade induces hyperexcitability of β-cells, with an increase in firing frequency, in response
to glucose or arginine leading to greater islet insulin secretion (Rosati et al., 2000). Likewise in
mouse β-cells selective inhibition of ERG1, by rBeKm1, enhanced the glucose stimulated
increase in intracellular calcium and secretion of insulin (Hardy et al., 2009). ERG1 current,
though half the density found in β-cells, was also present in mouse α–cells where its inhibition
impaired glucagon secretion probably through membrane potential depolarisation leading to
inactivation of sodium and calcium channels.
IKr is present in rat adrenal chromaffin cells in particular, according to the selective
expression of ERG1 protein, the adrenaline cell type (Gullo et al., 2003). Inhibition of IKr
resulted in depolarisation and an increase in firing frequency which led to an increase in
cytosolic calcium levels and induction of catecholamine release from cells. It is possible that
loss-of-function mutations in hERG1 could therefore give rise to a disproportionate circulating
adrenaline levels.
2.4.3 CANCER
Following the initial report of high levels of hERG1 mRNA and IKr in 17 human and murine
cancer cell lines of distinct histogenesis (Bianchi et al., 1998), hERG1 has been found to be
ectopically or overexpressed in various human tumour cell lines and primary cancers
(Cherubini et al., 2000; Crociani et al., 2003; Feng et al., 2014; Lastraioli et al., 2004; Pillozzi
et al., 2002; Shao et al., 2008; Smith et al., 2002). For example, 67 and 82 % of primary human
endometrial cancer tissue expressed hERG1 mRNA  and  protein  respectively  giving  rise  to
functional IKr as compared to 18 % of normal endometrium and an absence in endometrial
hyperplasia (Cherubini et al., 2000). Likewise no expression was detected in normal colonic
mucosa or adenomas whereas in human colorectal cancers hERG1 protein was expressed in ~60
% of primary tumours with the highest incidence in metastatic cancers (Lastraioli et al., 2004).
Here,  as  in  gastric  cancer  (Crociani  et  al.,  2014),  it  is  the  hERG1a  transcript  that  is
overexpressed, however in leukaemias and other cancers it is the hERG1b transcript (Crociani
et al., 2003; Erdem et al., 2015; Pillozzi et al., 2007). A similar association to aggressiveness
was found with glioma, the more malignant the glioma the greater the hERG1 transcript,
protein and IKr expression  (Masi  et  al.,  2005),  and  with  other  cancers  e.g.  gastric  cancer  and
melanoma (Arcangeli et al., 2013; Shao et al., 2008). Thus hERG1 expression could serve as a
biomarker for diagnostic and prognostic purposes (Ding et al., 2010; Dolderer et al., 2010;
Lastraioli et al., 2012, 2015). Furthermore the aberrant expression of hERG1 may also indicate
a precancerous phenotype (Dolderer et al., 2010; Lastraioli et al., 2006).
Ectopic expression of hERG1 is sufficient to induce cellular transformation thus transfected
mouse fibroblasts lose contact inhibition, change morphology, migrate more rapidly and
demonstrate anchorage-independent proliferation (Pier et al., 2014). But how is hERG1
ectopically or overexpressed in cancer? Overexpression in gastric cancer cell lines is suggested
to be attributable to the increased stability of hERG1a mRNA (Crociani et al., 2014).
Alternatively expression of hERG transcript may be augmented at the protein level due to
downregulation of miRNAs as suggested by glioblastoma multiforme (a high-grade
astrocytoma) and pancreatic cancer samples (Feng et al., 2014; Wang et al., 2015).
The overexpression of the hERG-USO isoform in human primary samples and cell lines of
neuroblastoma and leukaemia provides a modulating mechanism for the optimal expression of
hERG1 by tumour cells (Guasti et al., 2008). Overexpression of hERG1a can induce cell
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differentiation and promote apoptosis4 (Guasti et al., 2008; Han et al., 2004; Wang et al., 2002),
the hERG-USO isoform by decreasing the hERG1 current density, due to ER retention,
maintains an appropriate functional level and the neoplastic phenotype (Guasti et al., 2008).
Consistent with this cisplatin was found to increase hERG1 expression in human gastric cancer
cells, an action essential for the drug to induce apoptosis (R. Zhang et al., 2012). It is also
noteworthy that hERG expression can be downregulated in cancer as its promoter becomes
methylated, this epigenetic aberration occurs in a significant percentage of patients with various
types of non-Hodgkin lymphoma (Bethge et al., 2013).
A functional role of hERG1 in cancer cells was first demonstrated when leukaemia cell
lines  were  exposed  to  hERG blockers  and  their  proliferation  rate  was  reduced  (Pillozzi  et  al.,
2002; Smith et al., 2002). This result was subsequently repeated in various cancer cell lines, but
not all (Masi et al., 2005; Roy et al., 2008), and suggests the role of hERG1 in cell cycle
progression exhibits a dependency on the tissue origin of the neoplasm. Thus while hERG1
function is important in leukaemia cells as well as pancreatic and gastric cancer cells for G1/S
transition, since cells accumulate in G1 phase with block, for ovarian cancer cells it is elsewhere
in the cycle, as cells accumulate in S and G2/M phase (Asher et al., 2011; Feng et al., 2014; Li
et al., 2007; Shao et al., 2005, 2008).
The  proliferative  potential  of  cell  types  is  correlated  to  the  Vrest.  Cycling  cells  have  a
depolarised Vrest, however the relationship of membrane potential to cell cycle stages is more
complex. Between -30 and -50 mV, the Vrest of cancer cells (Bianchi et al., 1998), the hERG1
window current is substantial and so in high resistance cells may contribute significantly to
Vrest. For neuroblastoma cells that is certainly the case, so during the S phase of the cell cycle
there is a depolarisation of membrane potential (from -31 mV in G1 to -25 mV) due to an
oscillation in hERG1a and hERG1b isoform expression (Arcangeli et al., 1995; Crociani et al.,
2003). The decrease in the hERG1a:hERG1b ratio in S phase causes a shift of the activation
curve and consequently the window current occurs at more depolarised values. The mechanism
by which hERG1 modulates mitotic cycle progression of primary myeloid leukaemia cells as
well as leukaemia cell lines is though different with hERG1 not, at least always, contributing to
the  Vrest (Crociani et al., 2003; Crottès et al., 2011; Pillozzi et al., 2007). Moreover though
hERG1  contributes  to  the  Vrest of small cell lung carcinoma cell lines it is not this but the
channel protein itself independent of ion flux that influences proliferation (Glassmeier et al.,
2012).
As expected from the clinical data regarding acquisition of an invasive/metastatic
phenotype, hERG1 plays a role in tumour progression. Inhibition of hERG1 decreases the
invasiveness of colon and gastric cancer cells for example,  with the amount of hERG protein
and  IKr correlating with invasion capacity (Lastraioli et al., 2004; Shao et al., 2008).
Interestingly  the  migration  of  cells  of  an  anaplastic  thyroid  cancer  and  a  melanoma  cell  line
were also reduced by hERG inhibition but their hERG channels were non-conducting (Afrasiabi
et al., 2010; Asghar et al., 2012). In glioblastoma multiforme hERG1 activity is related to
neoangiogenesis rather than proliferation (Masi et al., 2005). Inhibition of hERG1 specifically
decreased the secretion of vascular endothelial growth factor (VEGF), via VEGF transcription
levels. Thus here hERG1 contributes to malignancy by promoting the secretion of angiogenic
factors from glial tumour cells.
4 The hERG1-apoptosis relationship is not simple. Block of hERG1 can also induce apoptosis of HEK-
hERG cells and gastric cancer cells but not of leukaemia or ovarian cancer cells (Asher et al., 2011; Li et al.,
2007; Pillozzi et al., 2002; Shao et al., 2005, 2008; Thomas et al., 2008).
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The pleiotropic effects exerted by hERG1 often result from its recruitment by cell adhesion
molecule β1 integrin into multiprotein membrane complexes, within which hERG1 physically
and functionally interacts with the partners (Pillozzi and Arcangeli, 2010). Engagement of β1
integrin as when a human neuroblastoma cell or colorectal cancer cell makes contact with
laminin or fibronectin results in an increase in hERG current, which for the former cell is
mediated by a pertussis toxin-sensitive G-protein and induces neurite emission (Crociani et al.,
2013; Pillozzi and Arcangeli, 2010). It is believed though that hERG1 channels modulate the
partner protein(s) through voltage-dependent conformational coupling rather than through
alterations of ion conductance i.e. ion-independent signaling (Pillozzi and Arcangeli, 2010).
In epithelial cells, such as colorectal cancer cells, the β1/hERG1 complex is translocated
into  caveolae/lipid  rafts  and  recruits  FAK,  a  cytoplasmic  tyrosine  kinase  (TK),  the  small
GTPase Rac1 and the p85 subunit of PI3K (Crociani et al., 2013; Pillozzi and Arcangeli, 2010).
This recruitment is dependent on hERG1 activity as it is impaired by hERG inhibition. The
function of the complex is to trigger angiogenesis and modulate cell invasiveness following
adhesion.
Two more types of these integrin/hERG1 complexes have been identified. In activated
normal haematopoietic precursors and acute myeloid leukaemia cells, where hERG1b is more
prevalent than hERG1a, a complex occurs consisting of β1 integrin, predominantly hERG1b and
VEGF receptor 1 (Pillozzi et al., 2007). Both integrin activation and hERG1 activity modulate
the activation of VEGFR-1, a TK receptor, which subsequently activates the mitogen-activated
protein kinase (MAPK) and PI3K/Akt signalling pathways. This complex regulates VEGF
induced leukaemia cell migration, the importance of which was shown in a murine model as
exit from bone marrow spaces into the bloodstream and invasion into extramedullary organs.
Furthermore angiogenesis was present within the bone marrow attributable to the autocrine
production of VEGF by leukemia cells which is hERG1 dependent.
In acute lymphoblastic leukaemia cells the complex incorporates the chemokine receptor
CXCR4 (Pillozzi et al., 2011). Leukaemia cells are protected from chemotherapy induced
apoptosis by bone marrow mesenchymal cells. These cells give rise to the formation of the
complex  through  both  the  interaction  of  their  vascular  cell  adhesion  molecule-1  with  the  β1
integrin and the release of the CXCR4 ligand stromal-derived factor 1α (SDF-1α)5. The
assembly activates the ERK1/2 and the PI3K/Akt pathways which phosphorylate substrates
regulating apoptosis producing antiapoptotic effects. The activation of these kinases and the
resulting chemotherapy resistance is dependent on the activity of hERG1 within the complex as
evident from hERG block reducing their phosphorylation and potentiating the proapoptotic
effects of chemotherapeutics in vitro and in vivo models.
The tumour microenvironment, due to imperfect angiogenesis and uncontrolled
proliferation, is characterised by hypoxia and this is a key element of tumour progression
which, through expression of hypoxia-inducible factor (HIF) dependent genes, drives towards a
more aggressive phenotype and mediates therapy resistance (Arcangeli, 2011). HIF dependent
genes include those triggering angiogenesis such is VEGF, which is functionally linked to
hERG1 (Crociani et al., 2014; Masi et al., 2005; Pillozzi et al., 2007). In colorectal cancer cell
lines the β1 integrin-hERG1-PI3K complex was shown to modulate the expression of HIFs, via
Akt and NF-κB, and consequently VEGF transcription and secretion (Crociani et al., 2013).
5 SDF-1α also induces proliferation and migration of leukemia cells with both processes mediated by
hERG1 (Li et al., 2009; Zheng et al., 2011). SDF-1α increases hERG1 current when applied acutely but also
increases hERG1 transcription.
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Thus the hERG1 conductance via this pathway can determine the growth and angiogenesis
within colorectal cancer cell derived tumours in vivo as well as their metastatic spread. Hypoxia
also effects hERG1, the window current of neuroblastoma cells is markedly increased due to a
large hyperpolarising shift in the activation curve (Fontana et al., 2001). This may
counterbalance the hypoxia associated depolarisation of Vrest that occurs with Na+/K+ pump
failure from ATP shortage. Likewise an increase in hERG1 conductance resulting from
hyperkalaemia in the ischaemic environment may also confer another selective advantage by
hERG1 (Bianchi et al., 1998). Into the microenvironment cancer cells shed microvesicles which
can influence, amongst other things, infiltration and cancer progression as in the case of
leukaemia cells they can induce their chemotaxis and enhance their adhesion to endothelial
cells (Zheng et al., 2012a). The shedding of microvesicles from leukaemia cell lines is
modulated by hERG1, moreover microvesicles express hERG1 on their surface and when
incubated with leukaemia cells increased their expression of hERG1.
 Thus overall hERG1 would seem a target for cancer therapy, though the concomitant risk of
proarrhythmia is a hurdle to such an approach (Crociani et al., 2014; Pier et al., 2014; Pillozzi et
al., 2011; Wulff et al., 2009). A proposed risk mitigation strategy is hERG1 isoform selective
inhibition i.e. targeting hERG1b for treatment of leukaemias where it is the predominant
isoform (Gasparoli et al., 2015). The risk/benefit profile of anticancer drugs is of course very
different to those drugs used to treat benign conditions e.g. arsenic trioxide, TK inhibitors (Yeh
and Bickford, 2009). Though the first in class of these inhibitors imatinib (Gleevec) has little
cardiotoxicity, the other standard first-line therapies of newly diagnosed chronic myeloid
leukemia dasatinib and nilotinib carry a warning and “black box” warning respectively in their
prescribing information of the risk of QT prolongation and sudden death (Yeh and Bickford,
2009; Raschi and De Ponti, 2012). Interestingly the underlying mechanism is through their TK
inhibition directly or indirectly down-regulating PI3K signalling which then affects multiple
cardiac ion currents with the decrease in IKr and increase in INa-L of particular importance (Lu et
al., 2012). Imatinib did not decrease PI3K activity or prolong APD. These effects on canine
cardiomyocytes  were  not  immediate,  though  all  three  drugs  have  also  been  shown  to  acutely
block hERG1 all be it e.g. imatinib at ≥100-fold its FTPC (Dong et al., 2013; Freebern et al.,
2007). However imatinib, when incubated at concentrations approximating FTPC with cells of
a leukemia cell line, downregulated hERG1 transcription and consequently protein levels
(Zheng et al., 2012b). This was accompanied by a decrease in the proliferation and an increase
in  the  apoptosis  of  the  cells  as  well  as  a  down-regulation  of  VEGF  mRNA  and  secretion  by
them. All of these effects, as noted earlier, could be hERG1 mediated so inhibition of hERG1
may contribute to the action of imatinib.
Inhibition  of  hERG1 may also  treat  some collateral  effects  of  cancer  (Wulff  et  al.,  2009).
Skeletal muscle atrophy occurs as a consequence of cancer, other diseases, muscle damage or
disuse and aging. In the atrophic skeletal muscle of tumour bearing or limb disuse mice
expression of mERG1a protein is upregulated (Wang et al., 2006). mERG1a channel function
induced atrophy through an increase in ubiquitin-proteasome proteolysis resulting from the
transcription and translation of Murf1, which encodes a ubiquitin E3 ligase (Pond et al., 2014;
Wang et al., 2006).
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3. AIMS OF THE STUDY
The  overall  aim  of  this  study  was  to  examine  different  aspects  of  hERG1  potassium  channel
functioning, specifically:
I. To investigate the effect of a novel gastrointestinal prokinetic, prucalopride, on
hERG1 and hERG1 K897T.
II. To characterise both in vitro and in vivo the  effect  of  the  common  hERG1
polymorphism K897T.
III. To elucidate the effect of the endogenous sphingolipid ceramide on hERG1.
IV. To characterise the cardiomyocytes derived from the induced pluripotent stem cells
(iPSCs) of a relatively asymptomatic LQT2 patient with a normal QTc interval.
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4. METHODS
Cell culture (I, II, III, IV)
Human embryonic kidney (HEK 293) and African green monkey kidney (COS-7) cells
were transiently transfected (by either lipid reagent or calcium phosphate precipitation
methods) with hERG1a WT or K897T cDNA in a pcDNA3 plasmid. Enhanced green
fluorescent protein cDNA was also transfected in electrophysiological studies as a marker.
Experiments were performed 36-72 hours later. In III a stably expressing hERG1a-HEK cell
line (generated by G418 antibiotic selection) was used.
In IV iPSCs were generated from the primary fibroblasts of a 61-year old male with a
R176W mutation of hERG1 by infection with retroviral vectors containing OCT3/4, SOX2,
KLF4 and MYC (as Takahashi et al., 2007). Two patient-specific cell lines were established
(UTA.00514.LQT2 and UTA.00525.LQT2). A number of control cell lines were used: the
human embryonic stem cell (hESC) line H7 and the iPSC lines FiPS 6-14, UTA.00112.hFF,
UTA.01006.WT and UTA.04602.WT. The pluripotency of the iPSC lines was demonstrated at
the mRNA (by RT-PCR) and protein (by immunocytochemistry) levels as well as by markers
for and tissues from the three germ layers in respectively embryoid body derived cells and
teratomas. iPSCs and H7 hESCs were differentiated to cardiomyocytes by co-culturing with the
mouse visceral endodermal-like END-2 cells. Subsequently the beating areas were
mechanically excised and cells dissociated by collagenase A treatment.
Patch-clamp recordings (I, II, III, IV)
Patch-clamp electrophysiology is the gold-standard assay for detailed and quantitative
mechanistic insight of ionic currents (Hamill et al., 1981; Neher and Sakmann, 1976), including
IhERG (Goineau et al., 2012; Pollard et al., 2010; Priest et al., 2008). In manual patch-clamp a
glass pipette is placed on the surface of a single cell and, with suction, a high resistance seal (a
giga-ohm seal) is formed enabling the recording of membrane currents through the ion channels
in the enclosed patch of membrane (e.g. Fig. 1). From the initial cell-attached configuration
other configurations including whole cell, where the membrane patch is ruptured resulting in
cytosolic access, may be obtained (Hamill et al., 1981). In whole cell patch-clamp, facilitated
by the low resistance electrical access, membrane currents of the entire cell can be recorded.
Studies I, II and III in this work have used this configuration in voltage-clamp mode, with an
EPC-9 amplifier and Pulse/Pulsefit software, on either fluorescent or stably expressing attached
cells at room (22-24 oC) temperature. Additional studies were also performed at physiological
(~36 oC)  temperature.  The  patch  pipettes  had  resistances  of  1.5  to  4  MW when filled with a
solution containing (in mM): KCl 150, MgCl2 2, BAPTA 5, HEPES 10 and MgATP 5 (pH 7.2
with KOH). The extracellular solution contained (in mM): NaCl 150, KCl 5.4, CaCl2 1.8,
MgCl2 1  and  HEPES  5  (pH  7.4  with  NaOH).  Capacitance  and  series  resistance  were
compensated, the latter by ≥70 %. The voltage protocols used are described in the individual
studies and detailed in the figures or legends here. The simulated cardiac ventricular-like
waveform had an amplitude of 115 mV, from holding potential of −80 mV, and an APD90 of
~350 ms. It should be noted that action potential waveform differences, between regions/layers,
results in varying hERG current profiles (Lu et al., 2001).
In IV to preserve the intracellular milieu of the cardiomyocytes the perforated patch
technique was employed. Specifically the antibiotic amphotericin B (0.24 mg/ml) was included
in the pipette solution, the resulting pores in the membrane patch are permeable to small
monovalent ions, but not to large ions or molecules, and permit electric access to the cell (Rae
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et al., 1991). Voltage-clamp (measuring IKr as the 1 µM E-4031 sensitive current) and current-
clamp (for action potentials) recordings from spontaneously beating dissociated cells were
conducted with an Axopatch 200B amplifier and pClamp 9.2 software at 36 °C. A coverslip
with cells was placed in the recording chamber and perfused with extracellular solution
consisting of (in mM) 143 NaCl, 4 KCl, 1.8 CaCl2, 1.2 MgCl2, 5 glucose, 10 HEPES (pH 7.4
with NaOH; osmolarity adjusted to 301 ± 3 mOsm). The pipette solution consisted of (in mM):
122 K-gluconate, 30 KCl, 1 MgCl2, 5 HEPES (pH 7.2 with KOH; osmolarity adjusted to 290 ±
3 mOsm). Additionally, using cardiomyocytes derived from the FiPS 6-14 and
UTA.00514.LQT2 cell line, IKr was  also  recorded  with  the  whole  cell  patch-clamp
configuration at room temperature in isotonic caesium conditions for isolation (Zhang, 2006).
The extracellular solution contained (in mM): 135 CsCl, 1 MgCl2, 10 glucose, 10 HEPES and
10 µM nifedipine (pH 7.4 with CsOH; osmolarity adjusted to 301 ± 3 mOsm). The intracellular
solution contained (in mM): 135 CsCl, 1 MgCl2, 10 EGTA, 10 HEPES (pH 7.2 with CsOH;
osmolarity adjusted to 290 ± 3 mOsm).
Field potential recordings (IV)
Cardiomyocyte aggregates were plated onto microelectrode arrays and field potentials were
subsequently recorded with a Multi Channel Systems platform at 37 ºC. The field potential
duration and beating frequency were determined with AxoScope software.
Western Blot (II, III)
Membrane  fractions  of  cells  were  isolated  (as  Zhou  et  al.,  1998a),  subjected  to  SDS-
polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes. The separated
proteins were incubated with primary (anti-hERG1, against a distal C-terminal epitope) and
secondary (anti-rabbit) antibodies.
Immunoprecipitation (III)
Cell lysates were incubated overnight with anti-hERG1, the resulting immunocomplexes
were precipitated using protein G-Agarose and detected by Western blotting with anti-ubiquitin
and anti-HERG antibodies.
Labelling of cell surface proteins (III)
Extracellularly exposed lysine residues of cell membrane proteins were tagged with the
amine reactive biotinylating reagent Sulfo-NHS-SS-biotin. The cells were lysed, hERG1
protein immunoprecipitated and subjected to SDS-polyacrylamide gel electrophoresis. The
hERG1-biotin complex was detected with streptavidin conjugated horseradish peroxidase.
Metabolic labelling (III)
Newly synthesised protein was labelled with [35S]methionine and [35S]cysteine and chased
for up to 24 hours with unlabelled methionine and cysteine. At various time points cells were
lysed and hERG1 protein immunoprecipitated. Following SDS-polyacrylamide gel
electrophoresis the 35S- labelled hERG proteins was detected by autoradiography.
Immunocytochemistry (III, IV)
In III cells on coverslips were fixed, permeabilised and incubated overnight with anti-
hERG1  (±  anti-Lamp-1)  antibody.  After  blocking  of  unspecific  sites,  cells  were  stained  with
goat anti-rabbit FITC-conjugated (± anti-mouse Cy3-conjugated) secondary antibody. The
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subcellular distribution of hERG was determined by confocal microscopy using NIH-image
computer program.
In IV, cells were fixed a week after dissociation following differentiation and the expression
of cardiac proteins (with anti-cardiac troponin T, anti-α-actinin and anti-connexin-43) assayed.
A larger set of cardiac markers, including hERG, was studied at the mRNA level with RT-PCR.
Patients and their evaluation (II)
The  DNA  samples  and  clinical  data  of  261  LQTS  patients  (carriers  of  KCNQ1  G589D)
were available. 53 individuals underwent an exercise stress test with a bicycle ergometer. The
QT intervals of these exercise ECGs were measured from the onset of the QRS complex to the
end of the T-wave defined by the tangent method and corrected for heart rate with Bazett’s
formula.
Genetic analysis (II, IV)
The determination of the hERG K897T SNP and R176W mutation status was by a variant
specific  test  of  PCR amplified  genomic  DNA using  a  primer-induced  restriction  assay.  In IV
karyotype analysis of the cell lines was performed.
Statistical Analysis (I, II, III, IV)
The student’s t-test (paired and independent data) and analysis of variance for multiple
comparisons was used. p<0.05 was considered significant. The difference in field potential
durations between different aggregate populations was determined by nonlinear regression
analysis.
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5. RESULTS & DISCUSSION
5.1 PRUCALOPRIDE AND THE hERG1 CHANNEL (I)
PRUCALOPRIDE AND ITS CARDIAC SAFETY
Drug-induced LQTS is an issue of considerable importance for both clinically used drugs
and those in development (Pollard et al., 2010; Wallis, 2010). Due to the extremely low
incidence of TdP and the lack of a better marker, QT interval prolongation though itself not a
safety risk per se has been the only surrogate end-point acceptable to pharmaceutical regulatory
agencies (Pollard et al., 2010). The evaluation of this index is enshrined in dedicated regulatory
guidelines for both clinical (ICH E14), which defines the “thorough QT/QTc (TQT) study”, and
non-clinical (ICH S7B) studies (Anon, 2005a, b). The association with inhibition of the hERG1
channel is compelling enough that as part of the integrated risk assessment in ICH S7B an in
vitro hERG assay6 is recommended to best specifically ascertain the degree and nature of any
interaction (Anon, 2005b; Wallis, 2010).
In the wake of cisapride-associated QTc prolongation and arrhythmias (Ahmad and Wolfe,
1995; Napolitano et al., 2000; Olsson and Edwards, 1992; Wysowski et al., 2001; Vitola et al.,
1998), the cardiac safety of this therapeutic class- gastrointestinal prokinetics- has been
scrutinised and extensively profiled (Beattie et al., 2013; Claassen and Zünkler, 2005; Drolet et
al., 2000; Meyers and Hickling, 2007; Potet et al., 2001; Toga et al., 2007). Prucalopride,
developed initially at Janssen Pharmaceutica NV of Belgium, is part of the next generation of
prokinetics with a serotonin 5-HT4 receptor agonism mechanism of action (De Maeyer et al.,
2008). Unlike its progenitors metoclopramide (Primperan), cisapride (Prepulsid) and tegaserod7
(Zelnorm) which suffer from a lack of 5-HT4 selectivity, prucalopride is both potent (~10nM in
binding and functional assays) and selective as evident from binding studies (>200-fold
difference in affinity from other receptors) and in vivo where 5-HT4 antagonist can block all its
induced effects (Beattie et al., 2013; De Maeyer et al., 2008; Pindon et al., 2002). In healthy
humans prucalopride, in contrast to cisapride, selectively stimulates colonic transit with little
effect on gastric emptying or small bowel transit (Bouras et al., 1999). The facilitation of
propulsive activity in the colon is believed to occur predominantly through activation of
receptors on both the excitatory cholinergic and inhibitory nitrergic efferent neurones of the
myenteric plexus enhancing the neuromuscular transmission (De Maeyer et al., 2008).
Prucalopride was developed therefore for treatment of lower, unlike cisapride, GI tract
hypomotility disorders.
In I the effect of acute application of prucalopride on hERG1 was investigated. Prucalopride
exhibited concentration dependent inhibition of the hERG1 current (Fig. 8), both during the
depolarising and repolarising steps of the voltage protocol. Thus the peak tail current amplitude
6 In the drug discovery process the hERG assay provides the earliest experimental indicator of TdP liability and may then be used in
the synthesis-screening cycle of the lead optimisation phase to enable a designing out of hERG activity (Pollard et al., 2010).
7 Post-Vioxx the association of ischaemic cardiovascular events with tegaserod led the FDA to recommend its withdrawal after ~5
years on the market for irritable bowel syndrome and constipation (De Maeyer et al., 2008; Pasricha, 2007). This link has been
disputed and the underlying mechanism is unknown (Beattie et al., 2013). Tegaserod was reintroduced later that year (2007) under a
restricted access program but is now no longer available.
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was reduced e.g. by 3 and 30 µM prucalopride to 0.62±0.05 and 0.23±0.02 (n=6 and 5) of that
during control conditions. The hERG tail current IC50 value was 4.1 µM with a Hill coefficient
of one, suggesting a drug-channel binding stoichiometry of one to one. Previously Potet et al.
(2001) reported a hERG IC50 value of 5.7 µM for prucalopride using a step pulse voltage
protocol with transiently transfected COS-7 cells. One notable difference between I and that
study was the recording temperature (room temperature in I versus 35 oC; Potet et al., 2001).
The comparable potencies would suggest that prucalopride block, like cisapride’s (Kirsch et al.,
2004; Walker et al., 1999; Windley et al., 2016), is temperature insensitive. The IC50 though of
certain drugs, e.g. erythromycin, is influenced by temperature (Eap et al., 2007; Kirsch et al.,
2004). According to the Committee for Medicinal Products for Human Use assessment report
of prucalopride the IC50 from various studies using hERG-HEK was from 4.1 to 22 µM
(European Medicines Agency, 2009). However no further information is available on this latter
value. Also of note is a stated IC50 of 10 µM for guinea-pig ventricular myocyte IKr.
Figure 8. Concentration dependent inhibition by
prucalopride of the hERG1a current of a transiently
transfected HEK 293 cell. The step pulse voltage protocol
used to elicit the hERG current is shown beneath.
Cisapride and domperidone, another, though chemically distinct, prokinetic with action via
peripheral dopamine D2 receptor antagonism, are both potent acute hERG1 blockers. The
hERG IC50 for cisapride is reported to be 10-26 nM (Crumb et al., 2016; Kirsch et al., 2004;
Margulis et al., 2010; Walker et al., 1999; Windley et al., 2016), though these are overestimates
as the nonphysiological voltage protocols negate its kinetics of block (Milnes et al., 2010; Potet
et al., 2001). Domperidone (Motilium) has a hERG IC50 value of 57-162 nM (Claassen and
Zünkler, 2005; Drolet et al., 2000) and, when intravenously administrated, has been associated
with TdP (Redfern et al., 2003). Furthermore domperidone in epidemiological studies was
shown  to  increase  by  2.8-fold  SCD  leading  to  a  reassessment  of  its  risk-benefit  ratio  and
questioning of its continued availability (Hondeghem, 2013).
In I, as extensively employed in academia and the pharmaceutical industry, homomeric
hERG1a channels were used as a model for the cardiac IKr channel. Differential drug
sensitivities between hERG1a and hERG1a/1b channels occur, though only 1.5 % and 8 % of
compounds were reported to be more potent (>2-fold difference) against hERG1a and
hERG1a/1b respectively (Abi-Gerges et al., 2011). Cisapride, like most of the diverse set of 50
compounds tested, exhibited similar IC50 values with homomeric hERG1a and heteromeric
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hERG1a/1b channels. Furthermore the pharmacological sensitivity of heterologously expressed
hERG1a seems unaffected by coexpression with WT KCNE1 (Guo et al., 2006; Ulens et al.,
1999) or KCNE2 (Scherer et al., 2002; Weerapura et al., 2002). Another assumption often made
in these in vitro studies (including I) is that the nominal concentration of the drug is equivalent
to the actual concentration available to interact with hERG. For most compounds this is likely
the case (Qu et al., 2011), however some compounds may be poorly soluble in the assay buffer
or adhere to glassware and the perfusion system reservoirs/tubing thus reducing exposure and
leading to underestimation of the potency towards hERG (Brimecombe et al., 2009; Margulis et
al., 2010). Such adsorptive loss may occur with cisapride (Margulis et al., 2010), though as
prucalopride is less hydrophobic this source of error is likely not problematic.
A hERG1 IC50 value is not sufficient to predict proarrhythmic potential (Mirams et al.,
2011). The IC50 values of the antipsychotics clozapine and quetiapine (Hill et al., 2014;
Kongsamut et al., 2002), the antidepressants imipramine and amitriptyline (Teschemacher et al.,
1999) as well as citalopram (Witchel et al., 2002), and the antimalarial chloroquine (Traebert et
al., 2004) fall within the same range (2-6 µM) and all are associated with QT interval
prolongation/TdP (De Bruin et al., 2005; Raschi et al., 2013; Redfern et al., 2003; Sarganas et
al., 2014; van Noord et al., 2009; Yap and Camm, 2003). Furthermore the early prokinetic
metoclopramide, which has an IC50 of 5.4 µM, is also associated with LQTS/TdP (Claassen and
Zünkler, 2005; Sarganas et al., 2014). Of the withdrawn drugs, the antitussive clobutinol and
opioid agonist levacetylmethadol also have similar IC50 values while the fluoroquinolone
antibiotic grepafloxacin has an IC50 of 50 µM (Bellocq et al., 2004; Kang et al., 2001b, 2003;
Katchman et al., 2002). Of greater significance is the ratio between the hERG IC50 and the
predicted (when in preclinical development) or measured maximal free therapeutic plasma
concentration (van Noord et al., 2011; Wallis, 2010). The hERG IC50/FTPC ratio (or hERG
safety margin) for grepafloxacin was 16, for chloroquine is 6 and for cisapride was 2 (Kang et
al., 2001b; Margulis et al., 2010; Traebert et al., 2004). From such data Redfern et al. (2003)
recommended at least a 30-fold hERG safety margin as drugs with ratios below this have a high
torsadogenic potential. Subsequent similar retrospective studies have likewise demonstrated a
higher risk, possibly 3-4 times, of serious ventricular arrhythmias and sudden death when a
ratio of 30 was taken as a cut-off point for drugs (De Bruin et al., 2005; van Noord et al., 2011).
Unsurprisingly the predictivity of TdP risk is substantially improved by an evaluation that also
incorporates INa and  ICaL drug block (Kramer et al., 2013; Mirams et al., 2011). The relative
potency, which negates the need for FTPC, of a compound on hERG1 versus CaV1.2 is seen as
a major determinant (Kramer et al., 2013).
At 2 mg orally once daily prucalopride increases the frequency of spontaneous complete
bowel movements in chronic constipation patients, as well as decreasing the related symptoms
and improving patient quality of life (Camilleri et al., 2008; Quigley et al., 2009; Tack et al.,
2009). In healthy humans repeated dosing at this therapeutic level resulted in the steady-state
plasma concentrations fluctuating between trough and peak values of 2.5 and 7 ng/ml,
equivalent to 6.8 and 19.0 nM (Van de Velde et al., 2008). The plasma Cmax value after
administration of a single prucalopride dose was 4.34 ng/ml (Frampton, 2009). Drugs can bind
to plasma proteins in the circulation, so reducing the available drug concentration and
consequently potency towards hERG (Margulis et al., 2010). For drugs which exhibit high
plasma protein binding the calculated free fraction may not correlate with hERG1 potency and
clinical QTc changes (Kongsamut et al., 2002; Margulis et al., 2010). Prucalopride however has
low plasma protein binding (28-33 %; Van de Velde et al., 2008), the free peak plasma
concentration after repeated dosing is calculated to be 12.7-13.7 nM resulting in a hERG
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IC50/FTPC margin of 299-323. Therefore in regard to direct hERG1 block by prucalopride the
relative risk of serious ventricular arrhythmias and sudden death is expected to be negligible
(De Bruin et al., 2005).
With the adoption of ICH E14 another clinical outcome a QTc increase of ≥5 ms, which is a
level of regulatory concern, has emerged (Gintant, 2011; Wallis, 2010).  Analysis of TQT
studies has demonstrated that QTc prolonging drugs are 7 times more likely to have a hERG
safety margin less than 30, within this margin there was moderate confidence in predicting the
QTc risk (Gintant, 2011). Elsewhere it has been suggested that for dofetilide a QT interval
prolongation in humans of 20 ms corresponds to 10 % inhibition of hERG, thus the threshold
QT change may be more accurately predicted by the hERG IC5 or IC10 value (Wallis, 2010).
These values for prucalopride are 0.22 and 0.46 µM which is 16-36 fold above the FTPC,
where a cut-off of twofold gives both sensitivity and specificity in predicting the outcome of a
clinical  QT  study.  Thus  prucalopride  should  be  negative  in  the  TQT  study.  However  the
translation of hERG1 safety margins, even in conjunction with data from in vitro APD assays
and in vivo QT studies obtained during the drug discovery process, to human clinical QT
studies is imperfect (Gintant, 2011; Trepakova et al., 2009; Wallis, 2010). One confounding
factor e.g. is that the most relevant pharmacokinetic parameter for interpretation of hERG data
is the intracellular cardiac myocyte concentration not FTPC, unless there is only passive
diffusion of the drug and equilibrium is reached (Michaud and Turgeon, 2013). The heart
however expresses some CYP isozymes and various drug influx and efflux transporters so
differential accumulation of drugs, including cisapride, occurs in the myocardium (McBride et
al., 2009; Michaud and Turgeon, 2013; Sugiyama and Hashimoto, 1998; Titier et al., 2004). It
should be noted that human atria and ventricles express 5-HT4 receptors, but only at very low
density, and activation could potentially be arrhythmogenic as 5-HT via cAMP increases ICaL
that may lead to Ca2+ overload (De Maeyer et al., 2008). However in this low efficacy system
prucalopride behaves as a partial agonist, whereas in other tissues it is a full agonist, giving a
smaller ICaL (EC50=0.2 µM) and APD50 increase, and antagonising the effect of the endogenous
ligand (Chai et al., 2012; De Maeyer et al., 2008; Pau et al., 2005).
The focus on hERG1 inhibition and QT prolongation, while proving successful in terms of
identifying potential torsadogenic risk and abating drug withdrawals from the market, has likely
resulted in errors, particularly false positives as hERG alone is not always sufficient and the
sensitive QT interval is not specific, leading to unwarranted chemotype/drug attrition and
labeling (Gintant, 2011; Kramer et al., 2013; Sager et al., 2014). To address this negative
impact a shift in the testing paradigm was proposed that includes the Comprehensive in vitro
Proarrhythmia Assay (CiPA) which should result in the revision of S7B (Sager et al., 2014).
One component of CiPA, which takes into account multi-ion channel block and various
proarrhythmic mechanisms, will require the testing of drug candidates against a recombinant
ion  channel  panel  consisting,  initially  at  least,  of  hERG1  (IKr), KCNQ1+KCNE1 (IKs),
KV4.3+KChIP2 (Ito),  Kir2.1 (IK1), NaV1.5 (peak and late INa) and CaV1.2 (ICaL)(Fermini et al.,
2016). The drug effects on the ion channel panel would then be incorporated in an in silico
human ventricular action potential model and the potential proarrhythmic risk, e.g triangulation
and EADs, elucidated. For cisapride it was recently shown that at ~50-fold FTPC little
inhibition (<15 %) of any current except for IhERG was exhibited (Table 2; Crumb et al., 2016).
Of the 30 drugs assayed 70 % blocked (≥20 %) IhERG at  3x  FTPC  while  each  of  the  other
currents was blocked by ≤20 % of the drugs (Crumb et al., 2016). While the other potassium
currents were rarely inhibited this is not always the case and thus may contribute to LQTS e.g.
norfluoxetine, a metabolite of fluoxetine, which in addition to acute and trafficking hERG block
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also blocks IKs (Rajamani et al., 2006; Veerman et al., 2013). Anyway without a doubt the
hERG1 assay will continue to be fundamental in the assessment of proarrhythmic risk for a
drug.
Only the effect of acute exposure to prucalopride was investigated in I.  Direct  and
trafficking inhibition of hERG1 coexists (Rajamani et al., 2006; Takemasa et al., 2007) and
does so for a large proportion of LQTS liable drugs (Wible et al., 2005). It is worth noting that
cisapride, at up to 100 µM, has no effect on hERG1 trafficking (Rajamani et al., 2006; Wible et
al., 2005). The effects of prolonged hERG1 inhibition may extend beyond LQTS to apoptosis
with the consequent loss of cardiomyocytes leading to heart failure. The α1-adrenoceptor
antagonist doxazosin is associated with an increased risk of congestive heart failure and induces
apoptosis of human cardiomyocytes in vitro. Thomas et al. (2008) showed that doxazosin
(which has a hERG1 IC50 of 0.3 µM) induced in hERG1 expressing HEK cells, but not in
untransfected cells, apoptosis. This hERG1 associated apoptosis can also be induced by
amoxapine and desipramine, both of which additionally exhibit direct and forward trafficking
block of hERG1 (Obers et al., 2010; Staudacher et al., 2011). The mechanism by which hERG1
inhibition promotes apoptosis and whether it extends to cardiomyocyte apoptosis and heart
failure remains unknown.
An adequate cardiac safety profile for prucalopride was borne out in subsequent clinical
studies. A TQT study, that included moxifloxacin 400 mg as a positive control, demonstrated
no significant differences in the QTc interval in healthy volunteers between prucalopride, at
either therapeutic or supratherapeutic (10 mg) doses, and placebo (Mendzelevski et al., 2012).
The mean QTc change from baseline was <5 ms at all time points over the ≥24 hr period post
final dose. The repeated dosing of 10mg resulted in a mean plasma prucalopride Cmax value of
42.7 ng/ml or 116.1 nM, thus a free concentration of 77.8-83.6 nM and a hERG safety margin
of 49-53. Therefore even at this supratherapeutic dose the negative TQT study result (i.e. no
effect on ventricular repolarisation) is not surprising. Furthermore two earlier placebo
controlled Phase I cardiovascular safety studies in which repeated doses of up to 20 mg daily
were given found, as in the TQT study, no QT intervals (Fredericia-corrected) of >500 ms or
increases >60 ms (Boyce et al., 2009). In the three 12-week placebo-controlled Phase III studies
that have established the efficacy of prucalopride in chronic constipation the incidence of
prolonged QTc interval during the treatment period (with 2 and 4 mg/day) was low and similar
to placebo (Camilleri et al., 2008; Quigley et al., 2009; Tack et al., 2009). No treatment-related
ECG abnormalities or cardiac arrhythmias were found in the TQT or other studies, even when
conducted in a potentially high risk patient population (Camilleri et al., 2009). Moreover some
evidence of prucalopride’s safety is offered by open-label, long-term (up to ~2 years) studies
(Frampton, 2009).
Prucalopride (Resolor® from Shire; 1-2 mg/day orally) was approved in Europe, in October
2009, “for the symptomatic treatment of chronic constipation in women in whom laxatives fail
to provide adequate relief”. In June 2015 the marketing authorisation was extended from
women to adults following a phase 3 trial in men where the efficacy and safety was similar to
the earlier studies with predominantly female patients (Yiannakou et al., 2015).
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PRUCALOPRIDE AND ITS MECHANISM OF BLOCK
The effect of prucalopride (at 10 µM) on hERG1a channel kinetics was investigated.
Though the rate of activation was unaffected, deactivation was significantly slowed by
exposure to prucalopride. Thus at a membrane potential of −70 mV the fast and slow
components of deactivation were increased from means of 168 ± 12 ms and 874 ± 51 ms in
control to 303 ± 35 ms and 1328 ± 91 ms (p<0.05 and p<0.005; n=6; the relative contribution of
the fast deactivating current component was not significantly altered). A significant
hyperpolarising shift of the half maximal activation potential was seen however as it was only -
1.9 mV any physiological relevance is unlikely and a time-dependent effect (e.g. Ferreira et al.,
2001; Rodriguez-Menchaca et al., 2014) cannot be excluded as the shift was not reversed on
wash-out.  Similar  to  a  number  of  other  drugs  (see  e.g.  González  et  al.,  2002;  Scherer  et  al.,
2008), prucalopride was shown to modify inactivation. Specifically prucalopride reversibly
accelerated the rate of inactivation, particularly at less depolarised membrane potentials, so at 0
mV the time constant decreased from 5.8 ± 0.5 ms to 3.9 ± 0.4 ms (p<0.005; n=5; wash-out: 5.7
± 0.4 ms). As a consequence the extent of inactivation was altered, being significantly increased
at -20mV. This would likely augment the inhibitory effect of prucalopride by further reducing
outward current during the plateau and repolarisation of the action potential. Moreover
prucalopride also slowed the time constant of recovery from inactivation however this was only
at unphysiologically negative membrane potentials (−100 to −120 mV).
The mechanism of block by prucalopride had not been detailed previously (or since).
Prucalopride was found, as with most hERG1 blockers including cisapride (Milnes et al., 2010;
Mohammad et al., 1997; Walker et al., 1999), to preferentially inhibit the activated
(open/inactivated) states. This was initially indicated by the voltage dependence of block, where
inhibition was significantly weaker at membrane potentials just positive to the threshold of
activation i.e. −40 and −30 mV. This is opposite to the voltage dependence of the closed state
hERG1 inhibitor BeKm-1’s block (Milnes et al., 2003b; Restano-Cassulini et al., 2006). The
state dependence of prucalopride was clearly shown in the response to a sustained
depolarisation (to 0 mV, where at room temperature 99.9 % of hERG1 channels would be
activated; Hill et al., 2014) where the initial outward hERG1 current was unchanged following
prucalopride equilibration but subsequently block progressively developed (Fig. 9A). This was
also evident in the data from the envelope of tail currents protocol used to determine the time
course of activation. Depolarisation to +20 mV resulted in relatively little inhibition with
durations up to 40 ms, reinforcing the view that inhibition of the closed state (and the
requirement for a binding site distinct from that of the inner cavity, as with BeKm-1; Tseng et
al., 2007) plays no significant part (Fig. 9B). After 40 ms the degree of blockade increased and
achieved steady-state levels within 600 ms, the development of inhibition had a time constant
of ~70 ms (n=3). Typically using a sustained depolarisation pulse voltage protocol, the kinetics
of block onset have ranged from time constants of seconds for methanesulfonanilides to tens of
milliseconds for bupivacaine, cocaine and ranolazine (González et al., 2002; Kamiya et al.,
2006; Rajamani et al., 2008; Snyders and Chaudhary, 1996; Zhang et al., 2001). It should be
noted that the kinetics of block exhibit a concentration dependency (Hill et al., 2014; Snyders
and Chaudhary, 1996; Windley et al., 2016; Zhang et al., 2001). For prucalopride, at 10 µM, the
principal time constant for the onset of block was 192 ms (Fig. 9A), this is comparable to that
of chloroquine at 0mV with a concentration resulting in a similar fractional block (Sánchez-
Chapula et al., 2002). The kinetics of prucalopride block are much quicker than that of cisapride
block (at 22 oC with 200 nM which inhibited IhERG ~80%: τ = ~4.7 s; Windley et al., 2016).
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Figure 9. Time dependence of IhERG blockade by prucalopride (10 µM). (A) Development of block over time during a
depolarisation step to 0 mV (for 7 s from −80 mV). The data from I Fig. 6B replotted: the mean relative current
(IPru/ICtrl) from 3 cells versus an abscissa of time with a logarithmic scale. The data was fitted with a double
exponential (in red). (B) From an envelope of tail currents protocol the relative amplitude of tail currents is plotted as
a function of the depolarising pulse duration. The cell was stepped from the holding potential of −80 mV to +20 mV
for variable durations with a tail current recorded at −120 mV. The voltage protocols in A and B were first performed
in control conditions and then following equilibration with prucalopride.
To clarify whether prucalopride can inhibit hERG1 channels in their inactivated state a
voltage protocol with an initial depolarisation step to +80 mV was used. Upon stepping back to
0 mV there was scant evidence of any time dependent development of block as the channels
reopen (I Fig. 6D). This implies that maximal inhibition occurred already at +80 mV where
hERG1 channels are predominantly in the inactivated state. Analogous results with this same
protocol are reported with e.g. the benzodiazepine midazolam, the antidepressant mianserin, the
hypnotic zolpidem (Jehle et al., 2013; Scherer et al., 2008; Vonderlin et al., 2015). This is in
marked contrast to the tricyclic antidepressant desipramine which blocks the open state with
little or no affinity for the inactivated state (Staudacher et al., 2011). An interaction of
prucalopride  with  the  inactivated  state  was  also  evident  from  the  channel  kinetic  changes,
where  a  stabilisation  of  that  state  was  indicated.  According  to  Walker  et  al.  (1999)  cisapride
caused an acceleration of the rate of inactivation and a negative shift in the voltage-dependence
of steady-state availability, though in a later study conducted at 37 oC there was no effect seen
(Milnes et al., 2010). Inactivation is reported to increase cisapride affinity for hERG by an
estimated 7.8-fold compared to the open state (Perrin et al., 2008), however differential binding
to the states is not evident in the kinetics of block and unblock (Windley et al., 2016). While
binding of prucalopride may not be monophasic (see Fig. 9A) like for clozapine, which has two
distinct kinetic components suggested to represent interaction with the open and inactivated
states  (Hill  et  al.,  2014),  such  detailed  analysis  was  not  performed.  What  is  clear  is  that
prucalopride binds to hERG1a channels in the open and inactivated states.
As with block, the kinetics of hERG1 channel unblock are drug specific. In the maintained
presence of prucalopride IhERG rapidly recovered from block (τ of ~260 ms) upon
hyperpolarisation. Prucalopride’s dissociation rate from, i.e. lower affinity for, the closed states
is similar to that of ranolazine, this is much quicker than cisapride (τ of ~6 s) but slower than



































The affinity of many hERG1 blockers for the activated states is evident as use dependence
whether frequency dependent, e.g. as with cisapride and verapamil, or independent, e.g. as with
E-4031 and terfenadine (Stork et al., 2007; Walker et al., 1999; Zhang et al., 1999). Underlying
the use and frequency dependence of block is overlap of the stimulation protocol and rates with
the rates of drug-channel interaction. Thus consistent with its rapid kinetics prucalopride does
not exhibit at 0.1 and 1 Hz frequency or use dependence i.e. steady-state block is reached by
end of each 300 ms test pulse to +40 mV with rapid dissociation from the channel during the
interpulse period at −80 mV. A lack of use and frequency dependence of hERG block is
similarly observed with ranolazine, cocaine and other compounds (Katchman et al., 2002;
Rajamani et al., 2008; Scherer et al., 2008; Vonderlin et al., 2015; Zhang et al., 2001). The use
of higher rates (up to 3 Hz) and a more physiological voltage waveform would also be of
interest.
Overall this suggests that prucalopride is not trapped within the hERG1 inner cavity at rest
by the activation gate like methanesulfonanilides and terfenadine (Kamiya et al., 2006;
Mitcheson et al., 2000b; Stork et al., 2007), where block is not associated with a change in the
deactivation rate and is practically irreversible. The time-dependent unbinding of prucalopride
on repolarisation resulting in loss of inhibition and an increase in IhERG may explain the
apparent slowing of deactivation. A number of drugs e.g. bupivacaine, chloroquine, cocaine and
ketoconazole also slow deactivation (Ferreira et al., 2001; González et al., 2002; Ridley et al.,
2006; Sánchez-Chapula et al., 2002; Zhang et al., 2001). The slowing of hERG1 deactivation
by untrapped, but not trapped, drugs with rapid binding kinetics has also been shown in silico
(Di Veroli et al., 2014). Though cisapride is untrapped, its relatively slow dissociation from the
channel means that it has no effect on the rate of deactivation (Milnes et al., 2010; Stork et al.,
2007; Walker et al., 1999).
While the importance of potency at hERG1 and its relation to QT prolongation and TdP was
expounded earlier, the mode of action (i.e. whether trapped), binding kinetics and state
dependence of a drug may also play a part in proarrhythmia (Di Veroli et al., 2014; Fermini et
al., 2016; Lee et al., 2016). Whereas slow binding/unbinding kinetics and the transient
occupancy of the activated state during the cardiac cycle results in inhibition equilibrium never
being reached, this is not the case when kinetics are rapid as block is achieved during
depolarisation. Thus at IC50, according to a simulation study, an untrapped drug with fast
binding kinetics would prolong the APD at 1 Hz compared to one with slow kinetics by >4-fold
(Di Veroli et al., 2014). This enhanced prolongation is similar to that found with the trapped
mode, which is independent of binding kinetics. Another simulation study likewise
demonstrated that rapid drug-channel interaction reduced IKr and delayed its peak resulting in
greater APD prolongation than expected (Lee et al., 2016). For prucalopride, the kinetics of
binding to and unbinding from hERG1 are unlikely then to provide any additional benefit to the
substantial potency derived safety margin. It should be remembered that I was performed at
room temperature. At physiological temperature the kinetics and drug-channel interaction may
be different as recently shown for cisapride (Windley et al., 2016). A potential consequence of
state dependency is differential sensitivity to heteromeric hERG1/IKr channels. The kinetic
changes arising from the fewer eag domains in hERG1a/1b channels results in a reduction in
inactivation and increased occupancy of the open state which decreases the affinity of E-4031
and dofetilide but increases the affinity of fluoxetine and ebastine (Abi-Gerges et al., 2011; Sale
et al., 2008).
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Though the molecular determinants (e.g. Mitcheson et al., 2000a) or even sideness (Crumb,
2014; Melgari et al., 2015; Zhang et al., 1999, 2001) of prucalopride binding to hERG1 were
not investigated in I the results are consistent with the site being within the inner cavity as
access, determined clearly by the activation gate, is critical for the association and dissociation
of prucalopride from the channel. Prucalopride is an analogue of cisapride (Fig. 10) which,
from mutagenesis studies, interacts with Thr623 and Ser624 at the base of the pore helix, via
hydrogen bonding, and Tyr652 and Phe656 (Imai et al., 2009; Kamiya et al., 2008; Mitcheson
et al., 2000a). For the aromatic residues their position in S6 and their nature, the hydrophobic
volume  of  the  656  side  chain  and  the  aromaticity  of  the  652  side  chain,  as  well  as  the
interaction between them determines sensitivity to cisapride (Chen et al., 2002; Fernandez et
al., 2004; Myokai et al., 2008). Furthermore as cisapride is asymmetric it interacts unequally
with residues of the four subunits so cisapride interacts with Y652 residues, but not F656, from
adjacent subunits (Dempsey et al., 2014; Imai et al., 2009; Myokai et al., 2008). Very recently
an additional novel binding mode was proposed based on interactions of hERG blockers,
including cisapride, with F557 of S5 where the drug is positioned immediately below the pore
helix and protruding into the lateral fenestration between adjacent subunits (Saxena et al.,
2016). The primary structural feature distinguishing prucalopride from cisapride is the loss of
the fluorophenyl ring (‡ Fig. 10). This moiety, from docking in homology models, interacts
with F557 or conventionally with F656 of the third subunit via π-π interaction (Imai et al.,
2009; Saxena et al., 2016). This latter interaction is important in cisapride binding as the hERG
IC50 is shifted from 10 nM in WT to 1.7 µM for the homotetrameric F656A mutant (Imai et al.,
2009). The absence of this interaction in prucalopride binding is further indicated by
unblocking kinetics which for cisapride are markedly faster with the F656A mutant (Myokai et
al., 2008). Moreover the integrity of interaction with Y652 (the aromatic ring of prucalopride,
denoted by bold asterisk for cisapride in Fig. 10) is suggested by the presence of voltage-
dependence of block which is proposed to occur by depolarisation induced changes in the





Figure 10. The structure of cisapride and prucalopride. From the structure-activity relationships of known hERG
blockers structural features of drugs such as hydrophobic or aromatic groups radiating from a central nitrogen, the
tertiary amine rendering compounds protonated at physiological pH, are predictive of hERG1 block (Aronov, 2008).
The important features of this classic pharmacophore model as exhibited by cisapride, a benzamide derivative, are
denoted. One strategy, as employed by the cisapride analog mosapride, to decrease hERG potency, but retain 5-
HT4 receptor activity, is to shorten the linker (between * and ‡) which affects the interactions of the drug’s aromatic
moieties (Durdagi et al., 2014; Potet et al., 2001). Prucalopride though differs and is the first representative of the
dihydrobenzofurancarboxamide chemical class (De Maeyer et al., 2008). It is also less lipophilic (clogP 1.44 vs 3.81
for cisapride), a physicochemical property that correlates with hERG1 blockade potency (Aronov, 2008).
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Other in silico studies have suggested more extensive cisapride-hERG interactions and
alternate orientation of the bound cisapride so that the fluorophenyl ring interacts with Y652
(Dempsey et al., 2014; Durdagi et al., 2014; Stary et al., 2010). While also other structural
differences between cisapride and prucalopride (conversion of methoxy to furan and/or loss of
the other methoxy) may contribute to the shift in potency. It should be noted that significant
effects on potency at and interactions with hERG1 are achievable by just single substitutions
within a compound and by enantiomers e.g. with quinidine/quinine, and methadone (Eap et al.,
2007; Karczewski et al., 2009; Sánchez-Chapula et al., 2003).
5.2 THE hERG1 K897T POLYMORPHISM (I, II)
Single-nucleotide polymorphisms (SNPs) are nucleotide changes that occur in >1 % of the
population that may (nonsynonymous) or may not (synonymous) change the amino acid
sequence of a protein. Even synonymous SNPs may have an effect e.g. large scale synonymous
changes in hERG1 mRNA were shown to differentially affect translation rate and protein
maturation/trafficking (Sroubek et al., 2013). SNPs generally do not result in overt disease but
may contribute to the variable penetrance or expressivity of a disorder. For example the minor
alleles  of  3´  UTR  SNPs  in  KCNQ1  act  as  modifiers  of  LQT1  phenotype  depending  whether
they occur in cis or  in trans with the mutation by decreasing the expression of either
respectively the mutant or WT allele (Amin et al., 2012).
The C-terminus of hERG1a beyond the cNBD contains 16 SNPs as well as 5 SIDS-linked
missense mutations and over 30 LQT2-linked missense mutations (C. Anderson et al., 2014).
One of these SNPs results in the changing of the conserved positively charged lysine at residue
897 to an uncharged polar threonine (K897T; rs1805123) as adenine is substituted by cytosine
at nucleotide 2690 in exon 11 (Iwasa et al., 2000; Laitinen et al., 2000). The K897T SNP is
highly prevalent in European and other populations e.g. the minor allele frequency is 27 % in
the French, 24 % in the German and 16 % in the Finnish and Indian populations (Bezzina et al.,
2003; Gouas et al., 2005; Koo et al., 2006; Laitinen et al., 2000). The minor allele frequency
though does exhibit ethnic dependent distribution being 4-5 times greater in Caucasians than
African Americans (Ackerman et al., 2003; D. Wang et al., 2014). A lower frequency is also
found in Japanese (2 %) and Chinese (5 %) populations (Iwasa et al., 2000; Koo et al., 2006).
In II a hERG1a K897T cDNA construct was transiently expressed in HEK 293 cells and
functionally studied using patch-clamp at room temperature. While the hERG1 current evoked
by depolarising steps and during repolarisation was qualitatively similar (II Fig.  1A  and  B),
immediately apparent was a difference in the current amplitude between hERG K897T and WT.
The hERG1 tail current density was significantly decreased by the minor variant (34 ± 4 pA/pF
compared to 64 ± 10 pA/pF; p<0.005). No difference was found in the voltage-dependence of
activation or activation rate at +20 mV. For hERG K897T and WT the mean activation time
constants were, respectively, 191.7 ± 39.4 ms and 170.5 ± 24.6 ms (n = 4 and 5; p = 0.6). There
was however a difference in the rate of deactivation, though only at less negative membrane
potentials. At −40 mV both the fast and slow time constants of deactivation were significantly
slower for hERG K897T.
The C-terminus is known to affect inactivation gating and voltage dependence (Aydar and
Palmer, 2001; Bhuiyan et al., 2008; Verkerk et al., 2005). The K897T variant induced a change
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in the voltage dependence of recovery from inactivation. This is reflected in the free energy
difference in channel gating transition:
ΔG = RT (V½/k)
This takes into account a shift in both V½ and k (though limitations are evident), values taken
from the Boltzmann fit (II Fig. 3 legend) and RT = 0.592 kcal/mol. For hERG K897T the
perturbation  (ΔΔG  =  ΔGvar-  ΔGwt)  in  the  free  energy  of  inactivation  is  -0.6  kcal/mol,  a
significant perturbation in inactivation gating (Piper et al., 2005) and equivalent to the presence
of the N-terminus (Wang et al., 1998). The negative value of ΔΔG indicates stabilisation of the
hERG1a channel inactivated state(s) relative to the open state(s). This is, however, not
paralleled by the time constants of inactivation gating. There was no change in the rate of
recovery from inactivation and the inactivation rate of hERG K897T was significantly slower,
infering stabilisation of the open state. An explanation for this paradox may be that hERG
K897T destabilises a transition state. Moreover the complex nature of the inactivation process
means that the measured rates may not be the forward and reverse rates of the same step in the
process. Therefore if hERG K897T destabilises the transition state for the rate limiting step in
inactivation, but this same step is not rate limiting in recovery from inactivation then the
differential rate effects can also be explained.
Residue 897 is expected to lie close to the cytoplasmic surface of the plasma membrane as
the immediate proximal region (amino acids 883-894) is a binding site for PIP2 and proposed to
interact with the negatively charged phosphate groups of the membrane phospholipid’s head
(Bian et al., 2004). Also in the immediate vicinity are two PKA phosphorylation sites (S890 and
T895), the K897T polymorphism results in a novel consensus PKA phosphorylation site (Cui et
al., 2000; Thomas et al., 1999). This raises the possibility that the SNP may have an additive
effect on the PKA modulation of hERG1. However, in II when the adenylyl cyclase activator
forskolin was present no differential shift of the half maximal activation voltage between hERG
K897T and WT was evident. This is in agreement with Scherer et al. (2002), who showed with
Xenopus oocytes that both forskolin and the phorbol ester PMA produced similar depolarising
shifts of the activation curve for WT and hERG K897T. Consequently the sensitivity of
hERG1a channels to PKA is unaltered by the K897T polymorphism. The SNP was found to
disrupt a Rho-stimulated protein kinase (PKN) consensus site but create a phosphorylation site
for  Akt  (protein  kinase  B)  resulting  in  an  alteration  of  the  hormonal  regulation  of  hERG1
(Gentile et al., 2008). Thus whereas thyroid hormone, via PI3K, increases WT current by
dephosphorylation of T895 through protein phosphatase 5, it decreases the 897T variant current
through Akt.
Additional experiments were conducted at physiological temperature (Fig. 11). Consistent
with hERG K897T exhibiting more complete inactivation the current amplitude at potentials in
the negative slope conductance region of the steady-state current-voltage relationship were
decreased compared to WT (Fig. 11C). However such biophysical changes do not give rise to
any apparent gross changes in the hERG1a current waveform evoked by a voltage command
modelled on a cardiac ventricular action potential (Fig. 11D). This is consistent with Anson et
al. (2004) who showed that the variants had qualitatively similar current waveforms, including
the  timing  of  the  peak,  though  differences  in  the  current  at  a  few  time  points  were  found.  It
should be noted that as hERG1 (and K897T) recovery from inactivation is so fast the voltage-
dependence of channel availability determines the number of channels that recover from
inactivation. Therefore, the expectation is that the resurgent current of hERG K897T during an
65
action potential would be reduced as in the repolarisation voltage range of −10 to −85 mV more
hERG channels would reside in the inactivated state. This was shown for the G584S LQT2
mutation which most noticeably results in a large negative shift in the voltage dependence of
inactivation (Zhao et al., 2009). In silico modeling predicted only modest action potential
prolongation by this mutation and a similar response to premature stimuli as WT. This mild in
vitro phenotype of hERG G584S appears to translate clinically, which differentiates it from the










Figure 11. The hERG1a K897T SNP at physiological temperature. IhERG recorded from a WT (A) and a K897T (B)
transfected HEK 293 cell. The voltage protocol is shown below. (C) The mean current-voltage relationship of the
two variants (n = 3) with current measured at the end of the 2 s depolarizing step. The current was normalised to the
value at −10 mV. (D) Currents (leak subtracted) evoked by a simulated cardiac ventricular-like action potential
waveform from COS-7 transfected cells.
As referenced above several contemporary and subsequent studies also investigated the in
vitro effects of hERG1 K897T (Table 3). Discrepancies between the studies are evident and
may in part be a consequence of the expression system used as well as differences in the
experimental  set-ups,  protocols  and  analysis  e.g.  though  the  experiments  of  Bezzina  et  al.
(2003) used transiently expressing HEK 293 cells as in II they were conducted at 36 oC with
the reported faster activation time course of hERG K897T occurring at membrane potentials
negative to −10 mV. In the full I-V relationship of Cordeiro et al. (2010) greater rectification of
hERG K897T in the negative slope region is apparent though a positive shift in the voltage-
dependence of channel availability for that variant was found. On the whole any changes in the
biophysical properties of the hERG K897T channel appear to be relatively minor which is in
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line with its polymorphism status. Furthermore all the other hERG1 polymorphisms
functionally characterised are more WT-like (Anson et al., 2004; Männikkö et al., 2010).
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Table 3. Comparison of the reported electrophysiological properties of the HERG K897T polymorphism (i.e. relative
to WT). * significant difference; Drugs used: a terfenadine, b prucalopride, c cisapride, d 48 compounds including
terfenadine, though slight difference with dofetilide.
The most consistent differential effect of hERG K897T, identified first in II, is the decrease
in current density (Table 3).  The reported reduction in tail current density ranging from 25-47
% (II; Anson et al., 2004; Cordeiro et al., 2010; Crotti et al., 2005).  The lack of a difference in
hERG K897T current amplitude reported by Scherer et al. (2002) may emanate from their
usage  of  the Xenopus oocytes expression system which can yield misleading results with
trafficking defective hERG1 variants (e.g. hERG-USO) and LQT2 mutations (e.g. R534C) that
demonstrate functional expression due to the lower temperature (~18 oC) at which the oocytes
are cultured (Anderson et al., 2006; Aydar and Palmer, 2006; Nakajima et al., 1999). It is
noteworthy in regard to the origin of this decrease in current density that the C-terminus plays
an important role in the assembly, trafficking and stability of hERG1 channels (Akhavan et al.,
2003; Aydar and Palmer, 2001; Biliczki et al., 2008; Christé et al., 2008; Gong et al., 2004b;
Kupershmidt et al., 2002; Mihic et al., 2011). To address this hERG1 protein expression was
investigated in HEK 293 and COS-7 cells. Though hERG K897T was present as both immature
core-glycosylated and mature fully glycosylated forms in Western blots (as respectively 135
and 155 kDa bands) a marked reduction in protein expression and the ratio of mature
membrane-associated to immature forms was evident with the two cell lines. This implies there
is inefficient biosynthesis or rapid degradation and defective trafficking of hERG K897T which
consequently decreases the number of functional channels available. A similar, but more
complete, effect occurs with the deletion of residues 860-899 which results in the absence of
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surface expression (no mature protein form or IhERG) and decreased immature protein (Akhavan
et al., 2003). However no such changes in Western blots from transfected HEK cells were
reported in other studies, with hERG K897T undergoing similar biochemical processing as WT
(Anson et al., 2004; Scherer et al., 2002).
This in vitro part of II was performed on homomeric hERG1a K897T channels only. While
applicable given that e.g. 3.3 % of the Finnish population is homozygous for T897 (Marjamaa
et al., 2009a), of wider consequence (28.8 % of that population) would be the study of the
hERG K897T-WT heteromer. The subtle effects noted here may well be attenuated, indeed
according to Nof et al. (2010b) there was no significant difference in current density compared
to WT alone when hERG K897T and WT were coexpressed.
The decrease in the IhERG should give rise to a loss-of-function phenotype with hERG
K897T. Indeed clinically a 50 % reduction of hERG1 (as expected for heterozygous nonsense
LQT2 patients) results in a 16.5 % prolongation of the mean QTc interval (480 ms vs 412 ms
for controls; Mann et al., 2016). Given the prevalence of K897T such an extreme effect is
unlikely. In a dynamic clamp study with guinea pig ventricular myocytes a 30 % decrease of
the modelled IKr conductance did not significantly affect APD but increased the temporal
variability in repolarisation (Altomare et al., 2015). Thus while reducing the repolarisation
reserve, overall a subclinical effect of K897T may be expected. Consequently in II the clinical
effects of the K897T SNP were studied in a LQT1 patient cohort (n = 261), all carriers of the
KCNQ1 G589D mutation. Within this population it was previously suggested that homozygous
897T females, but not males, may have a shorter QTc interval at rest (Laitinen et al., 2000). In
II it was shown that genotype had no significant impact on the risk of cardiac events with 23 %
of patients carrying the 897T allele and 31 % of homozygous WT being symptomatic. As IKs is
critical to cardiac repolarisation under β–adrenergic stimulation and this modulation is
disrupted by G589D any deficit in hERG1 may become evident by these patients undergoing an
exercise test (Banyasz et al., 2014; Jost et al., 2005; Marx et al., 2002). Therefore the QT-RR
interval relationship of 53 patients was investigated. Only in a subgroup, those with a prolonged
QTc (>440 ms at rest, n = 39), were genotype differences seen. The 897T genotypes had a
significant longer QT interval during exercise, but not during recovery, than homozygous WT.
The premise of conducting this clinical study in the Finnish KCNQ1 G589D founder population
appears correct as a larger study of 1,975 heterogeneous Finnish patients found no effect of
genotype during exercise (Koskela et al., 2008). The only significant difference was seen at rest
in women where K897T was associated with a longer QTc interval, consistent with an earlier
report (Pietilä et al., 2002).
Subsequent studies also suggest that K897T forms a latent genetic background. As a
consequence family members who are negative for the family-associated LQTS mutation have
an 11-fold increase in the risk of recurrent syncope, apparently without significant QTc
prolongation (Barsheshet et al., 2011). Clinical case reports identify hERG K897T as a genetic
modifier unmasking latent LQT1, which resulted in an overlapping ECG phenotype of both
LQT1 and LQT2 morphologies, and LQT2 (Cordeiro et al., 2010; Crotti et al., 2005; Nof et al.,
2010b). An outcome of the coexistence of hERG P926AfsX14 and K897T was sudden infant
death, while the carriers (parents and siblings) of either were asymptomatic (Nof et al., 2010b).
It should be noted that there was no difference in the allele frequency of 897T in SIDS cases (or
drug-induced LQTS) compared to reference populations i.e. no enrichment (Arnestad et al.,
2007; Paulussen et al., 2004; Yang et al., 2002). The K897T SNP may also increase the severity
of symptoms in Andersen-Tawil syndrome, whereas it may mask the abbreviated QT intervals
68
of SQT mutation carriers (Antzelevitch et al., 2007; Hu et al., 2011; Jagodzińska et al., 2016).
Finally this SNP may exacerbate arrhythmic risk in the days following myocardial infarction.
K897T in this setting (i.e. a remodelled substrate) was associated with an 8-fold increase in risk,
as 69 % of all patients who developed TdP had an 897T allele compared to 35 % without this
complication (Crotti et al., 2012).
The effect of hERG K897T beyond the heart however has seldom been investigated (Atalar
et al., 2010; Erdem et al., 2015; Sarzani et al., 2006). One may speculate that the loss-of-
function phenotype of hERG1 K897T would result in an oncogenic potential that is less
favourable. Consistent with such a supposition is the reduction in the hERG1b overexpression
of 897T paediatric acute myeloid leukaemia patients compared to 897K homozygote patients
(Erdem et al., 2015). Moreover possibly in line with only subtle kinetic alterations, this SNP is
not associated with schizophrenia (Atalar et al., 2010).
However, in contrast to the above Bezzina et al. (2003) reported that healthy female 897T
homozygotes had an abbreviated QTc (by ~14 ms) compared to heterozygotes and WT
homozygotes. Their observation of altered hERG activation was proposed, aided by in silico
human ventricular cell simulations, as underlying this clinical phenotype. Though using the
same electrophysiological data Glinka and Polak (2012) obtained contradictory simulation
results. Other population studies have also shown the 897T allele to be associated with shorter
QTc intervals (Gouas et al., 2005; Hajj et al., 2014; Marjamaa et al., 2009a; Newton-Cheh et
al., 2007; Pfeufer et al., 2005). Interestingly Gouas et al. (2005) suggested the effect of 897T
was dependent on the major allele of a 3´ UTR SNP in KCNQ1 i.e. not suppression of KCNQ1
expression (Amin et al., 2012).
It appears similarly complex in regard to AF. While no difference in the prevalence of
K897T in AF probands compared to healthy controls was found (Mann et al., 2012), in other
studies this SNP was associated with risk of AF. The effect of the minor allele may differ in
populations having been suggested to be protective in AF but to increase the risk of early onset
lone AF (Andreasen et al., 2013; Sinner et al., 2008). These findings may be explained by either
loss-of-function (decreased IhERG) or gain-of-function (via biophysical properties) with K897T.
Of note hERG1 T895M which is associated with lone AF and SIDS was recently
electrophysiologically determined to be a gain-of-function mutation (Hayashi et al., 2015;
Otagiri et al., 2008). Analogous to hERG K897T (II), this included a significantly slowed
deactivation at −40 mV but not at more hyperpolarised potentials (Hayashi et al., 2015).
The hERG K897T polymorphism did not affect the potency of prucalopride (IC50 =  2.7
µM),  with  no  significant  differences  in  the  extent  of  inhibition  at  any  of  the  tested
concentrations between the variants. Furthermore the prucalopride induced changes in hERG1
channel kinetics described earlier, i.e. slowing of deactivation and acceleration of inactivation,
were also evident with hERG K897T (Fig. 12). Other studies have also shown that hERG1
K897T exhibits a similar pharmacology as the WT hERG1a channel (Table 3), including one
by Männikkö et al. (2010) that tested 48 compounds using an automated patch-clamp device.
This is reassuring as this is an assumption made in the preclinical cardiovascular safety
assessment  of  NCEs.  Only  for  dofetilide  did  the  IC50 not overlap with WT, though the
difference was <1.5-fold. The similarity may not be surprising given that the site of the
polymorphism is remote from the canonical binding site, the inner cavity. It is also consistent
with the view that only subtle alterations in channel kinetics and occupancy of the activated
states occur between WT and K897T given the dependence/mechanism of block of the
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compounds. Differential kinetics can result in pharmacological differences e.g. steady-state
inactivation mutation hERG1 N588K increased the IC50 of both cisapride and terfenadine by
2.7-fold compared to WT (Perrin et al., 2008).
Figure 12. The effect of prucalopride (10 µM) on hERG K897T inactivation. (A) Inactivating currents at +20 mV in
the absence, presence of prucalopride and with wash-out. The peak currents have been aligned to illustrate the
timecourse. The three step voltage protocol is shown inset and consisted of a 2 s depolarisation to +50 mV, a 7 ms
repolarisation to −120 mV and depolarisation to potentials from −20 to +50 mV (though only +20 mV is highlighted).
(B) Plot of the hERG K897T time constant of inactivation at various membrane potentials in the absence and
presence of prucalopride (n = 5; *p<0.05, **p<0.005). A single exponential was fitted to the inactivating current of
the last voltage step.
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5.3 CERAMIDE AND THE hERG1 CHANNEL (III)
Sphingolipids, of which there are over 4000 species, are biologically active components of
cell membranes (Borodzicz et al., 2015; Chaurasia and Summers, 2015). The biosynthesis of
these sphingolipids (little is absorbed in the diet) initially occurs in the ER and generates
ceramide (Fig.  13) which is trafficked to the Golgi for conversion to sphingomyelin and other
complex sphingolipids (Chaurasia and Summers, 2015). Ceramide can be re-formed from
membrane sphingomyelin by hydrolysis via sphingomyelinase in response to e.g.
proinflammatory  cytokines  such  as  TNF-α and  interleukin-1β.  In  addition  to  its  role  as  a
precursor, ceramide is an important second messenger mediating through various signalling
cascades processes such as proliferation, differentiation and apoptosis (Borodzicz et al., 2015).
Ceramide has a significant involvement in pathophysiology, for instance in lipotoxicity, i.e.
where excess fat in obesity and dyslipidemia is supplied to the pancreatic islets, heart etc
resulting in dysfunction, and therefore diabetes, insulin resistance, cardiomyopathy, and
atherosclerosis (Chaurasia and Summers, 2015). Ceramide accumulates in
ischaemia/reperfusion injury and in advanced human heart failure the intracellular ceramide
level was found to be increased by 50 % (Borodzicz et al., 2015; Chokshi et al., 2012). It is
therefore of great interest to study the effect of ceramide on cardiac ion channels and the
resulting contribution to the electrophysiological remodelling seen in these disease states. Prior
to III acute  exposure  to  ceramide  was  shown  to  have  no  effect  on  IhERG (at 50 µM) but to
substantially reduce (by ~70 % at 10 µM) the IERG of  a  rat  lactotroph  cell  line  (Wang  et  al.,
2001; Wu et al., 2001).
Figure 13. Ceramide. For the cell permeable C6-ceramide used in III R = C5H11.
In III at  a  concentration  of  10  µM,  which  mimicks  the  intracellular  level  reached  during
physiological and pathophysiological stimulation (Hannun, 1996), C6-ceramide was shown to
induce a time dependent decrease of the hERG1a current in stably expressing HEK 293 cells.
Thus the peak tail current density in ceramide was reduced significantly more than current
rundown: after 15mins by 11.4 ± 3.2 % (vs 2.7 ± 1.0 % vehicle; n=6 for both; p<0.05) and after
60 mins by 30.2 ± 4.4 % (n=4; vs 13.1 ± 3.7 % vehicle; n= 5; p<0.05). Furthermore the
reduction in IhERG was  not  prevented  by  the  PKC inhibitor  calphostin  C (0.1  µM).  A detailed
electrophysiological characterisation was undertaken of cells incubated for 1 hour in 10 µM
ceramide or vehicle. The hERG1 activating current evoked by a depolarising step, the tail
current and the instantaneous current following relief of inactivation were all significantly
decreased by ceramide e.g. the current density was decreased by 22 % with depolarisation to 0
mV and the tail current by 30 % after depolarisation to +40 mV. The specificity of this response







current. Moreover a concentration dependent reduction in hERG1 current was evident with
ceramide, though significance was only achieved at 10 µM. Ceramide did not alter hERG1
steady-state activation or inactivation, but significantly accelerated the deactivation time
constants. The latter exhibiting a concentration dependent effect, thus the fast and slow time
constants were respectively 16 and 20 % faster at 0.3 µM and 33 and 42 % faster at 10 µM. Of
note similar electrophysiological results were subsequently reported with exposure to a DAG
analogue, however the decrease in IhERG was PKC dependent (Ramström et al., 2010).
The ceramide-induced decrease in IhERG paralleled a reduction in hERG cell membrane
protein expression as determined by western blot (a 30 % loss of intensity of the 155 kDa
band), biotinylation (a 42 % decrease in labelled hERG) and immunostainings. These cell
surface expression effects of ceramide on hERG1 may reflect protein synthesis and/or
trafficking disruption or increased degradation of membrane protein. The unchanged levels of
the core-glycosylated, immature 135 kDa form of hERG protein from pre-Golgi compartments
argues against an effect on channel synthesis. Analogous results are seen with hERG trafficking
inhibitors  such  as  pentamidine,  ketoconazole,  probucol  and  cardiac  glycosides  (J.  Guo  et  al.,
2007; Kuryshev et al., 2005; Takemasa et al., 2007; Wang et al., 2007). However a fundamental
difference between these trafficking inhibitors and ceramide is the temporal aspect of the hERG
decrement. A similar reduction in mature hERG protein occurs for ceramide at 1 hr as for
ketoconazole (30 µM, its approximate maximal effective concentration) at 8-24 hr (III Fig. 3A
cf Takemasa et al., 2007 Fig. 5A). Unsurprisingly when synthesis and processing of hERG was
explored more directly with pulse-chase experiments it was shown to be unaltered by ceramide.
Thus whether control or ceramide exposed similar quantities of the core glycosylated hERG
form were initially synthesised (at t0) and subsequently processed (e.g. t8hr ~27 % remained) to
the mature 155 kDa form giving at 8hrs an increase of ≈50 %. This therefore does not explain
the results of the above steady-state experiments and differs from hERG trafficking inhibitors
(Ficker et al., 2004). Instead ceramide was shown to increase hERG1 ubiquitination (according
to immunoprecipitation experiments) with subsequent targeting of the protein to lysosomes.
The lysosomal inhibitor bafilomycin A1, but not the proteosomal blocker MG132, augmented
hERG1 ubiquitination and prevented the reduction in hERG protein staining induced by
ceramide. Finally, exposure to ceramide resulted in hERG1 protein co-localising, according to
immunostainings, with the lysosomal-associated membrane protein Lamp 1. Thus it is
suggested that in hERG1a-HEK cells ceramide causes the ubiquitination of hERG1 leading to
channel internalisation and targeting to lysosomes.
Subsequent to III the regulation of hERG1 channel expression at the cell membrane has
been increasing explored (see section 2.2.4). Key to this regulation is Nedd4-2, which mediates
hERG1 ubiquitination (Albesa et al., 2011; Guo et al., 2012; Kang et al., 2015). Modulation of
Nedd4-2 activity either positively, e.g. by AMP-dependent protein kinase, or negatively, e.g. by
the PKC pathway and SGKs, results respectively in a decrease or increase in IhERG (Almilaji et
al., 2013; Lamothe and Zhang, 2013; T. Wang et al., 2014). The effectors of the ceramide-
induced ubiquitination of hERG1 were not identified in III, thus with the current knowledge an
investigation of the role of Nedd4-2 and the enhancement of its activity may be a starting point.
Interestingly, but contrary to the expectation with hERG1, ceramide (C4) was shown to increase
the trafficking of ΔF508 mutant cystic fibrosis transmembrane conductance (CFTR) to the cell
surface via activation of SGK1 and resultant Nedd4-2 inactivation (Caohuy et al., 2014). Of
note the trafficking of CFTR shares many similarities with hERG1 (Delisle et al., 2009),
recently Nedd4-2 recruitment and activation at the Golgi apparatus by Nedd4 family interacting
proteins was suggested to likewise reduce trafficking to the cell membrane (Fig. 7; Kang et al.,
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2015). However MG132 has been shown to prevent the down-regulation of the mature hERG1
protein by Nedd4-2 suggesting it targets hERG1 to the proteosome for degradation (Albesa et
al., 2011). Whether under different conditions different targeting by Nedd4-2 occurs or if a
different ligase (e.g. CHIP which appears to be important in peripheral quality control; Apaja et
al., 2013) is involved in this instance is unknown.
As mentioned above the specifics of the ubiquitination and internalisation mechanism in
regards to ceramide exposure remain to be determined, as does whether the internalised hERG
channels can be recycled back to the cell membrane. The most extensively studied situation has
been hypokalaemia. Chronic exposure to K+o below 5 mM decreases IhERG (with an IC50 of 2
mM) through enhanced ubiquitin-mediated internalisation via endocytosis and lysosomal
degradation of hERG1 channels (Apaja et al., 2013; Guo et al., 2009). The trigger for
internalisation is the entry of the hERG1 channels into a novel nonconducting state, which
likely results in the exposure of ubiquitin modification site(s) (Massaeli et al., 2010b).
Internalisation of hERG was shown to be a dynamin-dependent Cav mechanism (Massaeli et
al., 2010a). Another analogous case to III is drug-induced internalisation of hERG1 which can
occur acutely (≥30 min) with e.g. the antidepressants amoxapine and desipramine (Obers et al.,
2010; Staudacher et al., 2011). Furthermore desipramine in hERG-HEK cells induced rapid
ubiquitination of the recycling hERG channels and transit to lysosomes for degradation (Dennis
et al., 2011).
Two other reports have examined the effect of ceramide on hERG1a-HEK cells. As in their
earlier paper, Bai et al. (2007) found that ceramide (C2) exposure for up to 20 mins had no
significant effect on IhERG but with prolonged incubation caused a concentration dependent
reduction (IC50 = 19.5 µM). We though observed a small but significant decrease already after
15 mins, it is noteworthy however that the extent of inhibition by 10 µM ceramide after 1 hr
(III) or 10 hrs (Bai et al., 2007) incubation was similar (~30 %). One clear discrepancy between
the electrophysiological data of the two studies is in regard to the half maximum activation
voltage. This likely reflects the ceramide incubation time difference i.e. a depolarising shift
becomes evident with >1 hr exposure, but could arise from the different ceramide isoforms
used. The prolonged exposure to ceramide resulted in increased ROS generation which was
shown to partly, at least, underlie the C2-induced IhERG decrease. Certainly inconsistent with Bai
et al. (2007) and greater than in III, Ganapathi et al. (2010) reported a more rapid effect of
ceramide (C6) with a maximal 36 % reduction of IhERG within 10 mins. In this initial time
period, there was also a hyperpolarising shift of the voltage dependence of activation and, as in
III, an acceleration of the deactivation kinetics. Underlying these gating changes was a
recruitment of hERG1 to lipid rafts where the exogenous ceramide accumulates assuming a
biophysical role (Ganapathi et al., 2010). The ceramide-induced IhERG decrease had a distinct
unknown mechanism, as puzzlingly the authors were unable to replicate with up to 1 hr
ceramide exposure the loss of cell surface hERG expression proposed in III. The only longer
time point (24 hrs) did exhibit a 44 % reduction in hERG protein using a biotinylation assay.
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5.4 hERG1 R176W AND iPS-CARDIOMYOCYTES (IV)
The use of a heterologous expression system, as in studies I – III, affords a number of
advantages beginning with defining the cDNA introduced, thus the human form (whether WT
or mutant) can be expressed and investigated. The controlled nature with large amplitude
currents and minimal contaminating currents lends itself to detailed structure based (e.g.
mutation) analyses of ion channel function and interaction (e.g. drug). Though conventionally
used the results from such artificial models may poorly correlate or appear discrepant, at least
initially, with the clinical phenotype as the native situation is not fully recapitulated (Biliczki et
al., 2008; Watanabe et al., 2011; Zarraga et al., 2011). One explanation may be the cellular
context e.g. cell type dependence in the components involved in the TRH regulation of ERG
channels was found suggesting cell specific protein composition and availability modulates the
elements in signal transduction pathways (Carretero et al., 2012). This demonstrates the
necessity of studying modulation in native systems and it remains to be explored whether the
effects of ceramide obtained in heterologous expression systems translates to cardiomyocytes.
Another important point is that functional characterisation of hERG1 mutations and
polymorphisms have almost exclusive been described in the context of hERG1a isoform though
most also occur within the coding regions for hERG1b and the other isoforms. A few examples
employing other hERG1 isoforms exist (McPate et al., 2009; Stump et al., 2012a), thus while
the effect of the N588K mutation was similar to that found with hERG1a alone there was
greatly enhanced attenuation of inactivation by this SQT1 mutation in heteromeric hERG1a/1b
channels (McPate et al., 2009).
Ideally heterologous expression studies would be complemented by more integrated
approaches encompassing the in vivo complexity of the channel and its physiological effects.
Hitherto insights into the pathogenesis of LQT2 though have come almost entirely from
heterologous expression systems with transgenic animal models scarcely used (Babij et al.,
1998; Brunner et al., 2008; Teng et al., 2008). LQT2 mutants have also been exogenously
expressed in mouse and rat cardiomyocytes (Balijepalli et al., 2012; Lin et al., 2010). The use
of cardiomyocytes differentiated from human pluripotent stem cells, whether embryonic or
induced (i.e. generated by reprogramming of the mature somatic cells of an individual;
Takahashi et al., 2007; Yu et al., 2007) pluripotent stem (ES or iPS) cells, has great potential as
a human in vitro integrated model system (e.g. Liang et al., 2013; Ma et al., 2011; Peng et al.,
2010). Indeed use of human iPSC derived ventricular myocytes will be incorporated in the
forthcoming CiPA where they will provide confirmation of the ion channel and in silico results,
and reveal any unforeseen effects (Fermini et al., 2016; Sager et al., 2014). Also the exogenous
expression of the LQT2 mutants hERG1 R56Q and hERG1b-R25W in human iPSC derived
cardiomyocytes has taken place (Jones et al., 2016; Liu and Trudeau, 2015). Furthermore iPS
has offered a unique opportunity to study ion channel (or other) mutations in the disease
relevant cellular context by differentiation of patient-specific human iPSC lines (Hoekstra et al.,
2012; Takahashi et al., 2007). Moretti et al. (2010) first demonstrated that the LQTS phenotype
of individuals could be reproduced in vitro i.e. the atrial- and ventricular-like action potentials
of cardiomyocytes derived from iPSCs with a KCNQ1 R190Q mutation were prolonged.
In IV iPSC lines were established from a 61-year old man carrying an arginine to
tryptophan substitution in the N-terminal proximal domain at position 176 (R176W; a result of
the exon 4 change 526C>T) of hERG1. He, apart from occasional palpitations, was
asymptomatic with a QTc of 437 ms. His sister had overt LQTS (with QTc intervals up to 582
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ms) and died suddenly at 32 years when awoken by a telephone. His father also died suddenly
at the age of 40. In Finland hERG1 R176W together with three mutations (G589D and IVS7-
2A>G of KCNQ1, and hERG1 L552S) accounts for over 70 % of the genotyped LQTS patients
(Fodstad et al., 2004). hERG1 R176W was present in ~8 % of these genotyped LQTS patients,
with 40 % of male and 22 % of female carriers having a prolonged QTc and overall 16 %
symptomatic (Marjamaa et al., 2009b). In line with its founder mutation status hERG1 R176W,
in the heterozygous form, was associated with a low incidence of cardiac events (0 % syncope,
0 % life threatening; this compares to 29 % and 0 % for non-Finnish founder hERG1 mutations)
up to 18 years old (Koponen et al., 2015). Furthermore though prevalent (1 in 568) in the
general adult Finnish population and associated with a 22 ms longer QT, R176W is not a risk
factor  for  sudden  cardiac  death  (Lahtinen  et  al.,  2013;  Marjamaa  et  al.,  2009b).  Similarly
elsewhere hERG1 R176W (rs36210422) was found as a common variant (frequency of ~0.5 %)
in apparently healthy Caucasian populations (Ackerman et al., 2003; Mank-Seymour et al.,
2006). While enriched in the Finnish LQTS population, hERG1 R176W was also found in one
case of SUD and one of SUD in epilepsy as well as in dofetilide and terodiline induced TdP
cases (Mank-Seymour et al., 2006; Männikkö et al., 2010; Tester et al., 2012; Tu et al., 2011).
In addition hERG1 R176W was found, but no further mutations in hERG1 or the other genes
screened, in a case of a 12-year old girl who presented with a life-threatening cardiac event
following emotional stress (Donner et al., 2012). The above suggests hERG1 R176W exhibits
variable penetrance and expressivity. Moreover a more severe phenotype is reported in
compound heterozygotes i.e. when in combination with KCNQ1 mutations (Fodstad et al.,
2006).
The  differentiation  of  the  patient  and  control  iPSCs  as  well  as  H7  hESCs  towards  the
cardiac lineage was by co-culture with END-2 cells. Within 2 weeks spontaneously beating
areas were evident, these were excised and dissociated. The electrophysiological properties of
these spontaneously beating dissociated cells was characterised with patch-clamp. In current-
clamp two action potential configurations were seen: ventricular-like, where a plateau phase
was evident; and atrial-like, with a triangular shape. While the upstroke velocity, action
potential amplitude and maximum diastolic potential of the LQT2-iPSC derived
cardiomyocytes exhibited no difference from that of the control cardiomyocytes, the APD did.
The APD at 50 % and 90 % repolarisation of the atrial-like LQT2-iPSC derived cardiomyocytes
was also prolonged (APD50 and APD90 by 34 %) but did not reach statistical significance. At a
spontaneous action potential firing frequency of ~1 Hz, the APD of the ventricular-like LQT2-
iPSC derived cardiomyocytes was significantly prolonged (Fig. 14A; APD50: 436.4 ± 24.9 ms
vs hESC 291.9 ± 18.2 ms and control 264.2 ± 17.7 ms, p<0.001, hESC vs control p=0.71;
APD90 516.5 ± 26.1 ms vs hESC 338.6 ± 19.9 ms, control 310.5 ± 19.6 ms, p<0.001, hESC vs
control p=0.73). As shown in figure 14A the APD did not differ between cardiomyocytes
derived from the two LQT2-iPSC lines or the various control cell lines. Furthermore in one
LQT2-iPSC derived cardiomyocyte, but in no control iPSC derived cardiomyocytes (n=20 for
both), EADs were evident.
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Figure 14. (A) Box graph of the APD90 of cardiomyocytes derived from hESC, control iPSC and LQT2 iPSC lines
that had a frequency of ~1 Hz. The summary data and that from the individual cell lines (the number of cells is
shown beneath) are in black and grey respectively. (B) The IKr evoked from a control (UTA.04602.WT; above) and
LQT2 (UTA.00525.LQT2; below) iPSC derived cardiomyocyte by depolarisation to 0 and + 20mV (grey trace)
followed by a return to the holding potential of −40 mV.
 To confirm a loss-of-function was associated with hERG1 R176W resulting in APD
prolongation,  the  IKr of ventricular-like cardiomyocytes was recorded using two isolation
methods and different cell lines. As seen in figure 14B, the cardiomyocyte IKr (as E-4031-
sensitive current) exhibited inward rectification and large tail currents. The IKr magnitude of
LQT2-iPSC derived cardiomyocyte was significantly decreased compared to control.
Depolarisation to +20mV and the subsequent repolarisation generated IKr of 0.75 ± 0.05 pA/pF
and 1.80 ± 0.14 pA/pF from control iPSC derived cardiomyocytes compared with 0.35 ± 0.09
pA/pF and 1.08 ± 0.11 pA/pF from LQT2-iPSC derived cardiomyocytes (p<0.05 and <0.005,
n=3-5). Importantly when a step-ramp voltage protocol was employed a reduction in the
resurgent IKr was  evident.   A  reduction  in  IKr was also observed when isotonic caesium
solutions were used to isolate IKr. Thus the tail current density after depolarisation to +20 mV
was 4.1 ± 0.6 pA/pF and 2.5 ± 0.5 pA/pF for control and LQT2-iPSC derived cardiomyocytes
respectively (p>0.05, n=3 and 4).
 The delayed repolarisation of the LQT2-iPSC derived cardiomyocytes was confirmed at the
multicellular level in field potential recordings, being most evident at low spontaneous beating
rates. No arrhythmogenicity was seen at baseline with either control or LQT2-iPSC derived
cardiomyocytes on the microelectrode arrays. However EADs were more readily induced in
LQT2-iPSC derived cardiomyocyte aggregates, as in other studies (e.g. Matsa et al., 2011;
Mehta et al., 2014), compared to control on exposure to E-4031 or sotalol.
 This study provides further support that a heritable condition, LQT2, can be modelled in
vitro with human iPSC derived cardiomyocytes and is consistent with the growing number of
recent reports (Table 4). In one study iPSC lines were created from a proband and mother,
(7) (3) (3) (5) (8) (5)
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though the latter also carried the A561T mutation and had a prolonged (though not to the same
extent) QTc she was asymptomatic (Matsa et al., 2011). The derived cardiomyocytes
recapitulated the phenotypes in vitro with the APD of the maternal origin cells being shorter,
but longer than that of control cardiomyocytes, and EADs being non-inducible. The
intermediate phenotype is comparable to the one obtained in IV. The relatively mild
electrophysiological profile of the R176W iPSC derived cardiomyocytes bears most
resemblance to that of cardiomyocytes derived from the latent LQTS N996I carrier (Table 4).
Patient symptomaticity appears in general to correlate in vitro with greater APD prolongation
and prevalence of EADs, even for the same hERG1 mutation (Chai et al., 2015; Matsa et al.,
2011). Thus in contrast to R176W and N996I, the substantial reduction in cardiomyocyte IKr
observed with A561V and A614V results in a greatly prolonged APD and frequent EADs
mirroring the overt LQTS of the patients from which they were derived (Table 4).
Table 4. Comparison of the electrophysiologically characterised LQT2 iPSC derived cardiomyocyte data. APD90 of
LQT2 iPSC derived cardiomyocyte relative to control at ~1 Hz otherwise a, APD prolongation but frequency not
disclosed. The % of LQT2 iPSC derived cardiomyocytes in which EADs were observed otherwise b, spontaneously
occurring EADs noted but no figure given. diTdP refers to drug (clobutinol) induced TdP.
The electrophysiological phenotype described in IV appears more severe than the patient
phenotype, likely a consequence of various factors. Firstly dissociated single cardiomyocytes
may exhibit an exaggerated phenotype (Matsa et al., 2011; Spencer et al., 2014). Of note in this
regard was that the prolongation was much less (only 10–20 %) in multielectrode array
measurements where cellular coupling was preserved. Also though the QTc of the patient is
reported  within  the  normal  range,  variability  of  the  QTc  interval  with  hERG1  R176W  on
repeated measurement occurs (Donner et al., 2012). Furthermore the control iPSC lines are
suboptimal as their genetic backgrounds differ from the patient so differences may be over-
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(Spencer et al., 2014)
QTc=493 ms
Syncope
a 45 % 70 %
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(Jouni et al., 2015)
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(Mehta et al., 2014)
QTc=584 ms
TdP
191 % ~90 % b
A614V
(Itzhaki et al., 2011)
QTc=520 ms
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~200 % 64 % 66 %
N996I
(Bellin et al., 2013)
QTc=617 ms
Asymptomatic
142 % 33 % 0 %
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estimated. The use of isogenic cell lines, as in recent studies (e.g. Bellin et al., 2013), would
negate this and could provide insight into the contribution of the epistatic effects of background
to the heterogeneity of R176W’s clinical phenotype.
Previously hERG1 R176W was studied by heterologous expression in COS-7 and CHO
cells (Fodstad et al., 2006; Männikkö et al., 2010). hERG1 R176W was found to decrease the
tail current density by ~75 % compared to hERG1 WT, the decrement though was lessened (to
~23 %) and became insignificant upon co-expression (Fodstad et al., 2006). In IV, native
expression in cardiomyocytes derived from a heterozygous R176W individual, a 40 %
reduction in IKr density was found. The slight difference may result from the differing
composition of the channels (hERG1a vs native hERG1a/1b + accessory subunits/associated
proteins). How hERG1a R176W interacts with hERG1b is unknown and as the R176W variant
does not occur in hERG1b the relative abundance of this subunit may then give rise to
variability. The extent of the reduction (<50 %) is indicative of haploinsufficiency rather than a
dominant negative effect of the R176W subunits on the WT subunits. The steady-state voltage-
dependence or kinetics of IKr were not studied in IV due to the small amplitude of the current,
particularly that of R176W. In the earlier studies no significant (or slight) differences were seen
at room temperature between R176W and WT (Fodstad et al., 2006; Männikkö et al., 2010).
The lack of any major biophysical alterations to account for the loss of IhERG may suggest
hERG1 R176W is trafficking defective, however this has not been tested. A similarity with the
hERG1 R273Q mutation, identified in a SIDS case (Arnestad et al., 2007), is evident. When
this mutant was co-expressed it also generated WT-like current but with a tail current density
reduced by ~35 % (Rhodes et al., 2008). So far though when specifically studied no N-terminal
proximal domain variants affect protein synthesis or channel trafficking (Anderson et al., 2006;
Mechakra et al., 2014; Osterbur et al., 2015; Perry et al., 2016).
While iPSC derived cardiomyocytes exhibit an IKr density that is comparable to native
human cardiomyocytes due, at least in part, to the expression and functionality of hERG1b,
their electrophysiological phenotype is immature as exemplified by their spontaneous beating
(Cordeiro et al., 2013b; Doss et al., 2012; Hoekstra et al., 2012; Jones et al., 2014). Thus in IV
and elsewhere (e.g. Itzhaki et al., 2011; Jouni et al., 2015; Mehta et al., 2014) the ventricular-
like cardiomyocyte maximum diastolic potential was depolarised (-63 mV) and the maximal
upstroke velocity reduced (being up to 27 V/s) compared to the values (~-85 mV and >220 V/s)
of human ventricular cells (Drouin et al., 1995; Peeters et al., 1995). Strategies to improve the
maximum diastolic potential (and consequently the upstroke velocity) include using clusters of
cells and enhancing the small IK1 (Jones et al., 2014; Spencer et al., 2014; Vaidyanathan et al.,
2016) but the primary on-going goal is to obtain mature iPSC derived cardiomyocytes.
Meanwhile of note in regards to CiPA is the introduction of a human ex-vivo ventricular
trabeculae action potential model (Page et al., 2016), which also enables investigation of drug-
induced effects in the context of comorbidities such as type 2 diabetes.
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6. CONCLUSIONS AND FUTURE DIRECTIONS
 The  IKr/hERG1 channel plays an essential role in the repolarisation of the cardiac action
potential and in the excitability of neurones, smooth muscle and endocrine cells. Loss or gain-
of-function of hERG1 is associated with arrhythmogenesis and sudden cardiac death, while its
overexpression and ectopic expression is associated with cancer. This thesis provides insights
into the effect of genetic variation, drug and regulation on hERG1 function and cardiac
electrophysiology.
  The gastrointestinal prokinetic drug prucalopride exhibited concentration dependent
inhibition of hERG1a with rapid block and unblock of the activated states. At therapeutic
concentrations this should pose little proarrhythmic risk as the hERG safety margin is ≥300.
This has translated to the clinic with a negative TQT study and a benign cardiac safety profile
in the various phase III studies.
The sphingolipid ceramide was shown to induce a time dependent decrease in hERG1a
current as channels are ubiquitinated and internalised. Whether this also occurs in
cardiomyocytes or other native cell types remains to be determined. This mechanism could
contribute to the QT prolongation (and apoptosis) in diabetic cardiomyopathy, myocardial
ischaemia and HF.
 Two common genetic variants of hERG1 were investigated. The hERG1 SNP K897T was
found have a decreased hERG1 current density compared to wild-type when heterologously
expressed. While this loss-of-function in vitro phenotype may translate clinically to certain
subgroups (e.g. during exercise to KCNQ1 G589D carriers with prolonged resting QTc or
individuals following myocardial infarction), in the general population the minor allele is
associated with shorter QTc intervals. In a proof-of-concept study, using human iPSC derived
cardiomyocytes from a relatively asymptomatic individual, the variant hERG1 R176W caused a
reduction in IKr and action potential prolongation. In line with expectation the extent of the
reduction and prolongation (as well as EAD occurrence) was less than reported for iPSC
derived cardiomyocytes from highly symptomatic LQT2 patients. Of note hERG1 K897T has
now  also  been  studied  with  iPSC  derived  cardiomyocytes  from  a  proband  (with  a de novo
mutation in SCN5A and heterozygous for K897T), his WT father and homozygous K897T
mother (Terrenoire et al., 2013). No significant differences were seen in the IKr I-V  curves
(density or rectification) or in the voltage-dependence of activation between cardiomyocytes
from the family members.
A more integrated in vitro approach to evaluate the proarrhythmic risk of drugs (e.g. with
CiPA) and genetic variants has begun and will develop as the maturity of iPSC derived
cardiomyocytes improves along with the advances in assaying technologies (e.g. optogenetics).
Thus novel drug-induced cardiac repolarisation prolongation mechanisms, e.g. as with histone
deacetylase inhibitors (Kopliar et al., 2016; Spence et al., 2016), may be detected earlier.
Together with increasingly complex in silico modelling (from cell models to heart simulator in
model torso; e.g. Okada et al., 2015), the prediction of the action of a drug or variant would be
more informed and testable under physiological and pathophysiological conditions.
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Finally it should be remembered that the application of iPSCs to hERG1 study is not limited
to cardiomyocytes as hERG1/IKr is widely expressed and when inhibited yields multisystem
phenotypes at least in vitro/ex vivo systems. Thus e.g. human iPSC derived neurones could
provide a system to investigate endogenous hERG1-3.1 and the link between LQT2 and
epilepsy. It is surprising even with a homozygous nonsense mutation (Q1070X) which, due to
NMD, would result in near complete loss of hERG1 channels that the phenotype was
apparently cardiac restricted (Bhuiyan et al., 2008).
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